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5-HIAA 5-hydroxyindoleacetic acid 
ACTH Adrenocorticotrophic hormone 
APUDoma Amine precursor uptake decarboxylase tumour 
BB1R, BRS-1 Bombesin-receptor type 1, Neuromedin B receptor 
BB2R, BRS-2 Bombesin-receptor type 2, Gastrin-releasing peptide receptor 
BB3R, BRS-3 Bombesin receptor subtype 3 
BB4R, BRS-4 Bombesin receptor subtype 4 
BBS Bombesin 
BLP Bombesin-like peptide 
BSA Bovine serum albumin 
CBS Central Bureau for Statistics 
CCK Cholecystokinin 
CD105 Endoglin 
CgA Chromogranin A 
CNS Central nerve system 
CRC Colorectal cancer 
CT  Computed tomography 
DAB 3,3'-diaminobenzidine 
DNET Duodenal neuroendocrine tumour 
EC Enterochromaffin 
ECL Enterochromaffin-like 
ECM Extracellular matrix 
ELISA Enzyme linked immuno-sorbent assay 
EUS Endoscopic ultrasonography 
Flt-1 VEGF receptor 1 
F-PNET Functioning/functional pancreatic neuroendocrine tumour 
FSG Fasting serum gastrin 
GEP-NET Gastroenteropancreatic neuroendocrine tumour 
GI Gastrin increase 
GI-NET Gastrointestinal neuroendocrine tumour 
GIST Gastrointestinal stromal tumour 
GRF Growth-hormone releasing factor 
GRP Gastrin releasing peptide 
GRPR Gastrin releasing peptide receptor 
HRP Horseradish peroxidase 
IGF Insuline-like growth factor 
kDa Kilo Dalton 
KDR VEGF receptor 2 
MEN-1 Multiple endocrine neoplasia syndrome type 1 
MMP Matrix metalloproteinases 
MMP-7 Matrilysin, matrix metalloproteinase-7 
MRI Magnetic resonance imaging  
mRNA Messenger ribonucleic acid 
MVD Microvessel density 
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NEC Neuroendocrine carcinoma 
NET Neuroendocrine tumour 
NF-1 Neurofibromatosis type 1 
NF-PNET Non-functioning/non-functional pancreatic neuroendocrine tumour 
NMB Neuromedin B 
NMBR Neuromedin B receptor 
NME Necrolytic migratory erythema 
NSE Neuron specific enolase 
PALGA Nationwide network and registry for histo- and cytopathology in the Netherlands 
PBS Phosphate buffered saline 
PET Pancreatic endocrine tumour 
PNET Pancreatic neuroendocrine tumour 
PP Pancreas polypeptide 
PPI Proton pump inhibitor 
ROC Receiver operating characteristic 
RT  Room temperature 
s.e.  Standard error   
SEER Surveillance, Epidemiology and End Results database 
SEM Standard error of the mean 
sEndoglin Soluble endoglin 
SRS Somatostatin receptor scintigraphy 
SSPS Statistical Package for Social Sciences 
St. dev.  Standard deviation 
TBS Tris-buffered saline 
TGF-ß Transforming growth factor beta 
TNM Tumour node metastasis 
VEGF Vascular endothelial growth factor 
vHLD Von Hippel-Lindau disease 
VIP Vasoactive intestinal peptide 
WDHA Watery diarrhea hypokalemia achlorhydria 
WHO World Health Organization 












































Gastroenteropancreatic neuroendocrine tumours  
Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) comprise a 
heterogeneous group of uncommon neoplasms, including the pancreatic 
neuroendocrine tumours (PNETs) and gastrointestinal (GI) neuroendocrine 
tumours1 (GI-NETs, Table 1).  
 
 
Table 1. Neuroendocrine tumours 
 
Carcinoids 
     (gastrointestinal neuroendocrine tumours) 
Non-carcinoid gastroenteropancreatic tumours 
 (pancreatic, duodenal and gastrointestinal neuroendocrine                   
tumours) 
Catecholamine-secreting tumours 
(phaeochromocytomas, paragangliomas, ganglioneuromas,    
ganglioneuroblastomas, sympathoblastoma, neuroblastoma) 
Medullary carcinomas of the thyroid 
Chromophobe pituitary tumours 
Small cell lung cancer 
Merkel cell tumours 
 
Table 1. All tumours which are classified and defined as ‘neuroendocrine tumour’. 
 
The total incidence is estimated at 2-5 patients per 100.000 persons per year, 
although recent epidemiological studies have shown that their incidence is 
increasing remarkably2-5. Nevertheless, they only comprise approximately 2% of 
all malignant tumours of the gastrointestinal tract.  
GEP-NETs are considered to originate from the cells from the diffuse 
neuroendocrine system. There are at least 15 neuroendocrine cell types, scattered 
along the entire length of the gastroenteropancreatic tract. These cells are called 
neuroendocrine because their many similarities to neural cells. Not only do they 
have several histological similarities such as secretory granules and the expression 
of neuroendocrine cell markers, they also produce bioactive substances that have 
transmitter function. GEP-NETs are characterized by their ability to synthesize, 
store and secrete biogenic amines and neuropeptides. Although various 





A is nowadays widely used to identify GEP-NETs (Table 2). GEP-NETs occur 
mainly in the gastrointestinal tract and pancreas (2/3rd), the pulmonary system 
being the next most frequent location1,6,7.  
 
 
Table 2. Neuroendocrine cell markers 
 
General markers 
Chromogranin A, B 
Pancreatic polypeptide 
Neuron-specific enolase 
Human chorionic gonadotrophin alpha/beta subunits 
 
Specific markers 
Insulin              (insulinoma) 
Gastrin              (gastrinoma) 
Glucagon             (glucagonoma) 
Somatostatin             (somatostatinoma) 
VIP              (VIPoma) 
ACTH              (ACTHoma) 
GrH              (GrHoma) 
Serotonin             (carcinoid) 
Calcitonin                      (calcitoninoma) 
Table 2. Overview of general and specific neuroendocrine cell markers in GEP-NETs. 
 
The clinical presentation of GEP-NETs depends on the location of the primary 
tumour, the presence of metastases, and the peptide(s) secreted. The diagnosis of 
GEP-NETs is frequently delayed, and metastases are often present when the 
tumour is detected. The diagnosis of GEP-NETs is based on clinical presentation, 
hormone assays, and pathological examination of the tumour. The detection of 
some biochemical markers in plasma or serum of patients with GEP-NETs raises 
the suspicion of a specific tumour, whereas other markers are common to several 
types of GEP-NETs2 (Table 2). Commonly used imaging modalities include CT, 
MRI, transabdominal ultrasonography, gastrointestinal endoscopy, selective 
angiography, nuclear imaging such as somatostatin-receptor scintigraphy, 
endoscopic ultrasonography8. Frequently, primary tumours can not be localized, 




As GEP-NETs show a large variation in tumour behaviour and a wide spectrum of 
clinical manifestions, treatment of these tumours should be individualized per 
patient, based on the tumour type and presence of symptoms. Surgery is the 
treatment of choice in a large percentage of GEP-NETs, especially in patients with 
limited disease2. For patients with advanced or unresectable disease, surgery can 
be palliative, and even reduce morbidity and mortality. Furthermore, recent 
studies to medical treatment of GEP-NETs using somatostatin analogues show 
promising results. The prognosis of GEP-NETs varies strikingly, and is mainly 
dependent on the size and localization of the primary tumour, and metastatic 
involvement. However, GEP-NETs show less aggressive behaviour than the more 
common gastrointestinal carcinomas and pancreatic adenocarcinomas. 
The majority of GEP-NETs are sporadic, although they can be multiple and occur 
as part of a hereditary syndrome, such as Multiple Endocrine Neoplasia type 1, 
von Hippel-Lindau disease, or neurofibromatosis type 19. The model of 
neuroendocrine tumour development resembles that from colorectal cancer1 



















Loss of tumor suppressors 
(PTEN)
Loss of large LOHs
(3p-, 1p-, 18q-)






Malignant evolution Tumour spread  
Figure 1. The neuroendocrine tumourigenesis, from normal tissue to the formation of metastases, is 
shown. The first step in the development of neuroendocrine tumours is the transformation of 
normal neuroendocrine cells into hyperplastic and/or dysplastic tissue, as a result of gene 
mutations. Next, the tumour differentiates into a well-, moderately or poorly differentiated 
tumour, in which growth factors, oncogenes and tumour suppressor genes play an important role. 
Eventually, tumours spread into the circulation and form metastases. Figure based on Barakat et 
al1. 
 
The classification of the World Health Organization (WHO) for GEP-NETs is 





histopathology and biological behaviour of tumours, divided per tumour 
localization, i.e., stomach, duodenum and the upper part of the jejunum, 
appendix, small bowel, including the second part of the jejunum, colon and 
rectum, and pancreas. Finally they are divided into three classifications, based on 
differentiation and malignant behaviour, characterized by the presence of 
angioinvasion and/or metastases10 (Table 3).  
 
 
Table 3. World Health Organization Classification for GEP-NETs 
 
1a. Well-differentiated neuro-endocrine tumour with benign or uncertain behaviour 
1b. Well-differentiated neuro-endocrine carcinoma with low-grade malignant behaviour 
2. Poorly differentiated neuro-endocrine carcinoma with high-grade malignant behaviour 
 
 
Table 3. Classification of the World Health Organization for GEP-NETs, introduced in 2000. 
 
Pancreatic neuroendocrine tumours 
Pancreatic neuroendocrine tumours (PNETs) are often referred to as pancreatic 
endocrine tumours (PETs), pancreatic islet cell tumours or pancreatic islet cell 
carcinomas. They comprise less than 2% of all pancreatic cancers, and must be 
distinguished from the more common pancreatic adenocarcinomas, which have a 
poorer prognosis11,12. PNETs can secrete several hormones, dependent on the cell 
type of origin, and are therefore divided into functional and non-functional 
tumours. Tumours are referred to as functional in case of the presence of a clinical 
syndrome resulting from hormone production, e.g., gastrin, insulin, glucagon, 
vasoactive intestinal peptide (VIP) or somatostatin, by the tumour. In contrast, 
non-functional tumours can remain clinically silent for a relatively long time and 
are only detected when morbidity is caused by tumour mass leading to biliary 
duct obstruction, bowel obstruction, and development of metastases or invasion 
into adjacent organs2,12. Although PNETs have a relatively slow growing rate, the 
majority of tumours are malignant. Treatment of PNETs is directed to both the 
tumour and the associated clinical symptoms. Medical therapies like proton pump 
inhibitors and somatostatin analogues can control hormonal symptoms, whereas 




includes chemotherapy, hepatic artery or chemo-embolisation, radioablative  
therapy, and surgical resection2,13. 
 
Insulinomas 
Insulinomas are the most frequent occurring functional PNETs, and are primarily 
considered to be benign. They originate from the pancreatic beta-cells and are 
characterized by overproduction of the hormone insulin, leading to 
hypoglycemia-associated symptoms, like dizziness, lethargia and palpitations. The 
diagnosis of insulinoma can be established by determination of plasma insulin, 
proinsulin, C-peptide and glucose levels. Alternatively, a 48-72 hours fasting test 
can be performed to diagnose or exclude an insulin-secreting tumour2,14,15. About 
5-10% of the insulinomas are part of the hereditary MEN-1 syndrome, while the 
remaining part occurs sporadically. Females seem to be slightly more affected. 
Most insulinomas are located in the pancreas, with an equal distribution over the 
pancreatic head, body and tail. The prognosis for patients with insulinomas is 
relatively good, showing an overall 5-year survival around 97%16. 
 
Gastrinomas 
Gastrinomas are malignant gastrin-producing tumours, arising from the G-cells of 
the pancreas. Symptoms as dyspepsia, heart burn, diarrhea and peptic ulcers are 
the result of an increased gastrin production by the tumour, and are collectively 
named as the Zollinger-Ellison syndrome (ZES)15. ZES is seen more commonly in 
males than in females (ratio 3:2)16. Frequently, patients present with a long mean 
delay in diagnosis. With the widespread use of the proton pump inhibitors (PPIs) 
and other acid-suppressing medications, delays in presentation are even 
increasing. The diagnosis of ZES is suspected in case of increased fasting serum 
gastrin levels (hypergastrinemia), which have been reported to occur in 97% to 
99% of the patients17. However, in a large percentage of patients the fasting serum 
gastrin levels alone are not sufficient to diagnose ZES, and therefore additional 
testing is needed. The secretin stimulation test is considered as the most sensitive 





Although the majority of gastrinomas is located in the so-called gastrinoma 
triangle, the anatomical area comprising the pancreatic head, superior and 
descending portions of the duodenum and the nearby lying lymph nodes, other 
primary sites of gastrinomas that have been identified are stomach, jejunum, 
bilitary tract, kidneys, ovaries and liver19,20 (Figure 2). Gastrinomas occur mainly 
sporadic, although 30% of the tumours are part of the MEN-1 syndrome21. The 
peak incidence of gastrinomas lies between 40 and 50 years of age17. As 
gastrinomas have a relatively slow growth rate, 5- and 10-year survival rates are 
estimated to be 65% and 51%, respectively16. Even in case of metastatic disease, 
patients with gastrinomas have a relatively good chance of survival (5-year 
survival about 40% to 50%). However, patients with pancreatic gastrinomas show 
a worse prognosis than those with a gastrinoma located in the duodenum22.  
 
Figure 2. Gastrinoma triangle, which angles are formed by the cystic and common bile ducts, the 
junction of the neck and body of the pancreas, and the junction of the second and third portion of 
the duodenum. Figure adapted from Stabile et al.19  
 
Glucagonomas 
Glucagon-producing tumours, or glucagonomas, arise from the alpha-cells of the 
pancreas. Associated clinical symptoms are hyperglycemia, weight loss, anemia, 
venous thromboses and a typical skin rash called ‘necrolytic migratory erythema’ 
(NME)15. Glucagonomas are most frequently found in the pancreatic tail. 
Extrapancreatic glucagonomas are extremely rare16. Glucagonomas usually 




At time of diagnosis, metastases are found in approximately 60% to 70% of the 
patients16. Determination of glucagon serum levels contribute to the diagnosis of a 
glucagonoma (>500 – 1000 pg/mL)17.  
 
Somatostatinomas 
Somatostatinomas originate from the pancreatic delta-cells, and produce the 
hormone somatostatin. Although slow-growing, these tumours do show 
malignant behaviour. They occur mainly in the duodenum or pancreas, of which 
only tumours in the latter usually lead to a clinical syndrome17. Characterizing 
symptoms for the so-called somatostatinoma-syndrome are steatorrea, 
cholelithiasis, diabetes mellitus type-2 and hypochlorhydria. Somatostatinomas in 
the duodenum are often part of a genetic syndrome, such as the MEN-1 or 
neurofibromatosis (NF-1) syndrome15. No specific tests to establish the diagnosis 
of a somatostatinoma are available. Only pancreatic somatostatinomas are 
associated with elevated levels of somatostatin in plasma. Frequently, 
somatostatinomas are found by incidence, during gastrointestinal imaging studies 
for cholecystectomy or abdominal pain. The overall 5-years survival is about 75% 
or 60% in case of metastatic disease16.  
 
VIPomas 
VIPomas secrete vasoactive intestinal peptide (VIP), leading to the Verner-
Morrison syndrome or watery diarrhea hypokalemia achlorhydria (WDHA) 
syndrome. Symptoms characterized by WDHA are mainly the result of the severe 
secretory diarrhea, caused by the secretion of VIP, and are typically dehydration, 
hypokalemia and achlorhydria. Approximately 80% of VIPomas occur in the 
pancreas15, in particular the pancreatic tail47. Females are affected more frequently 
than males16.  Increased serum levels of VIP (>500 pg/mL) in combination with 
severe diarrhea are highly suggestive for VIPomas17. The 5-year survival rates for 
patients with VIPomas with or without metastases are estimated to be 60% and 






Other functional pancreatic neuroendocrine tumours 
Other functional PNETs include ACTHomas and GRFomas, which are both 
extremely uncommon16. ACTHomas secrete adrenocorticotrophic hormone 
(ACTH), leading to the Cushing’s syndrome. GRFomas produce growth-hormone 
releasing factor (GRF), and are characterized by acromegaly. Furthermore, PNETs 
can secrete calcitonin, enteroglucagon, cholecystokinin (CKK), gastric inhibitory 
peptide, gastrin-releasing peptide (GRP) and ghrelin, although rare16,17.  
 
Non-functional pancreatic neuroendocrine tumours 
Non-functional pancreatic neuroendocrine tumours comprise about 70% of all 
PNETs. These tumours are not related to any clinical syndrome caused by 
hormonal overproduction. However, they may show immunohistochemical 
positivity for hormones or neuropeptides, and frequently increased 
serum/plasma levels of chromogranin A or PP are found15,23. Whereas functional 
tumours cause symptoms relating to hormone production, non-functional 
tumours often cause tumour mass related complaints1. Furthermore, symptoms 
can be vague and aspecific, i.e., abdominal pain, anorexia, nausea and weight loss. 
Frequently, this leads to a delayed detection and the presence of local invasion 
and/or distant metastases at time of diagnosis. A small percentage of non-
functional PNETs are found incidentally at surgery or autopsy16. The majority of 
non-functional PNETs can be classified as well-differentiated neuroendocrine 
carcinomas23. It is important to distinguish these tumours from the more common 
and aggressive pancreatic adenocarcinomas. Most non-functional PNETs are 
located in the head of the pancreas. Non-functional PNETs can occur as part of the 
MEN-1 syndrome or may be associated with Von-Hippel Lindau disease (VHL). 
These tumours show a more aggressive course than their functional counterparts, 
although 5-year survival has been reported to lie around 65%16.  
 
Duodenal neuroendocrine tumours 
Duodenal NETs can generally be classified into five tumour types; gastrinomas, 




differentiated neuroendocrine carcinomas. The majority of these tumours occur in 
the first or second part of the duodenum. Duodenal NETs are usually small, i.e., 
<2cm in diameter. Although they are often limited to the (sub)mucosa, regional 
lymph node metastases can be found in about 40% to 60% of the patients. Liver 
metastases are seen less frequently (<10%). Duodenal NETs are usually single 
lesions. When multiple tumours are detected, the MEN-1 syndrome should be 
suspected. Functional syndromes are rare in these tumours, comprising mainly 
ZES or the carcinoid syndrome when they do occur24,25.  
 
Gastrointestinal neuroendocrine tumours 
Gastrointestinal neuroendocrine tumours (GI-NETs) are heterogeneous regarding 
histological differentiation, hormone production and biology. Frequently, GI-
NETs are referred to as carcinoids26. They derive from cells of the diffuse 
neuroendocrine system, and can be divided into serotonin-producing 
enterochromaffin (EC) or Kulchitsky’s cells, and the gastric histamine-secreting 
enterochromaffin-like (ECL) cells. Carcinoids are able to produce vasoactive 
substances like amines (serotonin, catecholamines, and histamine) and 
prostaglandins26,27. About only 10% of the carcinoid patients actually suffer from 
the classical carcinoid syndrome, characterized by symptoms as flushing, 
hypotension, diarrhea, wheezing, and heart disease, as a consequence of the 
serotonin secretion. GI-NETs occur predominantly in the gastrointestinal system 
(70%) or pulmonary tract (25%). Other known, but rare sites of GI-NETs are the 
ovaries, breast, larynx, thymus and gall bladder1. Among the gastrointestinal 
system, the small intestine and appendix are most commonly affected27-30.  
Dependent on their localization, GI-NETs can remain indolent for a long time. 
Frequently, symptoms arise when metastases have developed31.  
Besides the determination of chromogranin A levels, 5-HIAA measurements can 
aid in diagnosing serotonin-producing carcinoids. Although the specificity of the 
5-HIAA test is about 100%, sensitivity is only 35%. Treatment options for patients 





chemotherapy, and surgery. The decision for a medical or surgical approach is 
based on the location of the primary tumour, and the presence of metastases27-29.   
 
Multiple endocrine neoplasia type 1 syndrome (MEN-1 syndrome) 
The multiple endocrine neoplasia type 1 syndrome (MEN-1 syndrome) is an 
autosomal dominant inherited disorder, caused by mutations in the MEN-1 gene, 
located on chromosome 11q13. This syndrome is characterized by tumours in the 
parathyroid, pancreas, and anterior pituitary. Familial MEN-1 is defined as one 
patient with MEN-1 and one first-degree relative are affected with at least one 
tumour in one of the three key organs9.  
In 30% to 75% of the patients with MEN-1 pancreatic tumours are seen15. In 
particular gastrinomas are associated with this hereditary syndrome (20% to 60%), 
followed by insulinomas (30%) and VIPomas (5%). Non-functional PNETs occur in 
approximately 50% of the patients with MEN-1. MEN-1 related tumours occur at a 
relatively earlier age, and have a better prognosis compared to sporadic tumours. 
They may be multiple and vary in size from small microadenomas to large 
tumours23. Other hereditary syndromes which are associated with pancreatic or 
gastrointestinal neuroendocrine tumours are VHL-disease and tuberous sclerosis9. 
 
Neuropeptides 
GEP-NETs express a variety of peptide hormones and bioactive amines, including 
serotonin, chromogranin A, calcitonin, corticotrophin, neuron specific enolase, 
substance P, gastrin and bombesin-like peptides28,32. Bombesin was initially 
isolated from amphibian skin, and received its unusual name after the genus of the 
frog, i.e., Bombina bombina. Gastrin releasing peptide (GRP) and neuromedin B 
(NMB) are the mammalian analogs of bombesin, and belong to the family of 
bombesin-like peptides (BLPs)33. In humans, they are distributed in neural and 
endocrine cells, especially throughout the gastrointestinal tract. In addition to 
stimulating a variety of physiological responses in the human body, BLPs are 
involved in development and progression of several human cancers. For example, 




breast, cervix and prostate cancer cell lines, both in vivo and in vitro34,35. BLPs 
mediate their biological actions through binding to the G-protein coupled gastrin-
releasing peptide receptor (GRPR, BB2R), neuromedin B receptor (NMBR, BB1R), 
bombesin receptor subtype 3 (BRS3, BB3R) and bombesin receptor subtype 4 (BRS-
4, BB4R). Activation of various bombesin receptor subtypes has growth effects in 
both normal and neoplastic tissues, and several studies have reported an 
upregulation of bombesin receptors in tumour samples compared to associated 
normal tissue36-38.  
 
Angiogenesis 
Angiogenesis, the formation of new blood vessels from the existing vascular bed, 
is a physiological process involved in several events like wound healing and 
embryonic development39,40. Furthermore, it is a critical process for 
tumourigenesis, as tumours need the development of new blood vessels for their 
growth and further expansion41-44. Tumour cells stimulate mature blood vessels 
nearby to sprout new microvessels towards the tumour by production of 
angiogenic factors like transforming growth factor-beta (TGF-β), fibroblast growth 
factor (FGF) and vascular endothelial growth factor (VEGF). Obviously, 
angiogenesis provides the tumours with an efficient route of exit for tumour cells 
to leave the primary tumour, enter the blood or lymph stream and form 
metastases40 (Figure 3). In various cancers, increased vascular density has been 
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Figure 3. The process of angiogenesis in tumours step-by-step. 
a) Primary tumour; b) Tumour cells induce blood vessels to form microvessels in the direction of 
the primary tumour; c) Angiogenesis, the formation of new blood vessels from existing ones; d) 
Tumour cells escape from the primary tumour, enter the circulation (intravasation), and e) adhere 
to other blood vessels; f) Tumour cells leave the circulation (extravasation) and  migrate to other 
places; g+h); where they form (micro)metastases. Figure adapted from Zetter et al.44   
 
Vascular endothelial growth factor 
One of the key factors in angiogenesis is vascular endothelial growth factor 
(VEGF). VEGF has numerous effects on endothelial cells, including migration and 
differentiation47-49. Its physiological effects are mediated through binding to the 
VEGF receptor 1 (Flt-1) and VEGF receptor 2 (KDR) 50. Up-regulation of VEGF in 
tumours may result from oncogene activation, inhibition of tumour suppression 
factors, release of growth factors, hypoxia, or necrosis. VEGF primary acts as an 
endothelial cell mitogen and modulator of changes in vascular permeability, but 
also mediates the secretion and activation of enzymes involved in the degradation 








Endoglin, or CD105, is a transforming growth factor beta (TGF-β) receptor, which 
can bind TGF-β1 and TGF-β3 in the presence of the TGF-β receptor type II52-54. In 
the early stages of tumour formation, TGF-β inhibits the proliferation, 
differentiation and migration of cells, whereas endoglin counteracts these actions, 
thereby promoting angiogenesis55. Endoglin is predominantly expressed on 
endothelial cells of newly formed (angiogenic) blood vessels56. Its expression is 
up-regulated by hypoxia and TGF-β57. In several cancers, increased endoglin 




Matrix metalloproteinases (MMPs) are a group of proteolytic enzymes, involved 
in ECM degradation. In humans, at least 23 different MMPs are known. Based on 
their structure and their substrate preference, they are classified as gelatinases, 
collagenases, stromelysins, matrilysins, membrane-type MMPs, and others. MMPs 
are synthesized as pre-proenzymes. The expression of MMPs is transcriptionally 
controlled by inflammatory cytokines, growth factors, hormones, cell-cell 
interactions, and cell-matrix interactions. Next to their main function to degrade 
and remove ECM molecules from the tissue, MMPs are involved in pathologic 
processes like angiogenesis, tumour transformation and the development of 
metastases61,62.  
Matrilysin, or MMP-7, belongs to the subgroup of stromelysins. Matrilysin is 
secreted as pro-MMP-7, of which proteolytic removal of the 9 kDa prodomain 
from the N-terminus results in activation of the enzyme. Matrilysin is almost 
exclusively produced by epithelial tumour cells. Up-regulation of matrilysin in 
tumours is the consequence of mutations in the Wnt-signaling pathway63. 
Numerous studies have shown that matrilysin is significantly enhanced in several 
cancers, including breast, prostate, lung, skin, and colorectal cancer, and related to 






Insulin-like growth factor system 
The insulin-like growth factor (IGF) system is crucially involved in growth and 
development of tissues. Furthermore, by controlling cell cycle progression and 
preventing apoptosis, it plays an important role in tumourigenesis, tumour cell 
proliferation and metastatic spread65. The IGF-system is composed of two ligands, 
IGF-1 and IGF-2, three cell-surface receptors, IGF-1 receptor (IGF-1R), IGF-2 
receptor (IGF-2R), and the insulin receptor (IR), and a family of six IGF binding 
proteins (IGFBP-1 to IGFBP-6). IGFBPs are able to regulate the bioavailabity of the 
IGF ligands in the circulation. IGF-1 is predominantly produced in the liver, and 
has numerous functions. It acts as a mitogen and an anti-apoptotic survival factor, 
is involved in the glucose metabolism, and promotes cell migration. The effects of 
IGF-1 are predominantly mediated via the type I insulin-like growth factor 
receptor (IGF-1R), which can also bind IGF-2. Recent studies have shown that 
elevation of serum IGF-1 is associated with an increased risk of tumour 
development. Furthermore, IGF-1R has emerged as a key regulator of mitogenesis 
and tumourigenicity, because of its important role in cell transformation, tumour 
invasion, metastasis and cell survival enhancement65-67.  
 
Outline of the thesis 
Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are a group of 
uncommon and heterogeneous neoplasm, which show a large diversity in 
morphological, histocytopathological and clinical aspects. This thesis describes 
studies on the epidemiology, diagnosis, and pathogenesis of neuroendocrine 
tumours of the gastroenteropancreatic tract, in particular the pancreatic 
neuroendocrine tumours and the gastrointestinal carcinoids. The goal was to 
elucidate the mechanisms contributing to the diversity of GEP-NETs, and to 
investigate the role of various factors in the pathogenesis of these tumours  





















Figure 4. The processes associated with neuroendocrine tumour development, behaviour and 
progression, as discussed in this thesis, are depicted. As a result of gene mutations and the effects 
of growth factors produced by tumour cells, normal neuroendocrine tissue cells can proliferate and 
differentiate into a neuroendocrine tumour. Tumour processes like angiogenesis, tumour growth, 
metastases and the production of neuropeptides or hormones determine the clinicopathological 
behaviour and prognosis for the patients.  
 
An overview of the current diagnostic approach of GEP-NETs is given in  
Chapter 2. The need for a standardized diagnostic approach of GEP-NETs is 
advocated by the rise in incidence of these tumours, as illustrated in Chapter 3. 
This chapter describes an epidemiological study to the incidence of duodeno-
pancreatic neuroendocrine tumours from 1991 to 2009 in The Netherlands. 
Gastrinomas are the most frequent occurring type of malignant functional 
neuroendocrine tumours, usually located in the pancreatic region. However, 
Chapter 4 describes a case report of a patient suffering from the Zollinger-Ellison 
syndrome with recurrent gastrinomas in the liver, without evidence of any 





gastrinomas is highly questionable, an overview of all liver gastrinomas defined as 
primary in the literature is given. The diagnosis of a gastrinoma can be established 
by the use of the secretin stimulation test. Although this test is currently the most 
used diagnostic tool for gastrinomas, several aspects of this test have been 
debated. Chapter 5 describes an intra-individual comparison study using different 
dosages of secretin in patients and controls to investigate the most optimal 
criterion and secretin dosage for a positive secretin stimulation test to diagnose the 
Zollinger-Ellison syndrome.  
GEP-NETs are characterized by their ability to secrete neuropeptides, such as 
gastrin releasing peptide and neuromedin B, the mammalian counterparts of 
bombesin. A study on the expression of these bombesin-like peptides and their 
receptors in carcinoids of different origin, i.e., pulmonary and intestinal origin, is 
reported in Chapter 6. 
GEP-NETs are highly vascularized tumours. Angiogenesis, the formation of new 
blood vessels, is a crucial process in tumour development. Chapter 7 documents 
an investigation on the expression and role of vascular endothelial growth factor 
(VEGF) and endoglin (CD105), two key players in angiogenesis, in the 
tumourigenesis of GEP-NETs. 
In order to assess a potential growth activation process of GEP-NETs, the 
expression of insulin-like growth factor 1 (IGF-1), insulin-like growth factor 
binding protein 3 (IGFBP-3) and matrilysin (MMP-7) was also investigated. The 
role of this IGF-matrilysin network in the pathogenesis of GEP-NETs is described 
in Chapter 8.  
 
The aim of the studies described in this thesis was to identify markers with a role 
in the pathogenesis of GEP-NETs, which contribute to a better understanding of 
the biology, histopathology and complex heterogeneity of these tumours. 
Ultimately, these markers might assist in improved histological grading systems 
and classifications, advanced diagnostics and appropriately targeted treatment for 






1.  Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer 2004;11:1-
18. 
2.  Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle 
Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, 
Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72. 
3. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors 
(PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 
2008;19:1727-1733. 
4. Modlin IM, Moss SF, Oberg K, Padbury R, Hicks RJ, Gustafsson BI, Wright NA, Kidd M. 
Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. 
Med J August 2010;193:46-52.  
5. Franko J, Feng W, Yip L, Genovese E, Moser AJ. Non-functional neuroendocrine carcinoma 
of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest 
Surg 2010;14:541-548.  
6. Klöppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res 
Clin Endocrinol Metab 2007;21:15-31.  
7. Akerstrom G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin 
Endocrinol Metab 2007;21:87-109.  
8. Rockal AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res 
Clin Endocrinol Metab 2007;21:43-68.  
9. Starker LF, Carling T. Molecular genetics of gastroenteropancreatic neuroendocrine 
tumors. Curr Opin Oncol 2009;21:29-33. 
10. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system 
and its tumors: the WHO classification. Ann N Y Acad Sci 2004;1014:13-27. 
11. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors 
(PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 
2008;19:1727-1733. 
12. O’Grady H.L., Conlon K.C. Pancreatic neuroendocrine tumors. Eur J Surg Oncol 
2008;34:324-332. 
13. Mansour JC, Chen H. Pancreatic endocrine tumours. J Surg Res 2004;120:139-161.  
14. De Herder WW, Niederle B, Scoazec JY, Pauwels S, Kloppel G, Falconi M, Kwekkeboom 
DJ, Oberg K, Eriksson B, Wiedenmann B, Rindi G, O’Toole D, Ferone D. Well-
differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006;84:183-
188.  
15. Akerstrom G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin 





16. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 
2005;19:753-781.  
17. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: Pancreatic endocrine 
tumors. Gastroenterology 2008;135:1469-1492. 
18.  Lamers CB. Clinical usefulness of the secretin provocation test. J Clin Gastroenterol 
1981;3:255-259. 
19. Stabile BE, Morrow DJ, Passaro E Jr. The gastrinoma triangle: operative implications. Am J 
Surg 1984;147:25-31. 
20. Wu PC, Alexander HR, Bartlett DL, Doppman JL, Fraker DL, Norton JA, Gibril F, Fogt F, 
Jensen RT. A prospective analysis of the frequency, location, and curability of ectopic 
(nonpancreaticoduodenal, nonnodal) gastrinoma. Surgery 1997;122:1176-1182.  
21. Anlauf et al. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: 
Distinct clinico-pathological and epidemiological features. World J Gastroenterol 
2006;12:5440-5446. 
22. Klöppel G, Anlauf M. Gastrinoma – morphological aspects. Wien Klin Wochenschr 
2007;119:579-584.  
23. Falconi M, Plockinger U, Kwekkeboom DJ, Manfredi R, Korner M, Kvols L et al. Well-
differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 
2006;84:196-211. 
24. Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: Classification, 
functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol 
2005;19:675-697. 
25. Heymann MF, Hamy A, Triau S, Miraillé E, Toquet C, Chomarat H, Cohen C, Maitre F, Le 
Bodie MF. Endocrine tumors of the duodenum. A study of 55 cases relative to 
clinicopathological features and hormone content. Hepatogastroenterology 2004;51:1367-1371. 
26. Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of 
neuroendocrine tumours of the lung, páncreas and gut. Virchows Archiv 1995;425:547-560. 
27. Pinchot SN, Holen K, Sippel RS, Chen H. Carcinoid tumors. Oncologist 2008;13:1255-1269.  
28. Schnirer II, Yao JC, Ajani JA. Carcinoid-a comprehensive review. Acta Oncol 2003;42:672-
692. 
29. Pasieka JL. Carcinoid tumors. Surg Clin North Am 2009;89:1123-1137.  
30. Ghevariya V, Malieckal A, Ghevariya N, Mazumder M, Anand S. Carcinoid tumors of the 
gastrointestinal tract. South Med J 2009;102:1031-1040. 
31. Bodelier AG, Haak HR. Gastroenteropancreatic neuroendocrine tumours (carcinoid 





32.  Scott N, Millward E, Cartwright EJ, Preston SR, Coletta PL . Gastrin releasing peptide and 
gastrin releasing peptide receptor expression in gastrointestinal carcinoid tumours. J Clin 
Pathol 2004;57:189-192.  
33. Anastasi A, Erspamer V, Bucci M. Isolation and structure of bombesin and alytesin, 2 
analogous active peptides from the skin of the European amphibians Bombina and Alytes. 
Experientia 1971;27:166-167. 
34. Schulz S, Rőcken C, Schulz S. Immunohistochemical detection of bombesin receptor 
subtypes GRP-R and BRS-3 in human tumors using novel antipeptide antibodies. Virchows 
Arch 2006;449:421-7. 
35. Patel O, Shulkes A, Baldwin GS. Gastrin-releasing peptide and cancer. Biochimica et 
Biophysica Acta 2006;1766:23-41. 
36.  Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer J, Gugger M. Bombesin receptor subtypes 
in human cancers: Detection with the universal radioligand 125I-[D-Tyr6, β-Ala11, PHE13, 
NLE14] Bombesin(6-14). Clin Cancer Res 2002;8:1139-1146. 
37. Granberg D, Skogseid B, Welin S, Orlefors H, Oberg K, Wilander E. Gastrin-releasing-
peptide in neuroendorine tumours. Acta Oncol 2006;45:23-27. 
38. Scott N,  Millward E, Cartwright EJ, Preston SR, Coletta PL. Gastrin releasing peptide and 
gastrin releasing peptide receptor expression in gastrointestinal carcinoid tumours. J Clin 
Pathol 2004;57:189-192. 
39. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285: 1182-86. 
40. Folkman J, Holland JF, Bast RC, Morton DL et al. Tumor angiogenesis. Cancer Medicine 
1996;1:181-204. 
41. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Nat Cancer Ins 
1990;82:4-6. 
42. Giatromanolaki A, Sivridis E, Koukourakis MI. Angiogenesis in colorectal cancer: 
prognostic and therapeutic implications. Am J Clin Oncol 2006;29:408-417. 
43. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 
2003;3:401-410. 
44. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998;49: 407-424. 
45. Sun XF and Zhang H. Clinicopathological significance of stromal variables: angiogenesis, 
lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas. 
Mol Cancer 2006;5:43. 
46. Miller DW, Graulich W, Karges B, Stahl S, Ernst M, Ramaswamy A,  Sedlacek HH, Muller 
R, Adamkiewicz J. Elevated expression of endoglin, a component of the TGF-beta-receptor 
complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 1999;81:568-
572. 





48. Risau W. Angiogenic growth factors. Prog Growth Factor Res 1990;2:71-79. 
49. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999;9:211-220. 
50. Carmeliet P. VEGF as key mediator of angiogenesis in cancer. Oncology 2005;69:4-10. 
51.  Neufeld G, Cohon T, Gengrinovitch S, Poltorak. Z. FASEB J 1999;13:9-22. 
52. Lastres P, Letamendía A, Zhang H, Rius C, Almendro N, Raab U, López LA, Langa C, 
Fabra A, Letarte M, Bernabéu C. Endoglin modulates cellular responses to TGF-β1. J Cel 
Biol 1996;133:1109-1121. 
53. Letamendía A, Lastres P, Botella LM, Raab U, Langa C, Velasco B, Attisano L, Bernabéu C. 
Role of endoglin in cellular responses to transforming growth factor-beta. A comparative 
study with Betaglycan. J Biol Chem 1998;273:33011-33019.  
54. Cheifetz S, Bellón T, Calés C, Vera S, Bernabéu C, Massaqué J, Letarte M. Endoglin is a 
component of the transforming growth factor-β receptor system in human endothelial 
cells. J Bio. Chem 1992;267:19027-19030.  
55. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer 
progression. Nat  Genet  2001;29:117-129, 2001. 
56. Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T, Tokunaga O. Endoglin (CD105) 
expression in angiogenesis of colon cancer: analysis using tissue microarrays and 
comparison with other endothelial markers. Virchows Arch  2006;448:127-134. 
57. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabéu C. Endoglin expression is 
regulated by transcriptional cooperation between the hypoxia and transforming growth 
factor-beta pathways. J  Biol Chem  2002;277:43799-43808.  
58. Zijlmans HJ, Fleuren GJ, Hazelbag S, Sier CF, Dreef EJ, Kenter GG, Gorter A. Expression of 
endoglin (CD105) in cervical cancer. Br J Cancer 2009;100:1617-1626. 
59. Yoshitomi H, Kobayashi S, Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Miyazaki M. 
Specific expression of endoglin (CD105) in endothelial cells of intratumoural blood and 
lymphatic vessels in pancreatic cancer. Pancreas 2008;37:275-281.  
60. Romani AA, Borghetti AF, Del Rio P, Sianes M, Soliani P. The risk of developing metastatic 
disease in colorectal cancer is related to CD105-positive vessel count. J Surg Oncol 
2006;93:446-455. 
61. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and 
TIMPs. Cardiovas  Res  2006;69:562-573. 
62. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix 
metalloproteinases: an overview. Mol  Cell  Biochem  2003;253:269-285. 
63. Wilson CL, Matrisian LM. Matrilysin: an epithelial matrix metalloproteinase with 




64. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix 
metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and 
angiogenesis. Exp Biol Med (Maywood) 2006;231:20-27. 
65. Le Roith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 
2003;195:127-137. 
66. Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C, Church D, Hassan AB. 
Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 
2005;205:145-153.  
67. Vitale L, Lenzi L, Huntsman SA, Canaider S, Frabetti F, Casadei R, Facchin F, Carinci P, 
Zannotti M, Coppola D, Strippoli P. Differential expression of alternatively spliced mRNA 







An Overview of the Current Diagnosis and Recent 
Developments in Neuroendocrine Tumours of the 
Gastroenteropancreatic Tract:                                                 
the Diagnostic Approach  
 
Patricia Kuiper1, Hein W. Verspaget1, Lucia I.H. Overbeek2,  
Izäk Biemond1, Cornelis B.H.W. Lamers1 
 
1Department of Gastroenterology and Hepatology, 
















Neuroendocrine tumours of the gastroenteropancreatic tract (GEP-NETs) 
comprise a group of very heterogeneous neoplasms, which are considered ‘rare 
diseases’. Epidemiological studies on the incidence of GEP-NETs worldwide have 
reported a remarkable increase in the detection of these tumours.  
In a recent study, based on pathology reports (PALGA) to investigate the 
incidence of pancreatic and duodenal neuroendocrine tumours in The 
Netherlands from 1991 until 2009, we also noticed a significant increase in the 
incidence of these tumours. In particular, the incidence of non-functioning 
neuroendocrine tumours had significantly increased over this period. Remarkably, 
a substantial discrepancy was observed between the numbers of neuroendocrine 
tumours diagnosed in the clinical as opposed to the pathological setting, 
emphasizing that these tumours provide a real diagnostic challenge. To improve 
the diagnosis of GEP-NETs, we advocate that these complex neoplasms should 
receive more specialized attention.  
In this mini-review we provide an overview of the current diagnostic approach of 
GEP-NETs, and added the recent developments in establishing the diagnosis of 
these tumours, in order to increase the intelligibility and awareness of GEP-NETs 
among clinicians and pathologists. Early detection in order to prevent morbidity 



















Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are considered to be 
rare, heterogeneous and complex neoplasms1. They include the pancreatic 
(PNETs) and gastrointestinal (GI) neuroendocrine tumours (GI-NETs) or 
carcinoids, which share their origin of cells of the diffuse neuroendocrine system, 
but further show many differences regarding pathogenesis, clinical behaviour and 
prognostic outcome2,3. Characteristic for GEP-NETs is their ability to produce 
bioactive substances (Table 1)4. Based on the clinical symptoms and syndrome 
caused by these peptides, they can be divided into functioning (F-NETs) and non-
functioning tumours (NF-NETs). Due to their heterogeneity, GEP-NETs often 
provide a diagnostic challenge to physicians. Although GEP-NETs are generally 
more indolent than carcinomas, the majority are malignant, showing aggressive 
tumour behaviour and presenting with metastases at diagnosis1. GEP-NETs can 
occur sporadically, or as part of a hereditary syndrome like Multiple Endocrine 
Neoplasia syndrome type 1 (MEN-1), von-Hippel Lindau Disease (vHLD), 
neurofibromatosis type 1, or tuberous sclerosis5.  
In 2007, a summit meeting on the major clinical, pathological and scientific 
challenges in the field of GEP-NETs was held to debate on potential solutions6. 
There was consensus between the participants that there is a worldwide 
substantial lack of knowledge, experience and reliable research concerning GEP-
NETs. In line with these observations, we feel that also in our country, GEP-NETs 
indeed present a relatively unknown and underdeveloped subject with fairly 
limited knowledge under most physicians. However, since several 
epidemiological studies have shown an increase in the incidence of GEP-NETs 
worldwide, in combination with the fact that these tumours, when accurately 
managed, provide a relatively good prognosis for the patients, we feel that it can 
be worth to increase the awareness for and knowledge about GEP-NETs among 
clinicians and pathologists, in order to further increase the early detection and 




In this mini-review, we describe the current diagnostic approach of GEP-NETs, in 
combination with several common pitfalls and some recent developments to 
improve the diagnosis of these tumours. In addition, we provide a diagnostic 
algorithm to facilitate their diagnostic approach.   
 
Epidemiology 
Based on pathology information from PALGA the nationwide network and 
registry of histo- and cytopathology in The Netherlands, we calculated incidence 
of GEP-NETs from 2000 till 2008 in The Netherlands8,11. For both pancreatico-
duodenal NETs and GI-NETs a significant increase in incidence over time was 
noticed (Figure 1).  
 
Figure 1. Incidence of GEP-NETs from 2000 till 2008






































Figure 1. Current incidence of GEP-NETs in The Netherlands from 2000 till 2008. Using linear 
regression, trends in annual incidence rates over 2000 till 2008 were analyzed. A statistically 
significant increase was observed in the overall annual incidence of all GEP-NETs, and                 
GI-NETs and pancreaticoduodenal NETs separately, over the study period. 
 
However, these calculated incidence rates are based on pathology information 
only and therefore might represent an underestimation. In our study, we found 
that this was approximately 25%, due to the fact that some patients with clinically 




diagnosed gastrinomas were not included in the PALGA database, because they 
had not undergone any surgery, biopsy and/or other pathological evaluation for 
their tumour8. This discrepancy between clinical and pathology incidence of GEP-
NETs is an important issue concerning these tumours, which will be discussed 
later. Nonetheless, this pattern of increasing incidence rates indicates and confirms 
that GEP-NETs might not be as rare as previously thought. Whether this increase 
is due to improved detection methods rather than to a true rise in existence of 
these tumours is debatable. In that context it is important to note that we observed 
that 4% and 14% of the GI-NETs and pancreaticoduodenal NETs respectively, 
were found by incidence at autopsy, which indicates that, despite of improved 
detection methods, some GEP-NETs still do remain undetected.  
 
Current diagnostic procedure for GEP-NETs  
Symptoms of patients with GEP-NETs are in general related to the localization 
and hormonal production of the tumour1. Frequently, symptoms are vague and 
aspecific, although symptoms associated with a clinical syndrome may arise 
suspicion for a F-PNET (Table 1)1. 
Next to standard medical history and physical examination, laboratory analyses 
are crucial in the diagnosis12,13. To diagnose NETs, chromogranin A (CgA) levels 
can be determined in plasma/serum, or immunohistochemically14,15. Increased 
plasma/serum levels of CgA have been reported to correlate with a worse 
prognosis in these patients. Increased levels of 5-hydroxyindoleacetic acid (5-
HIAA, the breakdown product of serotonin) can be determined in a 24-hours 
urine sample collection, and indicate the presence of a serotonin-producing 
tumour. Increased levels of hormones like insulin, indicate the presence of a 










Table 1. Symptoms and syndromes associated with GEP-NETs1-4 
 
 
Gastrointestinal neuroendocrine tumours 
Functioning neuroendocrine tumours Non-functioning neuroendocrine 
tumours 
Carcinoid 
Flushing, diarrhoea, and wheezing 
Abdominal pain, weight loss, anorexia, 
jaundice, nausea and vomiting, intra-
abdominal haemorrhage 
 
Pancreatic neuroendocrine tumours 
Functioning neuroendocrine tumours 
Insulinoma 
Neuroglycopenic symptoms like headache, blurred vision, confusion, dizziness, lethargy, and 
amnesia. Autonomic nervous system symptoms like sweating, weakness, anxiety, tremor, 
palpitations, and nausea  
 
Gastrinoma 
Diarrhoea, abdominal pain, heartburn, weight loss, nausea and vomiting, faecal blood loss 
Glucagonoma 
Necrolytic Migratory Erythema, Diabetes Mellitus, cachexia 
VIPoma 
Watery diarrhoea, hypokalemia, achlorhydria, hyperglycaemia, hypercalcemia, flushing 
Somatostatinoma 
Diabetes Mellitus, cholelithiasis, steathorrea, anaemia, weight loss 
 










Non-functioning neuroendocrine tumours 
Abdominal pain, weight loss, anorexia, jaundice, nausea and vomiting, intra-abdominal 
haemorrhage 
 
Table 1. Overview of all symptoms and syndromes associated with GEP-NETs. 
 
Imaging of GEP-NETs includes endo- or gastroscopy, octreoscan, computerized 
tomography (CT) scan, or magnetic resonance imaging (MRI) scan16. 
Pathological examination of biopsies or surgical specimens reveal the verification 
of the neuroendocrine nature of the tumour by immunohistochemistry, for pan-
neuroendocrine markers like keratin, CgA, neuron specific enolase (NSE), 
synaptophysin, grimelius, and CD56. A proliferation marker (Ki67 or MIB1) must 




be used to assess the degree of differentiation and proliferation, to grade the 
tumours according the World Health Organization (WHO) classification17. 
Tumour characteristics like localization, size, composition, relationship to 
anatomic structures, resection margins, and the presence of metastases, should be 
assessed in order to classify the tumour along the TNM stage classification4. 
 
Pitfalls in the diagnosis of GEP-NETs 
One of the major pitfalls in the nomenclature of neuroendocrine tumours is the 
use of the term ‘carcinoid’. In 1907, Oberndorfer introduced this term for 
neuroendocrine tumours with a relatively ‘benign’ course18. Increasing knowledge 
about these tumours, however, had led to the conclusion that carcinoids also 
encompasses low-grade and high grade malignant tumours. Therefore, Soga et al. 
called the term ‘carcinoid’ a ‘misnomer’19. In fact, this term has been used for 
different goals; whereas pathologists label all tumours with neuroendocrine 
features as a ‘carcinoid’, clinicians use ‘carcinoid’ for serotonin-producing tumours 
that lead to the carcinoid syndrome. Therefore, Capella et al. suggested replacing 
‘carcinoid’ by ‘neuroendocrine tumour’ to include all tumours with 
neuroendocrine features, but also realized that abandoning this term completely 
would be too confusing, and therefore proposed to utilize it for the specification of 
a NET with serotonin production or producing any other substance which may 
lead to the carcinoid syndrome20. As a consensus in the use of the GEP-NETs 
nomenclature is highly desirable, we propose that henceforth 1) the term 
‘carcinoid’ should be used solely in the clinical setting, and only for those tumours 
that lead to the carcinoid syndrome as a result of the hypersecretion of serotonin, 
prostaglandins, or tachykinins by the tumour, characteristic of symptoms like 
flushing, diarrhoea and wheezing; 2) pathologists distinguish the various types of 
neuroendocrine tumours; neuroendocrine tumours should be defined according to 
the classification of the WHO, thereby replacing ‘carcinoid’ by ‘neuroendocrine 
tumour’ for well-differentiated low-grade malignant carcinoids, whereas 




Another misunderstanding among pathologists and clinicians has arisen due to 
the lack of a standardized definition of functioning and non-functioning tumours, 
as pointed out by Halfdanarson et al.  Although non-functioning tumours are 
characterized by the lack of a clinical syndrome, they might secrete hormonal 
peptides as well, but only those tumours leading to clinical symptoms are referred 
to as functioning7. For example, increased blood levels of pancreatic polypeptide 
or neurotensin can be found in NF-PNETs21. Warner et al. already reported that 
plasma hormone levels not always correlate with the presence of a clinical 
syndrome22. For example, in case of the Zollinger-Ellison syndrome, fasting serum 
gastrin levels may be non-diagnostic (i.e., <1000 ng/L), or symptoms might be 
masked by the use of proton pump inhibitors or histamin receptor antagonists, or 
pernicious anaemia. Furthermore, it is reported that the hormonal secretion by the 
tumour is not always reflected in immunohistochemical staining for this hormone 
at pathology23. For a standardized approach, we recommend that the clinical 
diagnosis is superior to the pathological observations concerning the designation 
of the tumour as ‘functioning’ or ‘non-functioning’. In other words, in the absence 
of immunohistochemical positivity for a certain hormone in combination with 
increased serum levels of that particular hormone and/or the presence of a clinical 
syndrome, the tumour should be defined as ‘functioning’. In the opposite 
situation, i.e., a positive staining at pathology, but absence of increased serum 
levels and/or a clinical syndrome, the clinical presentation should be decisive, and 
the tumour should be defined as ‘non-functioning’.    
Next, the existence of ‘benign’ GEP-NETs is disputed. Whereas the majority of 
GEP-NETs are considered to be malignant, insulinomas and appendiceal 
carcinoids are not. However, we believe that all GEP-NETs have malignant 
potential, and that early diagnosis of these tumours, because of the symptoms they 
cause, leads to the assumption that they are benign. Namely tumour size and/or 
invasion, and the presence of metastases, all characteristics which can be 
‘prevented’ by early detection, makes a tumour to be referred to as malignant.17,20 
The fact that the majority of NF-NETs have a poor prognosis underlines that 




absence of clinical symptoms leads to a delay in diagnosis and a consequently 
more progressed tumour.  
Another difficulty in diagnosing GEP-NETs arises as these tumours show a 
relative high frequency of ‘ectopic occurrence’. For example, gastrinomas, which 
are usually located in the pancreaticoduodenal region and lymph nodes, have 
been reported on ectopic locations such as ovaries, biliary tract, kidneys, stomach 
and liver24. Recently, we reported on a patient with recurrent hepatic gastrinomas, 
in whom no pancreatic, duodenal or other primary tumour could be detected 
despite of an intensive, 20-year lasting follow-up25. In literature, primary hepatic 
gastrinomas were described in about 20 patients, but real evidence for their 
primary origin (rather than being metastatic) was lacking. We believe that it is 
therefore uncertain whether these ectopic locations comprise primary gastrinomas 
rather than metastases of occult primaries. Furthermore, GEP-NETs have been 
reported on rare locations like oesophagus, gallbladder and biliary ducts, Meckel’s 
diverticulum, ampulla of Vater, genital tract and skin26,27. Lack of awareness that 
neuroendocrine lesions can also occur on these unusual sites results in the 
consequence that these tumours are frequently misdiagnosed or overlooked27. 
Therefore, we recommend that when imaging is not successful to detect a 
neuroendocrine tumour in usual sites, an intensive search for occult tumours at 
ordinary sites should be started.  
Additionally, it is important to realize that GEP-NETs frequently occur as or 
together with a second primary malignancy28. The presence of a simultaneous 
second primary or metastatic malignancy must be thoroughly examined, as 
several case reports describe the existence of a second tumour synchronous with a 
carcinoid lesion28-32. For example, gastrointestinal stromal tumours (GIST) are 
frequently seen in combination with (gastric) carcinoids29,31. Furthermore, patients 
suffering from hereditary syndromes like MEN-1, vHL-disease, neurofibromatosis 
type 1 or tuberous sclerosis, are at increased risk for a gastroenteropancreatic NET.  
Therefore, alertness for synchronous (neuroendocrine) tumours among clinicians 
is advocated. Furthermore, members from hereditary GEP-NET disorder families 




possible, DNA profile, or by measurement of markers for these or associated 
tumours. 
 
Recent developments in the diagnosis of GEP-NETs 
As CgA is produced by all types of neuroendocrine cells, it serves as a highly 
sensitive neuroendocrine cell marker14,15. In 2006, Kidd et al. demonstrated that 
also CgA mRNA and protein levels were useful in the detection of gastrointestinal 
carcinoids and metastases33. Recently, Modlin et al. showed that measurement of 
circulating mRNA of CgA (and other markers such as Tph1 and NSE) provides a 
promising new diagnostic method for NETs34. Next to CgA, several studies to 
other markers have been reported. In particular, investigators are interested to 
find markers which can discriminate between the diverse GEP-NET subtypes. 
Long et al. demonstrated that PAX8 might be a useful immunohistochemical 
marker in the discrimination of pancreatic and ileal NETs, as the latter lack 
expression of this transcription factor35. However, Hosoda et al. found that 
immunohistochemistry on EUS-biopsy specimens using a selected panel of 
markers, including CK-7, CDX-2, synaptophysin, CgA, and the KRAS mutational 
status, could be used to discriminate endocrine tumours from two other major 
types of pancreatic cancers (i.e., invasive ductal carcinoma and acinar cell 
carcinoma) 36. A comparable study was performed by Burford et al., who found 
that strong immunohistochemical expression for E-cadherin and B-catenin were 
characteristic for PNETs, and could be used to discriminate from solid 
pseudopapillary neoplasm, in which staining is absent37. Another selected panel, 
including CDX-2, NESP-55, TTF-1 and PDX-1, was described to be useful to 
discriminate between metastatic NETs of pancreatic, gastrointestinal and 
pulmonary origin, in a study of Srivastava et al. 38. In contrast, Fendrich et al. found 
that PDX-1 expression was present in pancreatic but not duodenal gastrinomas, 
and PDX-1 expression in combination with Shh and PP expression in resected 
metastases might aid to locate undetected or occult primary gastrinomas39. 
However, all above mentioned studies are non-conclusive, and further research 
and validation studies are needed before these diagnostic tools can be used in 




practice. Based on a literature review and analysis to the utility of plasma/serum 
CgA measurements in NETs, Modlin et al. concluded that CgA still serves as the 
most specific (86%) and sensitive (68%) biomarker in plasma/serum to diagnose 
NETs that is currently available40. 
The improvement of imaging techniques is one of the most probable explanations 
for the incidence increase of GEP-NETs. For example, in a study of Ishikawa et al., 
endoscopic ultrasound combined with contrast enhancement showed the best 
results in the preoperative localization of PNETs in comparison with other 
imaging techniques, like CT and US41. Prasad et al. reported that occult primary 
NETs could be detected by PET/CT using 68Ga-DOTA-NOC receptor in 59% of 
patients with confirmed NETs on biopsies from metastatic lesions, which was 
approximately three times higher than with CT alone42.  
Also on the field of genetic and molecular pathology, research is ongoing. 
Previously, three detailed review articles that describe recent advances in the 
molecular genetics of sporadic and familial GEP-NETs, were reported5,43,44.  
Therefore, this review will not discuss this subject into detail. 
 
Diagnostic algorithm 
The algorithm comprises a clinical and a pathological part. Although the 
pathological evaluation is important in the diagnosis, the clinical presentation 
largely determines the definition of a NET. However, we advocate an 
interdisciplinary cooperation between clinicians and pathologists in the diagnostic 
approach of GEP-NETs.  
Although research to specific biomarkers to detect GEP-NETs is ongoing, studies 
are still inconclusive. Therefore, we recommend CgA as a highly specific and 
sensitive neuroendocrine marker in the diagnosis of NETs. CgA measurement in 
plasma/serum, and immunostaining for this marker on biopsy or surgical 
specimens, should be performed routinely by clinicians and pathologists, 
respectively, in order to adequately diagnose (or exclude) a NET.  
Imaging techniques to detect NETs are improving. The use of various imaging 




modalities including PET-scan can be used in the localization of a NET. 
Repeatedly negative imaging results in detecting a primary NET should raise the 
suspicion of a physician for an ectopic localized NET. Furthermore, the presence 
of a secondary tumour should be investigated, in particular when a hereditary 
syndrome is present.  
For standardized documentation and in order to determine the therapeutic 




GEP-NETs compose a complex and heterogeneous tumour entity, which form a 
diagnostic challenge to physicians. In this review, we aimed to provide a clear 
overview of current diagnostic procedures and common pitfalls for GEP-NETs. 
Taking some recent diagnostic developments in account, we propose a diagnostic 
algorithm for GEP-NETs, to generate a more standardized diagnostic approach, 
























Figure 2. Diagnostic algorithm for GEP-NETs. Based on the current diagnostic approach, and 
inclusion of several pitfalls and various recent developments in the diagnosis of GEP-NETs, we 
provided a diagnostic algorithm to adequately diagnose these tumours.  




I. CLINICAL DIAGNOSIS 
1. Detailed personal history and physical examination 
See Table 1 for an overview of symptoms related to the various types of  
GEP-NETs. 
 
2. Determine localization if possible, using; 
-EUS or endoscopy in combination with CT-scan or MRI-scan 
-Somatostatin Receptor Scintigraphy or Octreoscan 
 
à Positive imaging: Continue with 3 
à Negative imaging: Thorough search for occult tumours at unusual locations,  
continue with 3 
 
3. Measure plasma or serum CgA levels 
To verify the neuroendocrine nature of tumour 
 
4. Measure hormone levels in serum 
To detect possible peptide production by the tumour in order to define the tumour as ‘functioning’ 
or ‘non-functioning’. 
 
Note: Only define a tumour as a ‘carcinoid’ in case of increased serotonin serum levels and/or 
urinary 5-HIAA elevations, and/or the presence of the classical ‘carcinoid syndrome’  
(Table 1). 
 
5. Confirm diagnosis with a specific diagnostic test 
Positive test: Diagnosis confirmed, continue with II 
Negative test: consider non-functioning tumour and/or differential diagnosis, continue with II 
 
6. Investigate the presence of a hereditary syndrome 
-Detailed family history 
-Investigation for associated tumours and/or lesions 
-Gene testing 
Note: Consider the presence of synchronous tumours in case of gastric carcinoids (GISTs) or the 








II. PATHOLOGICAL DIAGNOSIS 
1.Immunostaining 
-Staining for general NE markers including chromogranin A, 
synaptophysin, neuron specific enolase (NSE), keratin and grimelius, to determine the 
neuroendocrine nature of the tumour. 
 
Note: For the definition of a neuroendocrine tumour, at least one of above mentioned general 
neuroendocrine markers should show a positive staining 
 
-In case of a clinical (diagnosis or suspicion for) functioning tumour; 
Stain for specific hormones including serotonin, gastrin, insulin, glucagon, somatostatin,  
and/or VIP 
 
Note: Be aware that, also in case of a clinical functioning tumour, immunohistochemical staining for 
the particular hormone can be absent. Immunohistochemical staining should aid in determining 
the diagnosis, and determine the actual diagnosis. 
 
2. Determine WHO-classification 
-Determination of proliferation index by Ki67 or MIBG1 
-Determination of mitotic count 
-Investigate tumour characteristics; 
*size 
*histological pattern 




Note: Define the tumour as NET or NEC, not carcinoid. The term carcinoid should only be 
designed (by clinicians) to tumours with serotonin production and/or in the presence of the 
classical carcinoid syndrome (Table 1). 
 
3. Determine TNM stage 
-Determine tumour localization 
-Determine tumour size 
-Determine invasion of the tumour into surrounding organs/structures 
-Determine the presence of lymph node metastases 
-Determine the presence of distant metastases 
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Duodeno-pancreatic neuroendocrine tumours are rare, although current 
epidemiological studies worldwide suggest an incidence increase. We assessed the 
pathological incidence of duodeno-pancreatic neuroendocrine tumours over 18 
years in The Netherlands.  
Standardized excerpts from pathology reports of all patients diagnosed with 
duodeno-pancreatic neuroendocrine tumours from 1991 until 2009 were collected 
from PALGA and reviewed. This nationwide network and registry of histo- and 
cytopathology covers 100% of the pathology reports in The Netherlands. 
We identified 905 patients with pancreatic (n=692) or duodenal (n=213) 
neuroendocrine tumours. The majority of these patients (69.4%) had a non-
functional tumour. Functional tumours were diagnosed at a younger age 
compared to non-functional tumours (mean age ± s.d. 52.3 ± 17.7 years versus 60.0 
± 14.6 years, respectively, P<0.01). The average annual incidence per 1,000,000 
persons over 1991 to 2009 was 2.54 for pancreatic and 0.81 for duodenal 
neuroendocrine tumours. The highest incidence was found in patients 65 to 79 
years of age. The incidence of non-functional neuroendocrine tumours had 
increased significantly over two decades, P<0.01.  
The incidence of duodeno-pancreatic non-functional neuroendocrine tumours in 
The Netherlands increased over 1991 to 2009. The etiology for this change includes 
















Duodeno-pancreatic neuroendocrine tumours comprise a very heterogeneous 
group of neoplasms, with regard to morphologic, functional and behavioral 
features1. In 2000, the World Health Organization (WHO) introduced a 
classification for neuroendocrine tumours (NETs) of the gastroenteropancreatic 
tract using histopathological characteristics and tumour behaviour to categorize 
these tumours per site2.   Duodeno-pancreatic NETs are referred to as functional 
(or functioning) in case of the presence of a clinical syndrome resulting from 
ectopic hormone production, e.g., gastrin, insulin, glucagon, vasoactive intestinal 
peptide (VIP) or somatostatin, by the tumour, whereas non-functional NETs are 
not associated with a hormonal syndrome. Although these latter tumours may 
secrete biologic substances, like pancreatic polypeptide (PP) and chromogranin A, 
non-functional NETs can remain clinically silent for a relatively long time, and are 
only detected when morbidity is caused by tumour mass leading to biliary duct 
obstruction, bowel obstruction, and development of metastases or invasion into 
adjacent organs3,4. Duodeno-pancreatic NETs may be sporadic or component of 
the more comprehensive Multiple Endocrine Neoplasia type 1 syndrome (MEN-1), 
of which hyperparathyroidism and pituitary tumours are other frequent 
manifestations5. Although duodeno-pancreatic NETs have been considered as rare 
tumours, incidence rates have been reported to be increased substantially over the 
past years6-8. Furthermore, a high number of incidental findings of clinically silent 
duodeno-pancreatic NETs by autopsy studies was suggested9,10. Therefore, current 
incidence rates of duodeno-pancreatic NETs are likely to represent an 
underestimation. In the present study we aimed to provide insights into the 
epidemiology of both pancreatic and duodenal NETs in The Netherlands over a 
period of approximately 20 years. Therefore, we have carried out a search in the 
nation-wide network and registry of histo- and cytopathology in The Netherlands, 







Materials and Methods 
Collection of data by PALGA 
Data were collected from PALGA, the nationwide network and registry of histo- 
and cytopathology in The Netherlands11. This computerized database for 
pathology reports was founded in 1971, and since the participation of all 
pathology laboratories in 1991, national coverage was achieved. Currently, the 
PALGA databank contains about 50.5 million excerpts on nearly 11 million 
patients, with an annual addition of more than two million excerpts. A 
decentralized computer system collects the pathology reports from every 
pathology institution in The Netherlands automatically, and reports are sent to the 
central database on a daily basis. Reports are converted to excerpts that contain a 
limited number of encrypted patient data, a report identifier, (part of) the 
conclusions and the so called PALGA diagnosis, a coded diagnosis line based 
upon standard pathology terminology, containing topography (localization), 
morphology (nature of tissue change), etiology, function (functional abnormality), 
procedure and diseases. Encryption of the identifiers secures the patient’s and 
participating laboratory’s privacy.  
Our search was directed to patients filed with a histological proven diagnosis of a 
neuroendocrine tumour in pancreas or duodenum between January 1991 and 
December 2008. For each excerpt, gender, date of pathology intervention, 
conclusion first sentences and diagnosis line were made available for retrospective 
analysis. Terms used for this search query were ‘gastrinoma’, ‘insulinoma’, 
‘glucagonoma’, ‘APUDoma’, ‘neuroendocrine tumour of digestive tract’ and 
‘pancreas’ or ‘pancreatic islets’ and ‘duodenum’ in combination with ‘malignant 
endocrine tumour’. A query to identify patients with the MEN-1 syndrome, 
including hyperparathyroidism, was additionally performed under these patients.  
Excerpts described several pathologic interventions, e.g., biopsies, punctures, 
resections autopsies or revisions of a pathologic report. Some patients had 
multiple excerpts included in the database, but were analyzed as one patient.  
 
 




Histological proof of tumour diagnosis 
The routine procedure for neuroendocrine tumours at pathology starts with the 
identification of the epithelial and neuroendocrine nature of the tumour by 
immunohistochemical staining, with markers like keratin, chromogranin A, 
grimelius, synaptophysin, etc. Based on the presence of clinical symptoms or 
syndrome, hormonal production by the tumour is evaluated, to exactly reveal the 
tumour type (i.e., gastrinoma, insulinoma, etc.). As a consequence, tumours are 
classified on immunopostivity for hormonal markers and clinical symptoms or 
syndrome as specific tumour type. 
 
Incidence calculations 
The incidence rates were calculated as the number of new cases per 1,000,000 
persons, adjusted to general population data as obtained by the Dutch Central 
Bureau for Statistics (CBS)12. Data that were drawn from the CBS included age and 
sex of the total number of residents in The Netherlands per year, annual mortality 
rates and number of deaths caused by pancreatic malignancies. Age distribution in 
Table 2 was chosen referring to the distribution of the CBS, i.e., <20 years, 20-39 
years, 40-64 years, 65-79 years and >80 years.  The ‘not reported’ data refer to the 
use of excerpts, whereas complete pathology reports were not assessed because of 
privacy reasons. During the last three decades, the Leiden University Medical 
Centre has been the nationwide referral centre for patients with gastrinomas in 
The Netherlands. All patients diagnosed with or suspected of a gastrinoma, 
treated in our hospital, were traced and revised, to assess the extent of incidence 
underestimation based on pathology reports. 
 
Statistical analysis 
Statistical analysis was performed using Statistical Package for Social Sciences 
version 16 (SPSS) and GraphPad version 5. Results were reported as mean ± 
standard deviation (s.d.) or median, when appropriate. Using linear regression 
analysis, trends in annual incidence rates over the study period of 18 years were 







As a result of the search query, 1529 excerpts of 1263 patients were found between 
1991 and 2009. Patients with extrapancreatic or extraduodenal tumours were 
excluded, so that the final study cohort consisted of 692 patients with a pancreatic 
neuroendocrine tumour (PNET) and 213 patients with a duodenal neuroendocrine 
tumour (DNET) (Table 1). 
 
 
Table 1. Patient characteristics  
 




Mean ± s.d. (range) 
 




56.3 ± 16.3 (0-94) 
 
62.1 ± 14.1 (25-91) 
Functional tumours 52.59 ± 18.1 (0-98) 51.6 ± 10.3 (38-73) 


























Functional 259 (37.4%) 18 (8.5%) 
     Insulinoma 202 (78.0%) 0 
     Gastrinoma 21 (8.1%) 16 (88.9%) 
     Glucagonoma 23 (8.9%) 0 
     VIPoma 6 (2.3%) 0 
     Somatostatinoma 3 (1.2%) 2 (11.1%) 
     Mixed 4 (1.5%) 0 
 
Table 1. Characteristics of 692 patients with pancreatic neuroendocrine tumours and 213 patients 
with duodenal neuroendocrine tumours in the PALGA database from 1991 to 2009. 
 
For PNETs, there was a slight female predominance, while DNETs showed a 
higher percentage of males. The majority of both PNETs and DNETs were non-
functional tumours (Table 1). Functional PNETs comprised predominantly 
insulinomas (59.9% female), DNETs were mainly gastrinomas (62.5% male). 




Patients with PNETs were significantly younger than patients with DNETs, 
P<0.01. This difference was largely caused by the younger age of patients with 
pancreatic compared to duodenal non-functional NETs, P<0.01. Patients with 
functional PNETs and DNETs were significantly younger at time of the pathologic 
evaluation compared to patients with non-functional PNETs and DNETs, P<0.01 
and P<0.01, respectively (Table 1). Taking all PNETs and DNETs together, 
functional NETs were diagnosed at a younger age compared to non-functional 
NETs, 52.3 ± 17.7 vs 60.0 ± 14.6 years, respectively, P<0.01. 
The MEN-1 syndrome was present in 10 patients with functional (two pancreatic 
glucagonomas, two insulinomas, one gastrinoma and one mixed 
glucagonoma/insulinoma, four duodenal gastrinomas) and 11 patients with non-
functional NETs (10 pancreas, one duodenum).  
 
Incidence rates 
Using census statistics obtained from the Dutch Central Bureau of Statistics, the 
annual incidence rates per 1,000,000 population for PNETs and DNETs were 
calculated (Figures 1 and 2). The average annual incidence of PNETs per 1,000,000 
from 1991 to 2009 was 2.54. The total incidence of PNETs increased over the years 
(slope 0.12 with a 95% c.i. of 0.07 to 0.18, P<0.01). Non-functional PNETs showed a 
higher incidence compared to functional tumours. The incidence increased with 
advancing age at time of the pathology diagnosis. The highest incidence of PNETs 
was found in patients from 65-79 years (Table 2). Remarkably, the incidence in 
patients under 40 years of age was higher for functional PNETs compared to non-
functional tumours. We found a statistically significant increase in incidence of 
non-functional PNETs over two decades (slope 0.14 with a 95% c.i. of 0.09 to 0.19, 
P<0.01). In contrast, functional PNETs showed a slight but significant decrease in 
incidence over the study period (-0.01 with a 95% c.i. of -0.03 to -0.00, P=0.05). In 
the study period from 1991 to 2009, a total of 33,459 patients with malignant 
tumours in the pancreas were reported in the Dutch population. Crude incidences 







Figure 1. Incidence rates of pancreas neuroendocrine tumours from
1991-2008 in the Netherlands


































Figure 1. Annual incidence rates of pancreatic neuroendocrine tumours per 1,000,000 persons in 
The Netherlands from 1991 to 2009. 
 
The average annual incidence of duodenal NETs per 1,000,000 from 1991 to 2009 
was 0.81. The total incidence of these DNETs showed a similar pattern to PNETs, 
namely an increase over the years from 1991 to 2009 (slope 0.05 with a 95% c.i. of 
0.02 to 0.07, P=0.003), which was mainly due to a significant increase in incidence 
of the non-functional duodenum NETs (slope 0.04 with a 95% c.i. of 0.02 to 0.07, 
P=0.001) while the incidence of functional tumours remained relatively stable 
(slope 0.00 with a 95% c.i. of -0.00 to 0.02, P=0.40). 




Figure 2. Incidence rates of duodenal neuroendocrine tumours
from 1991 - 2008 in the Netherlands

































Figure 2. Annual incidence rates of duodenal neuroendocrine tumours per 1,000,000 persons in The 
Netherlands from 1991 to 2009.  
 
The highest incidence of duodenal tumours was also seen in the patient group of 
65-79 years of age (Table 2).  
 
 











P D T P D T P D T 
<20 yrs 0.2 0.0 0.2 0.1 0.0 0.1 0.1 0.0 0.1 
20-39 yrs 1.0 0.1 1.1 0.6 0.0 0.6 0.4 0.1 0.5 
40-64 yrs 4.0 1.2 5.2 1.4 0.2 1.6 2.6 1.0 3.6 
65-79 yrs 6.1 2.5 8.7 2.0 0.1 2.1 4.2 2.4 6.6 
>80 yrs 4.7 2.4 7.1 1.5 0.0 1.5 3.2 2.4 5.6 
 
Table 2. Incidence of pancreatic and duodenal neuroendocrine tumours per 1,000,000 persons by 





When pancreatic and duodenal tumours were analyzed together, a similar trend 
in incidence rates was seen; the incidence of non-functional tumours increased 
significantly (slope 0.18 with a 95% c.i. of 0.11 to 0.24, P<0.01) while the incidence 
of functional tumours slightly decreased over time (slope -0.01 with a 95% c.i. of -
0.03 to -0.01, P=0.16).  
Furthermore, 124 autopsy reports of 35 patients with functional PNETs, 75 non-
functional PNETs and 14 non-functional DNETs were included. Mean age at time 
of death did not differ between functional PNETs (67.4 ± 14.5 years), non-
functional PNETs (67.0 ± 15.0 years) and non-functional DNETs (69.4 ± 11.8 years). 
Patients were all younger than the mean age at death of the general population of 
The Netherlands (males 72.0 ± 0.8 years and females 78.2 ± 0.6 years) over the 
period from 1991 to 2009. When patients who where found to have a NET by 
incidence at autopsy were excluded from the analysis, the average annual 
incidence numbers were 2.17 for PNETs and 0.76 for DNETs, respectively. 
Furthermore, incidence numbers were still significantly increasing over the period 
from 1991 to 2009 (slope 0.13 with a 95% c.i. of 0.08 to 0.17, P<0.01 for PNETs and 
slope 0.04 with a 95% c.i. of 0.01 to 0.07, P<0.01 for DNETs).  
 
Tumour characteristics 
Tumour characteristics are presented in Table 3. 37.8% of PNETs and 66.7% of 
duodenal NETs were <2 cm in diameter. All duodenal NETs were <5 cm, but only 
78.4% of the PNETs were of that size. 6.2% of the pancreatic tumours had a size of 
>10 cm in diameter. Tumours were <2 cm, <5 cm or >10 cm in 65.2%, 91.1% and 
3.6% cases of functional PNETs and in 25.5%, 72.1% and 7.3% cases of non-
functional PNETs, respectively. Tumour size of non-functional PNETs (mean 3.9 ± 
3.2 cm) was significantly larger compared to tumour size of patients with 
functional PNETs (mean 2.3 ± 2.5 cm), P<0.01. Non-functional DNETs had an 
average size of 1.6 ± 1.2 cm, while functional DNETs were on average 0.7 ± 0.5 cm, 
P=0.10. Non-functional PNETs had a larger tumour size compared to non-
functional DNETs, P<0.01, and functional PNETs were also significantly larger 
compared to functional DNETs, P<0.01. Mainly lymph node metastases were 




present in both PNETs and DNETs. The majority of tumours were described as 
well-differentiated. PNETs were mainly high grade malignant, while DNETs were 
most often reported as low grade malignant tumours. Angioinvasion was present 
in the majority of tumours. 
 
Table 3. Tumour characteristics of pancreatic and duodenal neuroendocrine tumours. 
 
 









Tumour size n (%) n (%) 
 
Reported 259 (37.4%) 39 (18.3%) 
      
     <1 cm 20 (7.7%) 16 (41.0%) 
     1-<2 cm 78 (30.1%) 10 (25.6%) 
     2-<3 cm 50 (19.3%) 6 (15.4%) 
     3-<4 cm 36 (13.9%) 5 (12.8%) 
     4-<5 cm 19 (7.3%) 2 (5.1%) 
     5-<10 cm 40 (15.4%) 0 
     >10 cm 16 (6.2%) 0 
 
Not reported 433 (62.5%) 174 (81.7%) 
 
Metastases n (%) n (%) 
 
Reported 239 (34.5%) 44 (20.7%) 
     
     Lymph node 68 (28.5%) 24 (54.5%) 
     Liver 46 (19.2%) 8 (18.2%) 
     Lymph node and liver 12 (5.0%) 1 (2.3%) 
     Multiple or other 28 (11.7%) 0 
     No metastases 85 (35.6%) 11 (25.0%) 
 
Not reported 453 (65.5%) 169 (79.3%) 
 
Differentiation n (%) n (%) 
 
Reported 103 (14.9%) 31 (14.6%) 
      
     Well-differentiated 83 (80.6%) 17 (54.8%) 
     Intermediate  differentiated 17 (16.5%) 7 (22.6%) 
     Poorly-differentiated 3 (2.9%) 7 (22.6%) 
 





Grade n (%) n (%) 
 
Reported 120 (17.3%) 23 (10.8%) 
     
     Benign 23 (19.2%) 1 (4.3%) 
     Low grade malignant 19 (15.8%) 10 (43.5%) 
     High grade malignant 64 (53.3%) 8 (34.8%) 
     Uncertain behaviour 14 (11.7%) 4 (17.4%) 
Not reported 572 (82.7%) 190 (89.2%) 
 
Angioinvasion n (%) n (%) 
 
Reported 111 (16.0%) 10 (4.7%) 
     Yes 78 (70.3%) 9 (90%) 
     No 33 (29.7%) 1 (10%) 
Not reported 581 (83.9%) 203 (95.3%) 
 
 
The majority of PNETs was located in the pancreatic tail. Compared to non-
functional PNETs, more functional PNETs were located in the pancreatic tail, but 
less in the pancreatic head (Table 4).  
 
 



























































Table 4. Detailed information on the location of the tumour in the pancreas 
 
Clinical assessment of incidence calculations 
To get an idea about the potential underestimation of the incidence calculation by 
this study using histocytopathological information from the PALGA database, we 
also assessed from our own referral centre what percentage of patients clinically 
suspected of or diagnosed with a gastrinoma in pancreas or duodenum, were 




scored as a gastrinoma by the pathologists as well. We found that only 45.7% 
(16/35) of our clinical gastrinoma patients were scored accordingly by 
pathologists, whereas 28.6% (10/35) of the patients were scored otherwise, i.e., as 
undefined neuroendocrine tumour. 25.7% (9/35) of the patients had not 
undergone any surgery and/or other pathological evaluation for their tumour and 
were therefore not traceable in the PALGA database. One patient was not 
diagnosed in the clinical setting, but was found to have a gastrinoma by incidence 
at autopsy.  
 
Discussion 
Duodeno-pancreatic NETs are considered to be rare neoplasms with a relatively 
slow-growing nature13. Because of the common embryonic origin it is attractive to 
study both locations in one study. Although the majority of these tumours are 
malignant, they can remain indolent and undetected for a long period of time, 
leading to substantial delays in diagnosing. Specifically non-functional tumour 
patients often present with metastases and more advanced disease4.  
The present study describes the incidence rates of both pancreatic and duodenal 
NETs from 1991 to 2009 in The Netherlands. This study is not only the first to 
examine epidemiological features of NETs in The Netherlands, it is also unique in 
the analysis of the incidence of duodenal tumours.  
In the evaluation period from 1991 until 2009, 905 patients with pancreatic and 
duodenal NETs were registered in PALGA. The majority was described as non-
functional NETs, 69.4%. Similar to Fitzgerald et al. we found an increase in 
incidence over time for non-functional pancreatic and duodenal NETs7. We concur 
with their postulation that this increase is likely to be due to increased use and 
improved techniques of diagnostic modalities. Moreover, the WHO classification 
for neuroendocrine tumours of the gastroenteropancreatic tract, which was 
introduced in 20002, has most likely contributed as well. We assume that 
introduction of this classification not only resulted in more intelligibility for the 




the existence of these tumours. As feasible in Figures 1 and 2, incidence lines 
increased remarkably after 2000.  
Furthermore, Fitzgerald et al. found that the incidence of functional PNETs over 
their study period of 16 years remained stable7. We found that the incidence of 
these tumours slightly decreased from 1991 to 2009. As a result of the hormonal 
secretion of this tumour type, functional NETs might be suspected and detected 
due to the clinical symptoms in these patients. The role of improved imaging 
techniques in the diagnosis of these tumours is only marginal, if any. In contrast, 
non-functional NETs are often only discovered at an advanced tumour stage, 
corresponding with the relatively older age of these patients at the first 
(pathological) diagnosis and the larger size of these tumours, compared to 
functional tumours, as suggested previously and confirmed in the present study6-
8. Together, these findings imply that the increase in incidence numbers is most 
likely to represent an increase in detection, rather than a raise in occurrence of 
these tumours. The fact that in several autopsy studies neuroendocrine tumours 
are found by coincidence, confirms this implication9-10. We found that among the 
patients with duodeno-pancreatic NETs included in this study on autopsy reports, 
the majority of patients (117/124) were not included in the PALGA database for 
any pathologic evaluation related to a neuroendocrine disease. This suggests that 
in 12.9% patients (117/905) the pancreatic or duodenal neuroendocrine tumour 
might be an incidental finding at autopsy, not detected earlier during life. 
Furthermore, analysis of autopsy reports revealed that, unsurprisingly, patients 
with PNETs and DNETs die at a younger age, compared to the general Dutch 
population. However, no difference in age at time of death was found between 
functional and non-functional NETs.  
We found that most PNETs were located in the pancreatic tail (52.6%), followed by 
the pancreatic head (33.6%), which is in contrast to others, who found the 
pancreatic head as preferred location of PNETs14-16.  
It is noteworthy to emphasize that we intentionally did not include any data on 
survival of the patients. Most studies which do report survival figures are based 
on information from the Surveillance, Epidemiology and End Results (SEER) 




database, which collects cancer incidence and survival of the US population and 
includes data on clinical and pathology information on tumours. However, we 
have chosen to estimate incidence rates based on pathology data, because of 
several reasons. Firstly, The Netherlands Cancer Registry, which is comparable to 
the SEER database, does not include detailed data on (the type of) pancreatic 
and/or duodenal neuroendocrine tumours. Secondly, this cancer registry is 
partially based and dependent on information of the PALGA database. 
Furthermore, in the present study both benign and malignant neuroendocrine 
tumours were included, while in most other studies, based on information from 
the SEER database, only malignant tumours were covered. Therefore, we suffice 
with the estimation of epidemiological numbers, although a survival study might 
be an interesting future option.  
Indeed, we are aware of the fact that the incidence rates calculated in our study 
might be an underestimation, as an unknown number of patients without 
pathology/surgical interventions were not retrievable in the PALGA database and 
therefore not included in our study. We assume that this mainly concerns 
functional NETs, as these tumours cause clinical symptoms, in contrast to non-
functional tumours. From our own experience, we know that for example patients 
with gastrinomas can do well on medication and surgical intervention in these 
patients is not always necessary17. In the past three decades, our hospital has been 
the nationwide referral centre for gastrinomas in The Netherlands. Therefore, we 
approached the possible underestimation of incidence by exploring what 
percentage of patients with clinically detected gastrinomas was retrievable in the 
PALGA database. We found that 73.6% of the patients were present in PALGA, 
although only 45.7% was actually scored as a ‘gastrinoma’ by the pathologists. 
Thus the underestimation of PNETs and DNETs may be between 25% and 50%.  
We further recognize that the pathological diagnosis of pancreatic or duodenal 
NETs is not always necessarily in agreement with the clinical symptoms of the 
patients. This was already noticed by Chetty18. As Mansour et al. illustrated using 
gastrinomas, a general pathological differentiation between different types of 




immunohistochemical staining does not often lead to conclusive evidence19. 
Therefore, we think that the combination of both clinical data and pathological 
findings is needed to establish the correct diagnosis in patients with NETs.  
It is worth to iterate that our study is based on pathological reports, and therefore 
the incidence rates are most likely lower than the actual incidence when these 
would also be based on clinical records. However, the study period was depicted 
from 1991 to 2009, to warrant a 100% national coverage of all the pathologic 
institutions in The Netherlands by the PALGA database.  
In conclusion, we explored the pathological incidence of duodeno-pancreatic 
NETs in The Netherlands, and found that the incidence of non-functional NETs 
has increased over the past two decades. However, although this effect may be 
due to the improvement of diagnostic tools in the clinical field, these tumours are 
still detected at a relatively late stage illustrated by the larger size and a diagnosis 
at an older age than in those patients affected by functional neuroendocrine 
tumours.   
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In the literature only few cases of primary hepatic gastrinomas have been 
reported. Furthermore, most cases have a short follow-up and are limitedly 
documented. 
We report a case of a patient suffering from the Zollinger-Ellison syndrome with 
recurrent hepatic gastrinomas, in whom no gastrinomas in duodenum, pancreas 
or other extrahepatic site could be identified, despite the use of multiple, 
repeatedly performed imaging techniques and explorations during the past 20 
years.  
A review is given on primary liver gastrinomas published since 1981. 
Interestingly, the present case is the only one with documented recurrent 
gastrinoma in the liver. None of the previously reported cases had liver 
gastrinomas as part of the Multiple Endocrine Neoplasia type 1 syndrome. It is 
further noteworthy that the risk of metastases of liver gastrinomas appears to be 
low. The interpretation of these hepatic gastrinomas as primary lesions can be 
questioned, as most cases lack an investigational and well-documented follow-up.  
In this study, we report the first case of Zollinger-Ellison syndrome caused by 



















The Zollinger-Ellison Syndrome (ZES) is caused by a malignant gastrin-producing 
neuroendocrine tumour (gastrinoma), usually located in pancreas or duodenum1,2. 
Symptoms associated with ZES are acid peptic disease, malabsorption and 
diarrhea3.  
Most frequently ZES occurs as a sporadic disease, while 20 to 30% of the cases is 
part of the Multiple Endocrine Neoplasia type 1 syndrome (MEN-1)4,5. This 
autosomal dominant disorder, caused by mutations of the MEN-1 tumour 
suppressor gene located on chromosome 11q13, is characterized by multiple 
tumours in several neuroendocrine organs and tissues. In case of endocrine 
symptoms in combination with a positive family history for MEN-1 and aberrant 
levels of calcium, prolactin, parathyroid hormone or pancreas polypeptide, MEN-
1 can be suspected and confirmed by genetic analysis6.  
Gastrinomas are frequently located in pancreas (30-50%), duodenum (40-50%) or 
lymph nodes (19%), in the so-called gastrinoma triangle, which angle points are 
formed by the junction of the cystic duct and common bile duct, the junction of the 
second and third part of the duodenum and the junction between the neck and 
body of the pancreas7. Remaining gastrinomas (extrapancreatic, extraduodenal 
and extralymphatic) are called ectopic and have been reported to occur in thymus, 
ovaries, liver, jejunal mesenterium, stomach, heart, parathyroid glands, kidneys 
and common bile duct8-10. Although hepatic metastases of primary gastrinomas 
are common, primary hepatic gastrinomas are rare11. To date, about 16 cases of 
primary liver gastrinomas have been reported in the  
literature9, 10, 12-25. In a majority of these reports, the period of follow-up is short 
(<three years) and not well-documented. However, because primary hepatic 
gastrinomas are difficult to differentiate from liver metastases from an occult 
gastrinoma elsewhere located, an adequate and extensive follow-up is necessary. 
In this case report, we describe a patient with ZES with recurrent most likely 
primary hepatic gastrinomas and an extended follow-up of almost 20 years after 
the diagnosis and more than 30 years after the first clinical presentation. Despite 




endoscopies and extensive imaging studies, no primary duodenal or pancreatic 
gastrinoma could be identified in this patient. Instead, liver tumours suspected of 
primary gastrinomas have been resected twice. Furthermore, we discuss the 
existence of primary liver gastrinomas and give an overview of all case reports of 
primary hepatic gastrinomas reported in literature from 1981.  
 
Case Report 
In 1989, a 39-year-old white male of Hispanic origin was referred to the outpatient 
clinic of the Gastroenterology department of the Leiden University Medical 
Center, for localization and treatment of a suspected gastrinoma. At that time 
symptoms including diarrhea, gastric complaints, pyrosis, nausea and vomiting, 
were present for many years. Furthermore, patient reported a remarkable weight 
loss of more than five kg during a period of approximately six months. Fasting 
serum gastrin was elevated and the secretin provocation test was positive, 
supporting the diagnosis of ZES. Omeprazol 80 mg/day provided relief of his 
symptoms. Patient was taking no other medication. About fifteen years before 
presentation, patient had undergone anti-reflux surgery (Nissen fundoplication). 
His past medical history was further unremarkable, his family history was non-
contributory. Physical examination revealed no abnormalities, apart from severe 
scoliosis. Laboratory studies, including serum amylase, electrolytes, liver 
chemistry, blood cell counts and stool parameters were found normal, except for 
an increased fecal fat excretion (53 grams/day). Gastroduodenoscopy showed 
Barrett’s esophagus, a small duodenal ulcer, and prominent red gastric folds and 
several erosions in the stomach. Further laboratory analysis revealed an increased 
fasting serum gastrin of 889 ng/L (424 pmol/L), an elevated basal acid output (40 
mmol/hr) with a maximum acid output of 60 mmol/hr. Serum levels of calcium 
(2.36 mmol/L), parathyroid hormone (2.4 pmol/L), prolactin (4.9 ug/L) and 
pancreas polypeptide (10 pmol/L) were within normal limits, making the 
diagnosis of Multiple Endocrine Neoplasia type 1 (MEN-1) very unlikely. 
To localize a possible gastrinoma, several imaging evaluations were performed. 
However, no tumour was identified at that time by conventional procedures, such 




as computed tomography (CT), magnetic resonance imaging (MRI), selective 
arteriography and selective arterial secretin injection test. Endoscopic ultrasound 
did not show a tumour in gastroduodenum, pancreas or lymph nodes. Moreover, 
an Indium-111-somatostatin receptor scintigraphy, a technique which was at that 
time still in the experimental phase, was performed (University Hospital, 
Rotterdam). This scan revealed a possible localization of the tumour in the left 
liver lobe or gastric lesser curvature. To exclude a gastric localization, gastroscopy 
was repeated. However, no tumour was visualized. Consequently, in 1990, an 
explorative laparotomy was performed but again no gastrinomas were visible 
macroscopically. Peroperative ultrasonographic evaluation of the pancreas 
showed no abnormalities, while peroperative echography of the liver showed a 
lesion next to the inferior vena cava in the left liver lobe. Biopsies from this lesion 
were analyzed by immunohistochemistry, on both paraffin-embedded and frozen 
sections of the tumour, and were found positive for keratin, synaptophysin, 
gastrin and neuron specific enolase, but negative for other neuroendocrine 
markers. Based on these results, a liver localization of a gastrin-producing 
neuroendocrine tumour was suggested, and confirmed on CT. In order to localize 
a primary tumour, peroperative selective venous sampling for gastrin was 
performed26. No evidence of tumour localization in the duodeno-pancreatic area 
was found. Therefore, resection of liver segment II was performed. Postoperative 
histological examination confirmed that the specimen sampled from the liver 
contained a gastrinoma. Within five days after the partial resection, fasting serum 













































































Figure 1. Fasting serum gastrin levels in ng/L, measured on multiple occasions during the 
evaluation from 1989 until 2008, are presented. The gray region represents the area in which serum 
gastrin is within normal limits (<100 ng/L). Dotted lines indicate the first and second partial liver 
resections in 1990 and 1999, respectively. 
 
Approximately one and a half year after surgical excision of the liver gastrinoma, 
fasting serum gastrin increased to levels above the upper limit of normal (<100 
ng/L). Secretin provocation test was also positive (a rise of 296 ng/L; 142 pmol/L 
in serum gastrin after secretin injection).  
In the period from 1991 until 1999, several imaging techniques were performed 
without any detection of a pancreatic or duodenal gastrinoma. Multiple 
gastroscopies repeatedly revealed a Barrett’s esophagus and edematous folds in 
the gastric corpus. In 1995, a selective arterial secretin injection test27 was repeated 
and showed a small increased gradient of serum gastrin over the hepatic vein. In 
1998, octreotide scintigraphy (SRS) revealed multiple small liver lesions, which 
were confirmed on CT and MRI (Figure 2).  






Figure 2. Magnetic resonance imaging shows a liver lesion ventrolateral in the right liver lobe 
(Leiden University Medical Center, Department of Radiology). 
 
Patient had a partial resection of liver segments IVa and IVb. Postsurgically, 
fasting serum gastrin initially dropped from 690 (330 pmol/L) to 347 ng/L (166 
pmol/L) but rapidly increased thereafter. A secretin provocation test, performed 3 
months postoperatively, resulted in a postsecretin gastrin increase from 883 ng/L 
(422 pmol/L) to 4675 ng/L (2236 pmol/L).  
The patient remained under follow-up control for the next period. Apart from 
surgery for a prostate adenocarcinoma, no ZES-related complaints were present. 
In 2003, octreotide scintigraphy (SRS) revealed a dubious accumulation of 
radioactivity in the ventral right liver lobe, while contrast-enhanced CT and MRI 
scans of the abdomen were repeatedly normal. In 2006 the liver lesion was 
confirmed on MRI of the abdomen. Until present date, no lesion in pancreas or 
duodenum has been identified. In 2008, an attempt to treat the hepatic lesion with 
radiofrequency ablation was performed. However, the procedure was 




gastrin levels remain increased although patient is doing well without symptoms, 
using 80 mg/day of Pantoprazole.   
 
Table 1. Review of primary hepatic gastrinomas from literature 
 Patients Therapy Follow-up after resection 
Ref Age, sex FSG pre Resection FSG post Investigations Evidence m FSG last 
17 36, F ND No# ND ND No 24 ND 
10 61, F 1500 Yes* ND FSG No 132 82 (1m) 
24 44, M 2700 Yes* N FSG No 13 N (9m) 
22 8, M 893 Yes N FSG No 18 N (18m) 
9 23, M 670 Yes* ND SPT No 24 ND 
12 49, F ND Yes ND ND No 69 ND 
19 13, M 27175 Yes N FSG No 24 ND 
16 30, M 572 Yes 64 FSG No 60 ND 
20 50, F ND Yes N CT, US, EUS, FSG, SPT No 24 ND 
18 9, M 704 Yes 103 CT, FSG No 36 182 (12m) 
25 50, M 150 Yes N CT, FSG No 18 N (18m) 
23 57, M ND Yes* 50 CT, SRS, FSG No 14 N (14m) 
13 27, F 1224 Yes N CT, US, FSG No 42 N (42m) 
15 13, M 1141 Yes 30 SRS, US, FSG Yes 48 284 (6m) 
14 29, F 1149 Yes ND CT, MRI, EUS, SRS, FSG No 36 N (36m) 
21 50, M 1500 Yes N CT, SPT, FSG No 60 400 (>6m) 
CCR 39, M 1065 Yes 60 CT, MRI, SRS, SASI Yes 113 690 (109m) 
   +rec 39, M 690 Yes 347 CT, MRI, SRS, EUS Yes 100 724 (105m) 
Symbols: * Plus total gastrectomy, # Streptozotocin therapy 
Abbreviations: CCR + rec = Current case report + recurrence, Ref = References, m = Months, FSG pre = FSG 
preoperatively (ng/L), FSG post = FSG postoperatively (ng/L), FSG last = FSG last measured (months) (ng/L), FSG = 
Fasting serum gastrin, F = female, M = male, ND = Not done, N = in normal range (<100 ng/L), CT = Computed 
tomography, MRI = Magnetic resonance imaging, US = Ultrasound, EUS = Gastroduodenal endoscopic ultrasound, SRS = 
Somatostatin receptor scintigraphy, SASI = Selective arterial secretin injection test, SPT = secretin provocation test 
 
Table 1. A review of primary hepatic gastrinomas from literature is presented.  
 
Discussion 
This is an exceptional case of a ZES-patient with recurring hepatic gastrinomas, in 
the absence of MEN-1. As in general the majority of sporadic gastrinomas is 
localized in the gastrinoma triangle, an accurate investigational search to find a 
tumour in this area was initiated. Preoperative and postoperative techniques to 




localize a gastrinoma include CT, MRI, ultrasonography, somatostatin receptor 
scintigraphy or octreotide scintigraphy, selective angiography, gastroduodenal 
endoscopic ultrasonography, and more specialized tests such as selective arterial 
secretin injection and selective portal venous sampling27-33. 
Although our patient was subjected to all these imaging techniques for almost 20 
years, no evidence for an extrahepatic origin of a gastrinoma was found. However, 
we believe that it is very unlikely that any extrahepatic tumour, albeit small in 
size, is constantly missed. As preoperative localization techniques like MRI and 
CT have improved over time, it might be expected that, even if a tumour was 
missed repeatedly in the past, recent techniques would be able to detect 
gastrinomas of any size at any location. Furthermore, we believe that if any small 
gastrinoma would exist, in pancreas or duodenum, this tumour would grow and 
therefore be detected by now. However, in this patient, exclusively liver 
gastrinomas have been detected, resected and recurred twice. To date, a 
suspicious liver lesion is seen with multiple imaging modalities. Although it is not 
certain if this liver lesion is a new recurrence or growth of a residual tumour after 
the second partial liver resection, it is clear that the liver tumour has a slow 
growing rate. After the initial resection of the liver gastrinoma in 1990, it took 
about 9 years before a recurrent tumour became visible on imaging. After the 
resection in 1999, imaging techniques were initially negative before hepatic lesions 
could be visualized on MRI in 2006.  
In Table 1, several cases of primary liver gastrinomas reported in the literature 
from 1989 until 2008 are listed. In most cases, hepatic gastrinomas were defined as 
primary when no extrahepatic tumour had been found pre-, intra- and 
postoperatively or when postsurgically serum gastrin levels decline to the normal 
range (<100 ng/L)9, 12-20, 22-25. Moreover, the suspicion of a primary liver 
gastrinoma could postoperatively be confirmed by immunohistochemical staining 
for (neuroendocrine) markers, including gastrin. In only one case report the 
tumour is defined as primary preoperatively, based on percutanous transhepatic 
venous sampling21. In our patient, no lesions outside the liver were found and 




gastrinoma, fitting the criteria to define the liver gastrinoma as primary. In 
contrast, serum gastrin levels did normalize postsurgically after the first partial 
liver resection, but became abnormal after about one and a half year and remained 
increased after the second operation. Remarkably, in most reported cases the 
follow-up of the patient after resection of the liver gastrinoma was relatively short 
(<three years) 12, 19-22, 24, 25 or had a limited postoperative documentation12, 23. The 
possibility that an extrahepatic gastrinoma is present can therefore not be 
absolutely excluded. Our patient had undergone several imaging studies to 
localize a gastrinoma outside the liver, not only preoperatively, but also after the 
resection of the hepatic tumour and during follow-up.  
Moruira et al. studied the cases of five primary hepatic gastrinomas from the 
literature and added one case, and concluded that these gastrinomas occurred in 
slightly younger patients when compared to patients with gastrinomas elsewhere 
located20. Furthermore, Diaz et al. reported that primary hepatic gastrinomas are 
more common in men, and are not associated with MEN-115. As our patient was a 
relatively young male at the time of diagnosis, suffering from ZES not as part of 
the MEN-1 syndrome, this is in line with the interpretation of the liver lesion as a 
primary tumour.  
In general, it is difficult to state that in patients with a supposed primary liver 
gastrinoma, the possibility of a pancreatic, duodenal or other localization of a 
primary gastrinoma is excluded. As the liver occurs to be a frequent site for 
metastatic gastrinomas, hepatic gastrinomas can be incorrectly interpreted as 
primary when no extrahepatic gastrinoma can be detected. The probability that 
liver gastrinomas are by mistake diagnosed as primary, is also mentioned by 
Tiomny et al.25. Detection of liver gastrinomas usually raises the question if this 
tumour is primary or metastatic. Only with long term follow-up it is possible to 
answer this question. However, the risk of metastases from primary hepatic 
gastrinomas seems to be low, as only one case reports the development of lymph 
node metastases after liver resection15. To our knowledge, recurrent tumours in 
the liver after surgical removal of the primary hepatic gastrinoma have not been 
reported before.  




In some case reports listed in Table 1, patients have undergone a total 
gastrectomy, preventing the use of acid peptic complaints as marker for 
recurrence, while in other cases, the follow-up after resection relies only on the 
analysis of serum gastrin levels. We believe that, even in the absence of ZES-
related complaints or in case of normalization of serum gastrin immediately 
postoperatively, recurrence may occur, although many years later. Therefore 
investigational imaging, such as octreotide scintigraphy or gastroduodenal 
endoscopic ultrasound, is required for an adequate follow-up.    
In conclusion, we reviewed the literature on primary liver gastrinomas and added 
a patient suffering from the Zollinger-Ellison syndrome, with a liver gastrinoma 
without another localization of a primary gastrinoma, under evaluation for almost 
20 years.  
Although the absence of a primary gastrinoma outside the liver during this long 
follow-up is highly suggestive to define the gastrinoma in the liver as primary, the 
possibility of a metastasizing but not growing occult gastrinoma in the gastrinoma 
triangle is very unlikely, but can not excluded with absolute certainty. In general, 
we state that frequent measurements of serum gastrin in combination with 
repeated imaging investigations are indicated after resection of a liver gastrinoma. 
We presume that the follow-up period should last for several years, as we show in 
our patient that a primary hepatic tumour has a slow rate of recurrence. 
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The secretin stimulation test is the principal diagnostic tool to identify the 
Zollinger-Ellison syndrome (ZES).  
To investigate by intra-individual comparison which dose of secretin results in the 
highest diagnostic efficacy to identify the ZES.  
We analyzed 57 paired secretin stimulation tests, using both 0.26 µg/kg and 0.78 
µg/kg secretin, performed in 13 ZES patients and 12 controls, and confirmed the 
findings in a validation cohort. 
In our study, a gastrin increase of >100 ng/L was found to be the most sensitive 
and specific criterion for a positive test, also compared to the most frequently used 
criteria from the literature. Using this criterion, we found that the higher gastrin 
increases after 0.78 µg/kg compared to 0.26 µg/kg secretin contributed to a 
slightly more sensitive (82.9% vs. 80.5%) but less specific (68.8% vs. 81.3%) test. 
Application of this criterion in a confirmative set of 98 tests, using 0.26 µg/kg 
secretin in 21 ZES patients and 39 controls, provided similar results. In ZES 
patients with normal fasting serum gastrin levels (<100 ng/L), there was no 
diagnostic benefit from the use of a higher secretin dose. 
We conclude that the 0.26 µg/kg secretin stimulation test has the best diagnostic 



















Zollinger-Ellison syndrome (ZES) is caused by a gastrin-producing 
neuroendocrine tumour (gastrinoma), and is characterized by symptoms of gastric 
acid hypersecretion, i.e., peptic ulcer disease, malabsorption and diarrhea1. 
However, symptoms can be absent for a relatively long time, for example when 
proton pomp inhibitors (PPI) are used2. ZES can be suspected when fasting serum 
gastrin (FSG) levels are increased, although hypergastrinemia is seen in several, 
more common, diseases, as well as in PPI users3. As a considerable number of ZES 
patients have FSG levels within the normal range, i.e., <100 ng/L, or FSG levels in 
a non-diagnostic range, i.e., 100-1,000 ng/L, determinations of FSG levels alone 
will not be conclusive for the diagnosis of ZES and additional diagnostic methods 
are needed. For this reason, several gastrin provocation tests have been developed, 
e.g., calcium infusion test, meal stimulation test and secretin stimulation test. The 
secretin stimulation test has been shown to be the diagnostic tool of choice in 
subjects with FSG levels < 1,000 ng/L4,5. In the literature, several criteria for a 
positive test have been reported. We first investigated which criterion for a 
positive secretin stimulation test results in the highest sensitivity and specificity in 
our study cohort and used this criterion in further analyses. Furthermore, since the 
introduction of the secretin stimulation test, the most optimal dose of secretin to 
use in this test has been disputed. While some studies have shown that a low dose 
of secretin is sufficient to discriminate between ZES5,6 and other causes of 
hypergastrinemia, others believe that only a higher secretin dose can contribute to 
adequate diagnosing7-10. Therefore, we subjected ZES patients and non-ZES 
controls to sequential secretin stimulation tests with a low and high dose of 
secretin, and thereby obtained a per-person-comparison between different doses 
of secretin. To our knowledge, secretin stimulation tests have not been studied 
with different doses in the same patients before, except for one case report8. The 
aim of our study was to investigate whether; 1) the use of a higher dose of secretin 
in secretin stimulation tests leads to a higher gastrin increase, and if so, 2) does this 
contribute to a higher sensitivity and specificity of the secretin stimulation test for 




patients with normal FSG levels (<100 ng/L). Lastly, we applied the determined 
criterion for a positive secretin stimulation test in a confirmative set of 98 secretin 
stimulation tests using the low dose of secretin in 21 ZES patients and 39 non-ZES 
controls to validate our initial results.  
 
Materials and Methods 
Patients  
Sequential 0.26 µg/kg and 0.78 µg/kg secretin stimulation tests in 25 subjects, 
suspected of ZES based on increased FSG levels (hypergastrinemia) or because of 
clinical suspicions, were performed in our Gastroenterology Department of the 
Leiden University Medical Centre. In total, thirteen patients suffering from ZES, of 
whom four as part of the MEN-1 syndrome, and twelve non-ZES controls 
suffering from MEN-1 but not ZES (n=3), atrophic gastritis (n=2) or a non-ZES-
related (mainly other gastroenteropancreatic) disease (n=7), were included. In the 
majority of patients (12/13), the diagnosis of ZES was confirmed by identification 
of a tumour on imaging or at surgery. Thirteen patients were female and twelve 
patients were male. In a subset of patients, the secretin stimulation test was 
performed multiple times for follow-up. Therefore, the total number of tests 
exceeds 25. For a validation study, an additional group of 60 patients, suspected of 
ZES, was included. In total, 98 secretin stimulation tests with 0.26 µg/kg of 21 ZES 
patients (20/21 confirmed with imaging or at surgery) and 39 controls were 
analyzed, using the criterion for gastrin increase of >100 ng/L for a positive test. 
Seven patients suffered from ZES as part of MEN-1, while ten controls had the 
MEN-1 syndrome without ZES. It must be noted that in this validation group, 
fourteen patients (nine ZES patients and five non-ZES controls) were included 
who also had been tested in the study group, although at different time points.  
This study was performed according to the guidelines of the Medical Ethics 
Committee of the Leiden University Medical Centre in compliance with the 
Helsinki Declaration.  
 
 




Secretin stimulation tests 
Secretin stimulation tests were done in patients after an overnight fast and acid-
suppressing medications were continued, except for the day before and on testing, 
when possible. The secretin stimulation test was performed by the procedure as 
described previously11. Before, during and after intravenous injection of 0.26 µg 
secretin (Secretin, ClinAlfa, 255 ng is estimated to be 1 clinical unit) per kg of body 
weight during 30 seconds, blood samples were collected at -5, 0, +1, +5, +10, +15 
and +30 minutes. Serum gastrin levels were measured by a radioimmunoassay, 
using an antibody raised in rabbits against synthetic human gastrin I (unsulfated 
gastrin-17) covalently coupled to bovine serum albumin. Labeled gastrin 125I-Tyr12-
gastrin-I (human) was purchased by PerkinElmer, USA. The antibody binds to all 
known circulating gastrin fragments.  The upper limit of the normal range for 
fasting state was taken as 100 ng/L, samples were diluted with repeated 
measurements as necessary to generate gastrin levels in a measurable range. After 
a minimum delay of at least 60 minutes, the test was repeated using 0.78 µg of 
secretin per kg body weight. The basal fasting serum gastrin is calculated as the 
average of two fasting blood samples before secretin injection. The increase in 
gastrin levels in ng/L after stimulation was calculated by:  
[maximal value after secretin injection] – [basal fasting value prior to secretin stimulation]. 
In daily practice, according to our hospital protocol, a gastrin increase of more 




Statistical analysis was performed using Statistical Package for Social Sciences 
version 16 (SPSS). The Wilcoxon signed ranks test was performed for comparison 
of differences between serum gastrin levels before administration of distinct 
secretin doses. Linear regression analysis was used to evaluate the linear 
relationship between the different doses of secretin. In particular, an orthogonal 
regression was used, to minimize the orthogonal or perpendicular distances from 




(ROC) curve was used to determine the discrimination threshold of gastrin 
increase for a positive secretin stimulation test. A p-value of <0.05 was considered 




An overview of included patients in the initial study group (n=25) and 
confirmation group (n=60) is presented in Table 1.  
 
 
Table 1. Patient characteristics 
 
 
Initial study group 
 
Confirmation group 











Male 12 25 31 46 
Female 13 32 29 52 
 









Mean 51.9 - 46.4 - 





















Preoperatively  7 10 13 18 
Postoperatively 10 31 12 38 





















Non-ZES controls 3 4 10 13 
Table 1. Patient characteristics of study group and validation group.  
 
Determination of the optimal criterion for a positive secretin stimulation test  
In our hospital daily practice, a secretin stimulation test is defined as positive in 
case of a gastrin increase of more than 50% of basal value with a minimum rise of 
100 ng/L. In the literature, several criteria for a positive secretin test have been 
described. Therefore, the most sensitive and specific secretin stimulation test was 




assessed in our study population (Table 2). To determine the most optimal 
criterion for differentiation between Zollinger-Ellison syndrome and non-
Zollinger-Ellison disease within our study group, a ROC curve analysis was 
performed. The optimal cut-off point for absolute gastrin increase with 0.26 µg/kg 
secretin was found to be 100 ng/L, with a sensitivity and specificity of 80.5% and 
81.3% respectively. For 0.78 µg/kg secretin the cut-off point was found to be 95 
ng/L, with a sensitivity and specificity of 82.9% and 68.8% respectively, but for the 
cut-off point of 100 ng/L identical results were found. Therefore, in this study, an 
absolute gastrin increase >100 ng/L as the uniform criterion with the highest 
sensitivity and specificity was chosen and used in our further analysis. In 
combination, we found that the criterion of a gastrin increase >100 ng/L is optimal 
for the diagnostic effectiveness for ZES, as this criterion led to equal or higher 
sensitivity and specificity compared to other criteria. Only when 0.78 µg/kg of 
secretin is used in the secretin stimulation test, the criterion of a gastrin increase of 
>100 ng/L + >50% leads to a slightly higher sensitivity and specificity. 
 
Fasting serum gastrin analysis 
We were also interested whether a higher dose of secretin contributes to a more 
diagnostic efficiency of the secretin stimulation test, and therefore 57 secretin 
stimulation tests were sequentially performed with two doses of secretin. For 
optimal comparison of gastrin increases after stimulation with 0.26 µg/kg or 0.78 
µg/kg secretin, it is favorable that FSG levels before administration of secretin are 
comparable. We found that the FSG concentrations (mean 339 ng/L, range 7.5-
43200 ng/L and 289 ng/L, range 5-47850 ng/L for 0.26 µg/kg and 0.78 µg/kg, 
respectively) did not significantly differ in the paired analysis and that there was a 
significant correlation (Spearmans rho = 0.9854 with P<0.01) between FSG levels 












Table 2. Determination of optimal criterion 
 





















>110 ng/L$ 80.5% 81.3% 
>120 ng/L& 78.0% 81.3% 
>200 ng/L* 58.5% 81.3% 
>50%+ 80.5% 75.0% 
>100%¶ 65.9% 81.3% 

















>110 ng/L 82.9% 68.8% 
>120 ng/L 80.5% 68.8% 
>200 ng/L 73.2% 68.8% 
>50% 95.1% 68.8% 
>100% 78.0% 81.3% 
>100 ng/L+>50% 80.5% 87.5% 
 
Criteria of Lamers et al. (#,§)11, Deveney et al. ($)12,  
Berna et al. (&)5, McGuigan and Wolfe (*)10,  
Lamers and van Tongeren (+)13, and Modlin et al. (¶)14. 
 
Table 2. Specificity and sensitivity, using different criteria as reported in the literature, calculated 
for secretin tests using 1 and 3 clinical units per kg of secretin for diagnosing ZES. Remarkably, 
sensitivity was higher for 0.78 µg/kg compared to 0.26 µg/kg of secretin for each criterion, while 
specificity showed an opposite pattern, resulting in higher specificity when the secretin stimulation 
test is performed using 0.26 µg/kg of secretin. 
 
Gastrin increase analysis 
In Figure 1, gastrin increase levels after the use of 0.26 µg/kg of secretin are 
plotted on a logarithmic scale against gastrin increase levels after the use of 0.78 
µg/kg of secretin. To determine if the use of 0.78 µg/kg of secretin leads to a 
higher gastrin increase, an orthogonal regression analysis was performed. For the 
total group of 57 tests, this resulted in a slope of 1.400 ± 0.0770 with a 95% 
confidence interval between 1.245 and 1.554, indicating that the use of 0.78 µg/kg 
leads to a higher gastrin increase compared to the use of 0.26 µg/kg of secretin. 
This effect was also found when ZES patients were analyzed separately; 1.403 ± 




0.0929 with a 95% confidence interval between 1.215 and 1.591. Furthermore, in 
these ZES patients a previous low dose secretin provocation did not affect the 
response to the high secretin dose as illustrated by the significantly higher 
maximum gastrin level (mean 10,920 ng/L, range 29-110,000 ng/L versus 13,740 
ng/L, range 38-188,000 ng/L, respectively; P<0.03). The resulting mean maximum 
gastrin level ratio of 1.17 was similar to that observed in two patients where the 
two secretin stimulation tests were performed with an approximately two-week 
interval having a ratio of 1.16.  
In contrast, orthogonal regression analysis of non-ZES controls (n=16) revealed a 
slope of 0.6743 ± 0.0616, with a 95% confidence interval between 0.5421 and 0.8064, 
lower than 1. No points in Figure 1 are located in the right lower quadrant 
representing a gastrin increase with 0.26 µg/kg >100 ng/L and with 0.78 µg/kg 
<100 ng/L, which means that in none of the tests in this quadrant the use of 0.78 
µg/kg of secretin was superior to the use of 0.26 µg/kg. In contrast, there are three 
points (two controls and one ZES patient) located in the left upper quadrant 
representing a gastrin increase with 0.26 µg/kg <100 ng/L and with 0.78 µg/kg 
>100 ng/L, indicating that in one ZES patient the 0.78 µg/kg secretin stimulation 
resulted in a positive test, while the 0.26 µg/kg secretin stimulation test was 
falsely negative, but this was also the case in two non-ZES patients indicating 
false-positive results with 0.78 µg/kg in these patients. 
To asses whether this increase was clinically relevant, sensitivity and specificity 
were compared between 0.26 µg/kg and 0.78 µg/kg secretin stimulation tests. 
Hereby the secretin stimulation test was defined as positive when gastrin increase 
was >100 ng/L. This led to a higher number of truly positives for 0.78 µg/kg 
secretin stimulation tests, but to a higher number of false positives as well. 
Therefore, sensitivity was slightly higher in tests using 0.78 µg/kg compared to 
0.26 µg/kg secretin stimulation tests (82.9% vs. 80.5%), but specificity was lower 





























































Figure 1. Gastrin increase levels after the use of 0.26 µg/kg of secretin are plotted against gastrin 
increase levels after the use of 0.78 µg/kg of secretin. A logarithmic scale is used. Arrows indicate 
gastrin increase levels of values which would originally fall outside the graph, therefore exact 
values are mentioned above the arrows. Numbers next to individual points represent 2 patients 
with an exceptional disease course; 1-1 till 1-7 represent a patient with normal postoperative serum 
gastrin levels without any symptoms or signs of recurrence; 2-1 till 2-5 represent a patient with 
initially normal but thereafter increased postoperative serum gastrin levels, while tumour 
recurrence could not be confirmed on imaging studies.   
 
Effect of the use of 0.78 µg/kg on ZES patients with normal fasting serum gastrin levels 
To assess whether the use of 0.78 µg/kg of secretin is more contributory to 
diagnose ZES in patients with normal FSG concentrations (<100 ng/L), this group 
of ZES patients was analyzed separately (Figure 2a and b). In total, 12 tests of four 
patients after resection were examined. A Chi-square analysis revealed no 
significant difference between groups, as the use of 0.78 µg/kg led to an almost 
equal number of true positive tests (6/12 vs. 5/11, Figures 2b and 2a, respectively) 
as the use of 0.26 µg/kg in the secretin stimulation test when a cut-off for gastrin 
increase of 100 ng/L was used. Thus, when gastrin increase are <100 ng/L or 




when FSG levels are >100 ng/L, the diagnosis remains uncertain but in the case of 
normal FSG levels <100 ng/L) in combination with a gastrin increase >100 ng/L, 
the diagnosis of ZES is highly likely.  
Figure 2a.




























































Figure 2a,b. Fasting serum gastrin levels are plotted against gastrin increase after stimulation with 
a low (0.26 µg/kg, 2a.) or high (0.78 µg/kg, 2b.) secretin dose are presented. A logarithmic scale is 
used. Arrows indicate gastrin increase levels of values which will originally fall outside the graph, 
therefore exact values are mentioned above the arrows. 
 
Validation study  
Based on the results described above, we concluded that an absolute gastrin 
increase >100 ng/L leads to the highest sensitivity and specificity in the study 
group. Therefore, this criterion was validated in 60 patients suspected of ZES, by 
performing 98 secretin stimulation tests using 0.26 µg/kg of secretin. Using the 
criterion of a gastrin increase of >100 ng/L for a positive test, 35/42 tests of 39 
non-ZES controls were indeed negative, while 45/56 tests of 21 ZES patients were 
truly positive. This led to a sensitivity of 80.3% and specificity of 83.3%, 
comparable to the sensitivity and specificity of the initial study cohort (80.5% and 
81.3%, respectively).  





Hypergastrinemia is a common characteristic of the Zollinger-Ellison syndrome, 
although the extent of hypergastrinemia can differ considerably between patients. 
Furthermore, the use of acid suppressing medications may delay the diagnosis of 
ZES, by masking the symptoms in ZES patients or mimic ZES by causing 
hypergastrinemia in patients without ZES. Therefore, FSG levels alone are not 
conclusive in a considerable number of ZES patients. Particularly, in case of mild 
to moderate hypergastrinemia (100 – 1,000 ng/L), additional diagnostics are 
required to confirm or exclude the diagnosis of ZES3. The secretin stimulation test 
is preferred above the calcium or meal stimulation tests, as the secretin stimulation 
test is more sensitive, easy to perform and less inconvenient for patients14. 
However, several aspects of the secretin stimulation test have been disputed, e.g., 
the criterion for a positive test and the dose of secretin to be used. In most 
previous publications, serum gastrin responses to secretin of > 200 ng/L, 
introduced by McGuigan and Wolfe, are used as the criterion for a positive 
secretin stimulation test10. Recently, Berna et al. studied the secretin stimulation 
test in 293 patients and 537 patients from the literature, and recommended to use a 
gastrin increase of 120 ng/L4,5. We investigated the most optimal criterion 
(sensitivity) for a positive test to diagnose ZES in our study group and not the best 
criterion to exclude the disease in other patients and controls (specificity). By both 
sensitivity/specificity determinations and ROC analysis we found a post-secretin 
gastrin elevation of >100 ng/L to be the most optimal discriminating value 
between ZES and non-ZES patients. Applying this criterion in a validation cohort 
of 21 ZES patients and 39 non-ZES controls led to a similar sensitivity and 
specificity for this criterion and confirmed the initial findings. 
As also the most optimal dose of secretin has been disputed, we investigated 
whether a higher dose of secretin would lead to more sensitive and specific tests, 
by subjecting ZES patients and non-ZES controls to sequential secretin stimulation 
tests using both a low and a high dose of secretin. Comparison-studies for secretin 
doses have been reported before, but, except for a case report in which two doses 




comparison with patients from literature and were not performed in the same 
subjects8. Although the number of included patients in this study is relatively low, 
this is the first study in which Zollinger-Ellison patients and non-ZES patients are 
subjected to multiple secretin stimulation tests with different doses, making this 
an intra-individual comparison. We found that the use of 0.78 µg/kg of secretin 
provokes a higher post-secretin serum gastrin increase, resulting in a higher 
number of true-positive ZES patients but also in a higher number of false-
positives, leading to a higher sensitivity but a decrease in specificity, compared to 
the use of 0.26 µg/kg of secretin. Therefore, we concluded that a higher dose of 
secretin did not contribute to a better discrimination between ZES patients and 
non-ZES controls in secretin stimulation tests. In general, a relatively small group 
of Zollinger-Ellison patients have FSG levels in the normal range (<100 ng/L), 
often after gastrinoma excision, and are therefore hardly recognized as (recurrent) 
ZES. In the present study, patients suffering from ZES having normal FSG levels 
(<100 ng/L), had no diagnostic benefit from the use of a higher secretin dose in the 
secretin stimulation test. Hence, the use of 0.26 µg/kg of secretin seems to be 
appropriate. From a financial point of view, the use of a low dose of secretin is 
preferential, as a three times higher dose leads to higher costs, but does not 
contribute to a more valuable secretin stimulation test. 
It is generally known that the use of PPIs or other acid suppressing medications 
can lead to elevated fasting serum gastrin levels, and therefore might falsely 
suggest ZES. Indeed, Hirschowitz et al. have shown that longterm use of PPIs in 
non-ZES-patients increases FSG-levels but does not lead to a further gastrin 
increase in the ZES patients15. In addition, a recent case report by Goldman et al., 
suggests that the use of a PPI can also lead to a false positive secretin stimulation 
test resulting in diagnosing ZES in non-ZES controls16.  In our study, however, 
39% (7/18) of the PPI-using non-ZES controls, with a FSG level of >100 ng/L, had 
a false positive secretin stimulation test, as opposed to 30% (3/10) of those free of 
acid-suppressing medication. These findings illustrate that there is no direct 
relation between PPI use and a false positive secretin stimulation test. Therefore, 




we believe that it is not necessary to discontinue acid-reducing medications for the 
secretin stimulation test, also to reduce the risk of developing ulcer complications. 
In conclusion, we found that a gastrin increase after stimulation with secretin of 
>100 ng/L leads to the highest sensitivity and specificity to diagnose ZES. 
Applying this criterion in our study revealed that the use of a higher dose of 
secretin did not contribute to a more valuable secretin stimulation test in 
diagnosing ZES. Therefore, we recommend the use of 0.26 µg/kg of secretin in 
secretin stimulation tests to diagnose or exclude ZES, with a gastrin increase >100 
ng/L as the optimal criterion for a positive secretin stimulation test.  
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Carcinoids are mainly found in the gastrointestinal (65%) and bronchopulmonary 
tract (25%). These neuroendocrine tumours secrete a wide range of bioactive 
peptides, including gastrin releasing peptide and neuromedin B, the mammalian 
analogs of bombesin. The purpose of this study was to investigate the quantity 
and localization of bombesin receptors in gastrointestinal and pulmonary 
carcinoids, and to reveal whether bombesin-like peptides and their receptors are 
of any value in distinguishing pulmonary carcinoids from carcinoids of intestinal 
origin. 
Carcinoid tumours with pulmonary (n=9) and intestinal (n=15) localizations were 
analyzed by immunohistochemistry, autoradiography and radioimmunoassay, to 
examine the presence of bombesin receptor subtypes and determine bombesin-like 
peptide levels in these tumours.  
All three bombesin receptor subtypes (GRPR, NMBR and BRS-3) were present on 
pulmonary and intestinal carcinoids by immunohistochemistry. In pulmonary 
carcinoids, low receptor ligand binding densities together with high and low 
bombesin-like peptide levels were found. Intestinal carcinoids showed 
predominantly high receptor ligand binding densities in combination with low 
bombesin-like peptide levels.  
The expression of bombesin receptor subtypes is independent from the carcinoid 
tumour origin, and is therefore not recommended as a distinction marker, 
although carcinoids of pulmonary and intestinal origin possess different receptor 
binding affinities for bombesin and dissimilar bombesin-like peptide levels. The 
combined presence of bombesin and its receptors might suggest the presence of a 












Carcinoids are tumours from the diffuse neuroendocrine system, which derive 
predominantly from serotonin-producing enterochromaffin (Kulchitsky’s) cells or 
gastric histamin-secreting enterochromaffin-like cells and comprise more than 50% 
of the well-differentiated neuroendocrine tumours (NETs). The majority of 
carcinoids are located in the gastrointestinal tract (65%) or bronchopulmonary 
system (25%). Their clinical course and prognosis is mainly dependent on the site 
of the primary tumour1. Initially, carcinoids were classified according to their 
embryonic origin, into foregut (originating from esophagus to pancreas, lungs 
included), midgut (originating from third part of the duodenum to ascending 
colon) and hindgut tumours (originating from transverse colon to rectum)2. 
Currently, based on histological classifications of the World Health Organization 
(WHO), neuroendocrine tumours are arranged according to tumour localization 
and differentiation3.  
Carcinoids are able to produce and secrete a variety of biogenic amines and 
peptides, including serotonin, chromogranin A, neuron specific enolase, substance 
P, gastrin and bombesin4. Bombesin and its mammalian analogs gastrin releasing 
peptide (GRP) and neuromedin B (NMB) belong to the family of bombesin-like 
peptides (BLPs), which were initially isolated from amphibian skin5. In humans, 
they are distributed in neural and endocrine cells, especially throughout the 
gastrointestinal tract. In addition to stimulating a variety of physiological 
responses in the human body, BLPs are involved in development and progression 
of several human cancers. For example, it has been shown that these peptides can 
stimulate the growth of lung, CNS, breast, cervix and prostate cancer cell lines, 
both in vivo and in vitro6,7. BLPs mediate their biological actions through binding 
to the G-protein coupled gastrin-releasing peptide receptor (GRPR, BB2R), 
neuromedin B receptor (NMBR, BB1R), bombesin receptor subtype 3 (BRS3, BB3R) 
and bombesin receptor subtype 4 (BRS-4, BB4R). Activation of various bombesin 
receptor subtypes has growth effects in both normal and neoplastic tissues, and 
several studies have reported an upregulation of bombesin receptors in tumour 




‘Bombesin receptors are one of the most frequent receptor classes that are 
overexpressed or ectopically expressed by human cancers’8. By binding to their 
membrane-bound receptors on tumour cells, BLPs are able to activate autocrine 
loops, leading to growth of the tumour. In pulmonary neuroendocrine tumours 
(small cell and non-small cell lung cancer), an autocrine loop involving BLPs has 
been suggested9,10. Also in colon cancer, BLPs have been reported to act both as 
morphogens and mitogens11. Aims of this study were 1) to investigate the quantity 
and localization of bombesin receptors in combination with bombesin-like peptide 
level expression on pulmonary and gastrointestinal carcinoids, and 2) whether 
carcinoids of different origin, i.e., from the pulmonary or gastrointestinal system, 
can be distinguished based on bombesin (receptor) expression. We used three 
different techniques, i.e., storage phosphor autoradiography, radioimmunoassay 
and immunohistochemistry, to determine presence of three different bombesin 
receptor subtypes and bombesin peptide levels in carcinoids of pulmonary and 
intestinal origin.  
 
Material and Methods 
Patients and tissues 
After surgical removal, tumour tissues were collected at the department of 
Gastroenterology, Leiden University Medical Center, Leiden, (n=4), the 
department of Pathology, Antoni van Leeuwenhoek Hospital, Amsterdam, (n=11) 
and the department of Pathology, The Netherlands Cancer Institute - Academic 
Medical Center, Amsterdam, (n=9), frozen at -80 ○C for ligand binding studies or 
embedded in paraffin for immunohistochemical staining. In total, 24 tissues from 
patients with carcinoids were studied. Carcinoids included primary typical (n=8) 
and atypical (n=1) lung carcinoids, primary small bowel well-differentiated 
neuroendocrine carcinomas (n=9), primary duodenum well-differentiated 
neuroendocrine carcinoma (n=1), primary rectum neuroendocrine carcinoma 
(n=1), liver metastases from a primary small bowel well-differentiated 
neuroendocrine carcinoma (n=1), and lymph node metastases from primary small 
bowel well-differentiated neuroendocrine carcinomas (n=3). Neuroendocrine 




tumours were classified according to the World Health Organization Classification 
for Neuroendocrine Tumours3, and in this study further referred to as ‘carcinoids’. 
 
Immunohistochemical analysis 
The primary antibody for BRS-3 was a polyclonal rabbit antibody raised against a 
synthetic peptide, corresponding to the carboxy terminal tail of the BRS-3. This 
antibody was provided by Schulz et al.6. The primary antibody against the NMBR 
was a polyclonal rabbit antibody, raised against the carboxy-terminus of the 
human NMBR (Biotrend Chemikalien GmbH, Cologne, Germany). The primary 
antibody for GRPR was a polyclonal rabbit antibody, raised against a synthetic 
peptide conjugated to KLH, corresponding to the 2nd extracellular loop (Abcam 
Inc., Cambridge, UK). Immunohistochemistry was performed as follows. Briefly, 
tissues were fixed in formalin, embedded in paraffin and cut into seven μm 
sections. After deparaffinization and rehydration, endogenous peroxidases were 
blocked in methanol containing 0.3% H202 (Merck). Antigen retrieval was 
performed by boiling in citrate buffer pH 6.0 for 12-17 minutes. Primary 
antibodies were diluted in phosphate-buffered saline (PBS) with 1% bovine serum 
albumin (BSA, for NMBR and GRPR antibodies) or Tris-HCl-PBS pH 6.4 with 0.5% 
Thimerosal (Sigma-Aldrich, for BRS-3 antibody) and incubated overnight at room 
temperature (RT). Incubation with biotinylated goat anti-rabbit immunoglobulins 
for 30 minutes at RT was followed by incubation with horseradish peroxidase 
(HRP)-streptavidin complex (both Dako, Glostrup, Denmark) for 30 minutes at 
RT. Staining was visualized using 0.05% diaminobenzidine (DAB, Sigma-Aldrich) 
containing 0.0038% H202 in 0.05 M Tris-HCl buffer pH 7.6. For NMBR staining, 
the visualization step was intensified by addition of 0.15% Imadizole.   
Cervix carcinomas were used as positive controls12, whereas for negative controls 
primary antibodies were omitted. Representative photomicrographs were taken 
with a Olympus BX-51TF microscope with a DP23-3-5 camera. 
Specificity of the primary antibodies against NMBR and BRS-3 was confirmed by 
preincubation with a 10-fold surplus of the immunizing peptide for four hours at 




necessary to avoid aspecific binding of the formed antibody-blocking peptide 
complex. Further protocol was performed as described above. No immunizing 
peptide for our GRPR antibody was available but incubations without primary 
antibodies were negative, and Western blot analysis performed previously13 
confirmed the specificity for this antibody.  
 
Immunohistochemistry scoring 
Evaluation of immunohistochemical staining for the different antibodies was 
performed by two independent observers. The following characteristics were 
investigated; presence/absence of specific staining on tumour cells of carcinoids, 
staining intensity and comparison between carcinoid groups. Intensity of staining 
(0=negative, 1=slightly positive, 2=moderately positive, 3=positive, 4=strongly 
positive, 5=exceptionally positive) and the number of cells showing 
immunopositivity (0=no positive cells, 1=0-25% positive cells, 2=25-75% positive 
cells, 3=75-100% positive cells) were included in the final score for each antibody. 
Maximum achievable score was therefore eight. 
 
Storage Phosphor Autoradiography  
Before use, tissues were cut into 14 μm sections at -20 ○C using a cryostat 
microtome and mounted on gelatin coated glass slides. Slides were dried 
overnight at -80 ○C to stimulate adhesion. Storage phosphor autoradiography was 
performed as described previously14,15. Briefly, slides were pre-incubated with 50 
nM Tris-HCl containing 0.5% Bovine Serum Albumin (BSA, Sigma-Aldrich, 
Steinheim, Germany) at RT at pH 7.0 for 20 min. Then slides were incubated with 
pre-incubation buffer and Bacitracine 0.25 mg/ml, Leupeptine 4 μg/ml, 
Chymostatin 2 μg/ml, NaCl 130 mM, KCl 7.7 mM, MgCl2 5 mM and EGTA 1mM, 
together with 75 pM [125I]Tyr4-bombesin (2200 Ci/mmol: PerkinElmer, Inc. Boston 
MA, USA) for 3 hr. For each slide, an alternating slide was incubated with the 
previous in combination with the addition of 1 μM non-radioactive bombesin, to 
determine aspecific binding. Slides were washed in the pre-incubation buffer three 




times for 5 minutes at 4 ○C, rinsed in distilled water and dried at RT under a cold 
stream of air.  
To determine receptor density, dried tissue sections were placed in a storage 
phosphor cassette for 48 h at RT and subsequently scanned by Phosphorlmager. 
Images were processed with ImageQuant software (Amersham Biotech - 
Molecular Dynamics, Inc. Sunnyvale, CA, USA). Slides with two drops of 10 ul 100 
pM labeled bombesin were included for standardization. Human intestinal 
smooth muscle cells of non-carcinoid patients were used as positive controls. 
Receptor binding was calculated as fmol of radioactive peptides bound per mg 
protein (with an estimation of 10 mg protein per 100 mg wet tissue). Tumour 
localization was confirmed on consecutive Hematoxylin-Eosin stained slides. 
For a subset of samples, radiolabeled ligands for NMB (1132.3 g/mol, Bachem, Inc. 
USA) and GRP (2859.4 g/mol, Bachem) were used for cold saturation inhibition 
curves to identify the bombesin receptor subtypes present in the samples. The 
procedure was performed as described above.  
 
Radioimmuno assay  
After frozen tumour sections were trimmed, tumour tissues were homogenized in 
0.1M TrisHCl 0.1% Tween80 buffer pH 7.5 on ice. Levels of BLP were measured in 
the supernatant. The radioimmunoassay was performed in a two-step incubation; 
samples, or bombesin as standard, and diluted anti-bombesin antibody were first 
incubated for 48 hours at 4 ○C. This antiserum K162 was generated by 
immunization of rabbits with synthetic bombesin. Final dilution of the bombesin 
antibody used in the assay was 1:40.000. After 48 hours, labeled bombesin (125I[D-
Tyr4] bombesin, 200Ci/mmol: PerkinElmer, Inc. Boston MA, USA) was added and 
further incubated for 24 hours. Bound and free ligands were separated by 
precipitation with sheep anti-rabbit antibody coupled to microsepharose beads 
(Pharmacia decanting suspension 3) and counted in a γ-counter. Concentrations 







Statistical analysis was performed using Statistical Package for Social Sciences 
version 16 and GraphPad Prism version 5. Data were summarized as median. 
Mann-Whitney U-test was used to compare mean receptor densities, bombesin-
like peptide levels and immunohistochemical scores for bombesin receptor 
subtypes between pulmonary and intestinal carcinoids. Fisher Exact test was used 
to examine the significance of association of receptor densities and bombesin-like 
peptide levels between pulmonary and intestinal carcinoids. Spearman 
correlations were used to investigate significant correlations between various 




Staining of BRS-3, GRPR and NMBR on carcinoids was found to be predominantly 
cytoplasmic, with some incidental membrane-bound staining (Figure 1), as in the 
positive controls, i.e., cervix carcinomas. For BRS-3 also nuclear immunopositivity 
was seen but considered aspecific, as the addition of a blocking peptide to the 
primary antibody did not lead to clearance of this staining. In total, 20 of 24 
carcinoids expressed BRS-3, whereas 21 of 24 carcinoid tumours expressed NMBR. 
All 24 carcinoids were positive for GRPR. Immunostaining for all three bombesin 
receptor subtypes simultaneously was seen in 20/24 carcinoids.  































Figure 1. Immunostaining for the three bombesin receptors on an intestinal and a pulmonary 
carcinoids Magnification x 400. The carcinoids are stained with antibodies for BRS-3 (a,b), GRPR 
(c,d) and NMBR (e,f). Incidental membrane-bound staining is indicated with ►. 
Immunohistochemical scores were 3 for BRS-3 (a), 5 for GRPR (c) and 4 for NMBR (e) in the 
intestinal carcinoid, and 4 for BRS-3 (b), 8 for GRPR (d) and 3 for NMBR (f) in the pulmonary 
carcinoid. 
 
Comparison of immunohistochemical scores between groups revealed that in 
pulmonary carcinoids (n=9), GRPR staining was significantly higher compared to 
intestinal carcinoids (n=15, median scores 6 and 5 respectively, P=0.02, Figure 2). 
This was mainly due to a higher GRPR staining intensity (median scores 3 and 2, 
P=0.02). Median total scores for BRS-3 were equal in pulmonary and intestinal 




NMBR total score, staining intensity and number were higher in pulmonary 
carcinoids compared to intestinal carcinoids, this did not reach statistical 
significance. Furthermore, inter-antibody comparison of the immunohistochemical 
scores for the different bombesin receptor subtypes was not applicable because of 
the intrinsic differences between the antibodies.  



























Figure 2. Graphic presentation of immunohistochemical scores for BRS-3, GRPR and NMBR 
staining in pulmonary (n=9) and intestinal (n=15) carcinoids. Median scores are indicated by bars. 
Scores are composed of staining intensity (0-5) and number of cells with immunopositivity (0-3), 
total scores may therefore range from 0 (no staining) to 8 (very positive).  
Of note; GRPR scoring is remarkably higher compared to scoring for BRS-3 and NMBR 
immunostaining, which is mainly due to antibody characteristics, it is of no value to compare 
immunoexpression between the different bombesin receptor subtypes. 
   
Quantification of binding sites for bombesin on carcinoids 
Storage Phosphor Autoradiography was used to identify the presence of bombesin 
receptors on 24 carcinoids. Autoradiographic ligand binding on these tumour 
tissues was found to be diffuse. Receptor densities were found in a range of 0 to 87 
pmol/g tissue. Receptors were present, i.e., detectable, in 13/15 and 7/9 intestinal 
and pulmonary carcinoids, respectively. In pulmonary carcinoids, receptor 




densities were high (≥10 pmol/g tissue) in 1/9 samples, while in intestinal 
carcinoids 7/15 samples showed high receptor densities. Median receptor binding 
was almost significantly higher in intestinal carcinoids (n=15) compared to 
pulmonary carcinoids (n=9), P=0.07 (Table 1).  
 
Table 1. Receptor densities (fmol/mg tissue) 
 





























SEM = Standard error of the mean 
 
 
Table 1. Overview of receptor densities and bombesin-like peptide levels in pulmonary and 
intestinal carcinoids.  
 




Figure 3. Autoradiographs of ligand binding of I-[D-Tyr]-bombesin in two carcinoid tissues. a1, a2) 
Carcinoid in abdominal lymph node (metastasis). b1, b2) Carcinoid in distal ileum. Binding 
detected with storage phosphor autoradiography was quantified using ImageQuant software. 
Total binding represented by a1 and b1. Aspecific binding represented by a2 and b2. To calculate 
specific binding, aspecific binding was subtracted of total binding. 
 
Quantification of bombesin-like peptide levels in carcinoids 
BLP levels in 24 carcinoid tissue homogenates were determined using a 




tissue. Low (<10) levels were detected in 14/15 intestinal and 5/9 pulmonary 
carcinoids, respectively. Median BLP levels were significantly higher in 
pulmonary carcinoids (n=9) compared to intestinal carcinoids (n=15), P=0.02 
(Table 1).  
 
Receptor densities and bombesin-like peptide levels in carcinoids 
In 4/9 pulmonary carcinoids, low (<10 pmol/g tissue) receptor densities in 
combination with high (≥10 ng/g) BLP levels were found, 4/9 pulmonary 
carcinoids had both low receptor densities and BLP levels. Only 1/9 pulmonary 
carcinoids had a high receptor density and low BLP levels. The majority of 
intestinal carcinoids (14/15) had low BLP levels, eight of these in combination 
with low receptor densities and six with high receptor densities. One intestinal 
carcinoid, originally located in rectum, had both high receptor densities and high 
BLP levels. A significant negative correlation, Spearman rho=-0.47, was found 
between receptor densities and BLP levels for all carcinoids, P=0.02, with a similar 
trend when pulmonary and intestinal carcinoids were separately analyzed (rho -
0.32 and -0.39, respectively). Overall Chi Square analysis revealed a significant 
difference in receptor status in combination with BLP levels between pulmonary 
(n=9) and intestinal (n=15) carcinoids (P=0.03) (Figure 4). 
 




Figure 4. Receptors binding
and Bombesin-like peptide levels



















Figure 4. Receptor densities and bombesin-like peptide levels in pulmonary and intestinal 
carcinoids. A logarithmic scale is used.  
 
Discussion 
Carcinoids can arise in many places of the human body, but are mainly situated in 
the pulmonary or gastrointestinal tract. Not only localization, but also hormonal 
production, histological differentiation and clinical behaviour of the tumour 
contributes to the heterogeneity of these neuroendocrine tumours3. We evaluated 
the quantity and localization of the different bombesin receptor subtypes GRPR, 
NMBR and BRS-3 in carcinoids of lung and intestine, to reveal whether carcinoids 
of different locations, i.e., from pulmonary or gastrointestinal system, can be 
distinguished by bombesin peptide and receptor characteristics. We found that in 
the majority of carcinoids (83.3%) all three receptor subtypes were present 
immunohistochemically. Therefore, overall bombesin receptor expression seems 
not to be a very useful marker to distinguish carcinoids based on tumour origin. In 




GRPR and NMBR immunostaining scores were higher in pulmonary carcinoids 
compared to intestinal carcinoids, only the first being statistically significant 
(P=0.02). Immunopositivity for GRPR, BRS-3 and NMBR was diffuse and 
predominantly cytoplasmic, with some membrane-bound staining, identical to the 
staining of GRPR on cervix carcinomas as described by Cornelia et al.12, on 
gastrointestinal carcinoids by Scott et al.16 and on pancreatic and prostate 
carcinomas by Schulz et al.6, although the latter also showed strong membrane-
bound staining in breast cancer. Whereas immunohistochemistry gives 
information about the presence or absence of bombesin receptors on carcinoid 
tissues, no clues about the binding affinity of these receptors for bombesin can be 
obtained from this expression.  
Therefore, we subjected carcinoid tumours to autoradiographic ligand binding. 
Previous study on ileal and colonic tissue showed no binding sites with high 
affinity for GRP, suggesting that GRPR, but not NMBR and BRS-3, was present in 
human ileum and colon15. We found an almost significantly higher median 
receptor binding density in intestinal carcinoids compared to pulmonary 
carcinoids (P=0.07), suggesting diversity in the receptors present on the two types 
of carcinoids and suggesting that, although many receptors were demonstrated 
immunohistochemically in pulmonary carcinoids, not all these receptors have a 
high binding affinity for the bombesin ligand. The expression of bombesin 
receptors for GRP and NMB have been studied on carcinoids before by Reubi et 
al.17, who studied 51 bronchial and intestinal carcinoids by autoradiography, and 
found a preferential expression of NMBR in intestinal carcinoids while BRS-3 
expression was highest in bronchial carcinoids. Because in the current study, a 
universal ligand for bombesin receptors was used to study ligand binding by 
autoradiography, it is not possible to determine which bombesin receptor subtype 
is present, but similar to Reubi et al.17 the carcinoids were found to have diverse 
BLP binding capacities. However, no endogenous BLP levels were determined in 
their study.  
To investigate whether the binding affinity of bombesin receptors correlated with 
peptide levels of BLP, we also performed a radioimmunoassay for the latter. A 




significant negative correlation between receptor ligand binding and BLP levels 
was found for all carcinoids with a similar trend when pulmonary and intestinal 
carcinoids were analyzed separately. BLP levels were significantly higher (P=0.02) 
in pulmonary carcinoids compared to intestinal carcinoids. The higher ligand 
binding in combination with lower BLP levels on gastrointestinal carcinoids 
compared to pulmonary carcinoids, might be due to occupancy and/or 
inactivation of the receptor on the latter group of carcinoids, leading to 
impairment of the ligand binding.  
From several studies, it is known that in lung carcinomas, including SCLC and 
NSCLC, and colon cancer, autocrine growth loops for GRP and NMB exist9-11. By 
these loops, tumour cells are able to stimulate their own growth and proliferation. 
Our observation that both bombesin receptors and peptide are present in the same 
tissues, provides circumstantial evidence that a paracrine or autocrine growth loop 
for BLPs exists in carcinoid tumours, although more studies are needed to further 
explore this hypothesis.  
The aim of this study was to investigate whether carcinoids of pulmonary and 
intestinal origin could be distinguished by bombesin (receptor) characteristics. 
Other studies have also tried to find differences in bombesin expression patterns 
to distinguish carcinoids of different origin; whereas Reubi et al. concluded that 
(by autoradiography) BRS-3 is preferentially but not exclusively found in lung 
carcinoids as opposed to NMB-receptors in gastrointestinal carcinoids17, Granberg 
et al. suggested that, when GRP immunoreactivity is found, the primary tumour is 
most probable of pulmonary origin18. Based on our results, with a relatively low 
number of patients, which can mainly be ascribed to the rarity of neuroendocrine 
tumours in general, we conclude that in both pulmonary and intestinal carcinoids, 
all three bombesin receptors are present, although the quantity and ligand binding 
affinities are diverse on carcinoids of different origin; apparently on pulmonary 
carcinoids, bombesin receptors have a low binding affinity for bombesin, while 
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Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are uncommon, 
heterogeneous neoplastic lesions. Angiogenesis, the process of new blood vessel 
formation, is required for tumour growth, progression and the development of 
metastases. This process is induced by several growth factors, including vascular 
endothelial growth factor (VEGF), and transforming growth factor beta 1 (TGF-
β1). Endoglin is a co-receptor for TGF-β1 and a marker for angiogenic endothelial 
cells. The aim of the present study was to evaluate the expression and potential 
prognostic role of VEGF and endoglin in GEP-NETs.   
Microvessel density (MVD) in GEP-NETs was evaluated using endoglin and CD31 
immunohistochemistry. In addition, tissue levels of endoglin and VEGF were 
determined in homogenates by ELISA. 
Endoglin was highly expressed on tumour endothelial cells. CD31 microvessel 
density in GEP-NETs was significantly higher compared to endoglin MVD. Two to 
four-fold higher tissue levels of endoglin and VEGF were seen in tumours 
compared to associated normal tissue. This increased endoglin tissue expression in 
tumours was significantly related to tumour size, presence of metastases and a 
more advanced tumour stage, whereas expression of VEGF was not.  
Based on these findings, we suggest endoglin to be a potential marker to detect 
present and to predict future metastases. Assessment of endoglin tumour levels 
provides information on tumour aggressiveness which might be useful in the 















Gastroenteropancreatic neuroendocrine tumours (GEP-NETs), including 
gastrointestinal carcinoids and pancreatic neuroendocrine tumours (PNETs), 
comprise a very heterogeneous group of neoplasia, with respect to tumour 
biology, histocytopathology and prognosis1. Despite a slow-growing nature, they 
are primarily malignant2. Angiogenesis, the formation of new blood vessels from 
the existing vascular bed, is a crucial process in tumour progression. When 
tumours reach a size of approximately 1 or 2 mm, they become dependent on 
neovascularisation, not only to provide them with nutrients and oxygen, but also 
as an exit route for metabolic waste products, further growth of the primary 
tumour, and eventually, metastatic spread3. One of the key factors in angiogenesis 
is vascular endothelial growth factor (VEGF) which has numerous effects on 
endothelial cells (ECs), including induction of migration and differentiation4. 
Several studies have addressed the prognostic implications of VEGF in patients 
with GEP-NETs, and trials investigating the action of the anti-VEGF antibody 
bevacizumab in patients with GEP-NETs are ongoing5,6.  
Another important growth factor, with a pivotal role in angiogenesis is 
transforming growth factor beta 1 (TGF-β1), a multifunctional cytokine that is 
involved in numerous physiological and pathological processes7. Endoglin 
(CD105) is a co-receptor for TGF-β1. As a result of its principal expression on ECs 
of newly formed blood vessels, several studies have suggested that endoglin is a 
specific marker of neovascularisation in various cancer types8-10. In pancreatic 
carcinomas, high endoglin microvessel density (MVD) has been found to be 
related to shorter survival and therefore, is suggested to be a prognostic marker11. 
In colorectal cancer, the vessel count by positive endoglin staining is able to 
identify patients at high risk of metastases12. 
In the present study, we assessed the tissue expression and levels of two key 
players in the process of angiogenesis, namely endoglin and VEGF, to assess their 






Materials and Methods 
Patients 
After surgical removal, tumour tissues were collected at the Department of 
Gastroenterology, Leiden University Medical Centre (LUMC), Leiden, and either 
frozen at -80○C and/or embedded in paraffin for immunohistochemical staining. 
Sixty-eight homogenates (27 tumour samples and 41 normal samples) of 27 
patients were available for the determination of tissue levels of endoglin. For the 
measurement of VEGF levels, one tumour sample was exhausted; therefore, the 
total number of tumour samples comprises 26.  For CD31 and endoglin 
immunostaining, 50 and 49 samples, respectively, of 39 patients, were available. 
For most patients, but not all, both homogenates and paraffin slides were 
available. In total, 41 patients with GEP-NETs were included. GEP-NETs 
comprised pancreatic neuroendocrine tumours (PNETs) and gastrointestinal 
neuroendocrine tumours, which were also referred to as ‘carcinoids’.  
Clinicopathological information was obtained by evaluation of patients’ medical 
files and pathology reports, when available. According to the classification of the 
World Health Organization for GEP-NETs, tumours were categorized into well-
differentiated neuroendocrine tumour (NET), well-differentiated neuroendocrine 
carcinoma (NEC), or poorly differentiated NEC13. From some patients, the WHO 
classification was not assessable due to the lack of specified classification. This 
study was performed according to the guidelines of the Medical Ethics Committee 
of the LUMC in compliance with the Helsinki Declaration. 
 
Immunohistochemistry 
Immunohistochemistry was performed as follows. Tissues were fixed in formalin, 
embedded in paraffin and cut into 5 μm sections. After deparaffinisation and 
rehydration, endogenous peroxidases were blocked in methanol containing 0.3% 
H202 (Merck, Darmstadt, Germany). Antigen retrieval was performed by boiling in 
0.01M citrate buffer pH 6.0 for 10 minutes. Slides were incubated overnight at 
room temperature (RT) with primary antibodies: biotinylated goat anti-human 
endoglin (1:200, R&D Systems Europe, Abingdon, UK), or mouse monoclonal anti-




CD31 (1:400, Dako, Glostrup, Denmark) diluted in phosphate-buffered saline 
(PBS) with 1% bovine serum albumin (BSA), as described previously14. 
Immunodetection was performed with a biotinylated goat anti-mouse antibody 
(for CD31) and horseradish peroxidase (HRP)-streptavidin complex (both Dako) 
for 30 minutes at RT. Staining was visualized using 0.05% 3,3’-diaminobenzidine 
(DAB, Sigma, Darmstadt, Germany) containing 0.0038% H202. Colon carcinomas 
were used as positive controls. Negative controls were included by omitting the 
primary antibodies. Representative photomicrographs were taken with an 
Olympus BX-51TF microscope equipped with a DP23-3-5 camera. 
The endoglin and CD31 MVD in the tumour-bearing area were quantified by 
computerized analysis. Four representative tumour areas for either endoglin or 
CD31 were selected and photographed at a 100x magnification. Images were 
binarized and the extent of staining was quantified using ImageJ 1.43u (National 
Institutes of Health, Bethesda, MD, U.S.A.). Finally, the average MVD out of four 
photographs was taken. The microvessel quantification was performed blinded, 
that is, without knowledge of patients or tumour characteristics, and expressed as 
the number of pixels per field x 1,000.   
 
Quantitative human endoglin and VEGF determinations in tissue samples 
Tissues were homogenized and protein concentrations were determined according 
to Lowry et al.14,15. Endoglin levels were determined in tissue homogenates, using 
a commercially available quantitative immunoassay (ELISA) for human endoglin, 
performed according to the manufacturer’s instructions (R&D Systems), as 
described before14. VEGF tissue levels were determined using a commercially 
available duoset (R&D Systems) as described before16. Endoglin and VEGF levels 
were expressed as ng/mg and pg/mg protein, respectively.  
 
Statistical analysis 
Statistical analysis was performed using Statistical Package for Social Sciences 
version 16 (SPSS) and GraphPad Prism version 5. Unpaired t test and one-way 




various data sets. Orthogonal regression analysis and Pearson’s correlation (r) 
were used to explore the relationship between two variables. Survival curves were 
plotted using the method of Kaplan and Meier. Results are reported as mean ± S.E. 
A p-value of <0.05 was considered statistically significant.   
 
Results 
Overall, 41 patients with NETs were included (Table 1) of which the majority were 
female. Most patients (28/41) had a solitary primary tumour, while 13/41 patient 
had multiple primaries. Primary tumours of 23/41 patients were localized in the 
pancreas, 5/41 in the duodenum, 10/41 in the small bowel , 1/41 in the appendix, 
1/41 in the sigmoid, and in one patient, the exact primary tumour location was 
unknown. Functional tumours were mainly insulinomas (42.1%) and gastrinomas 
(52.6%). Tumour size was significantly different between the groups, P=0.01, with 
a smaller tumour size for functional PNETs. Metastases were seen in the majority 
of patients, with an almost equal distribution of lymph node or liver location. 
Angioinvasion was present in only 18.3% of the tumours.  
Endoglin and VEGF tissue levels were measured in 27 tumour samples from 18 
patients with GEP-NETs. Endoglin and VEGF levels were significantly increased 
in tumours compared to (associated) normal tissues (Table 2). However, among 
the various types of GEP-NETs, both endoglin and VEGF levels were comparable. 
Interestingly, metastatic tumours showed significantly higher endoglin levels 
compared to those in primary lesions. VEGF levels were also increased in 
metastases, although not significantly. Furthermore, well-differentiated NECs 
showed significantly higher endoglin levels compared to well-differentiated NETs. 
Again, this difference in VEGF levels was not statistically significant, although 
levels in well-differentiated NECs were also increased. Of particular interest, we 
observed that primary tumour tissues of patients who had developed (lymph 
node or liver) metastases displayed significantly higher endoglin levels than from 
those without metastases. Neither endoglin nor VEGF levels were (significantly) 
related to other clinicopathological parameters including patients’ age, sex, the 




hormonal status (i.e., functional or non-functional) of the PNETs, or the presence 
of angioinvasion. 
 
Endoglin tissue levels, but not tissue levels of VEGF, were found to increase with 
tumour size (Figure 1). Finally, endoglin tumour levels showed no significant 
correlation with VEGF tumour levels (r=0.11 with P=0.59). 
Table 1. Patient and tumour characteristics 
Patients (n=41) Tumours (n=60) 
 
Age  Years 
 
Primary or metastatic n (%) 
Mean ± s.d. 47 ± 14 
 
Primary   45 (75.0%) 
Range 20 - 77 Metastasis 15 (25.0%) 
 
Sex n (%) 
 
Angioinvasion n (%) 
 
Male 17 (41.5%) 
 
Present 11 (18.3%) 
Female 24 (58.5%) Absent 49 (81.7%) 
 
Tumour type n (%) 
 
Tumour size Mean ± s.d. (cm) 
 
Carcinoid 12 (29.3%) 
 
Carcinoids 3.4 ± 2.7 
Functional PNET 19 (46.3%) Functional PNETs 1.9 ± 1.7 
Non-functional PNET 10 (24.4%) Non-functional PNETs 3.6 ± 2.4 
 
Tumour grade n (%) 
 
Well-differentiated NET 13 (31.7%) 
Well-differentiated NEC 26 (63.4%) 
Poorly differentiated NEC 1 (2.4%) 
Unknown 1 (2.4%) 
 
Metastases n (%) 
 
Present 26 (63.4%) 
     Lymph node only 9 (34.6%) 
     Liver only 7 (26.9%) 
     Both 10 (38.5%) 
Absent 15 (36.6%) 




Figure 1. Orthogonal linear regression analysis
of tumour size and endoglin levels




























Figure 1. Orthogonal regression analysis of endoglin tissue levels and tumour size (n=26). 
Increasing endoglin levels in tumours are significantly correlated with a greater tumour size, 
r=0.62 with p<0.01.  
 
The immunohistochemical expression of endoglin and CD31 was analyzed in 39 
patients with GEP-NETs. All tumours showed expression for CD31 and endoglin 
on intratumour vascular ECs. Endoglin expression was mainly observed on ECs of 
small tumour-associated blood vessels, while its expression in normal, non-



















Figure 2. Immunostaining of gastroenteropancreatic neuroendocrine tumours
A
B



























Figure 2. Immunostaining of endoglin and CD31 on peritumoural and intratumoural vessels in 
GEP-NETs. A) Endoglin staining is limited to angiogenic vessels, whereas CD31 stains both old 
and new blood vessels in tumour tissue. Magnification 100x. B) Representative endoglin staining in 
a pancreatic neuroendocrine tumour and a gastrointestinal carcinoid metastasis (mesenterium of 
small bowel). Magnification 100x. Inserts show a higher magnification at 200x.  
 
The CD31 MVD was found to be significantly higher than the endoglin MVD in 
73% of the tumour samples, P<0.01. No significant differences in endoglin and 
CD31 MVD were observed between carcinoids and PNETs (Table 3). Furthermore, 
both endoglin and CD31 MVD were not significantly related to clinicopathological 






















Endoglin (ng/mg) VEGF (pg/mg) 
 n Mean S.E. P n Mean S.E. P 
 
Tissues         
    
   Normals 38 12.1 2.0 <0.01 38 75.0 9.5 <0.01 
   Tumours 27 26.8 4.5  26 316.8 46.0  
 
Tumour type - tumours         
    
   Carcinoid 8 35.3 11.4 0.37 8 354.9 72.0 0.67 
   Functional PNET 14 25.4 4.7  13 274.4 46.7  
   Non-functional PNET 5 16.8 8.7  5 366.2 186.8  
 
Origin         
   
   Primary tumours 19 18.8 3.9 <0.01 18 293.2 52.0 0.45 
   Metastastic tumours 8 45.7 9.0  8 369.9 95.8  
 
WHO classification         
    
   Well-differentiated NETs 6 7.6 5.2 0.02* 6 200.2 52.8 0.21* 
   Well-differentiated NECs 20 32.9 4.0  19 328.5 60.2  
    Poorly-differentiated NECs 1 19.0 ND  1 795.0 ND  
 
Primary tumours: Metastases       
   
   Present 12 24.8 5.2 0.04 11 339.5 76.4 0.28 
   Absent 7 8.5 3.5  7 220.6 54.8  
 
Table 2. Mean values of endoglin and VEGF levels in GEP-NETs in relation to major 
clinicopathological parameters. Bold p-values are considered statistically significant.  


















Table 3. MVD determined by endoglin and CD31 in GEP-NETs in relation to clinicopathological 
parameters. Bold p-values are considered statistically significant. *Values x 1,000 pixels per area. ** 
Result of unpaired t test to compare well-differentiated NETs with well-differentiated NECs. 
 
Endoglin and CD31 MVD were significantly correlated with endoglin tumour 
levels; r=0.64 with P<0.01 (Figure 3) and r=0.58 with P<0.01, respectively. VEGF 
tumour levels were not correlated with endoglin MVD (r=0.28 with P=0.25), but 
were borderline significantly correlated with CD31 MVD, r=0.43 with P=0.07.   
 
Table 3. MVD scores in GEP-NETs in relation to clinicopathological parameters 
 
 
MVD-endoglin  MVD-CD31 
 n Mean* S.E.* P  n Mean* S.E.* P 
 
Tumour type - tumours          
    
   Carcinoid 11 55 107 0.30  13 123 23 0.75 
   Functional PNET 24 65 8   23 106 18  
   Non-functional PNET 14 85 18   14 100 17  
 
Origin          
   
   Primary tumours 36 66 8 0.58  37 111 13 0.69 
   Metastatic tumours 13 75 15   13 101 24  
 
WHO classification          
    
   Well-differentiated NETs 13 69 18 0.93**  13 76 12 0.08** 
   Well-differentiated NECs 33 67 7   34 121 15  
   Poorly-differentiated NECs 1 212 x   1 82 x  
 
Primary tumours: Metastases     
    
   Present 19 66 9 0.96  20 138 18 0.05 




Figure 3. Correlation between MVD and tissue levels of
endoglin in tumours

























Figure 3. Correlation analysis of the endoglin MVD and endoglin tissue levels in tumours (n=17). 
For one patient in whom endoglin tissue levels were assessed, no paraffin slides for MVD 
determination was available. Endoglin MVD is significantly correlated with tumour levels of 
endoglin, r=0.64 with p<0.01.  
 
To evaluate the prognostic potential of endoglin and VEGF tissue levels, Kaplan 
Meier survival analysis was performed (Figure 4) by dividing the patients into two 
groups (i.e. low versus high) using the mean value of endoglin and VEGF tumour 
levels (Table 2). Both endoglin and VEGF tissue levels were not significantly 
related to patient survival. Furthermore, patients were divided into two groups 
based on the MVD of endoglin and CD31. Both parameters were not significantly 
correlated with overall survival of these patients. 




A) Endoglin tissue levels
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B) VEGF tissue levels
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Figure 4a. Survival analysis on tissue levels
 
C) Endoglin MVD
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Figure 4b. Survival analysis on MVD
 
 
Figure 4. Kaplan Meier survival analysis for endoglin tumour levels (a), VEGF tumour levels (b), 
endoglin MVD (c) and CD31 MVD (d). Patients were divided into two groups based on mean 
tumour levels (a,b) or mean MVD-scores (c,d). None of the parameters showed a significant 
relation with survival of the patients.   
 
Discussion 
In this study, we observed that the expression of the angiogenic cell marker 
endoglin was related to tumour size, aggressiveness and metastatic potential in 
patients with GEP-NETs, whereas expression of another key player in 
angiogenesis, namely VEGF, was not.   
In general, GEP-NETs are highly vascularised. In recent years it has become clear 




and the therapeutic role of angiogenesis inhibitors in the treatment of cancers is 
increasing17,18. In this study, we investigated whether endoglin and VEGF were 
related to any clinicopathological characteristics of GEP-NETs and evaluated their 
potential prognostic implications.  
By immunohistochemistry, we observed high endoglin expression on vascular 
ECs in tumour tissues of GEP-NETs. In contrast to CD31, immunopositivity of 
endoglin was mainly observed on newly formed blood vessels, which indicates 
that endoglin is more representative of tumour neovascularisation than the pan-
endothelial marker CD31.   
Furthermore, we found that endoglin tissue levels were significantly higher in 
tumours compared to normal tissues. Interestingly, we observed that an increased 
endoglin expression was indicative of metastatic disease. Endoglin levels were 
higher in metastases compared to primary tumours, and primary tumours with 
metastases showed higher endoglin levels compared to tumours without 
metastases. Additionally, endoglin levels were increased in well-differentiated 
NECs compared to well-differentiated NETs, and higher endoglin levels were 
related to larger tumour size in patients with GEP-NETs. In several cancers, the 
extent of tumour angiogenesis was shown to be reflective of their potency to 
become invasive and form metastases19,20. Our data indicate that tissue endoglin 
may serve as a potential assessment marker for the tumour aggressiveness (i.e., 
NEC versus NET) and the presence of metastases following tumour resection. In 
the context of anti-cancer therapy, anti-endoglin treatment might provide a new 
effective anti-angiogenic strategy for GEP-NETs, but more research is needed. 
However, several promising in vivo and in vitro studies using anti-endoglin 
antibodies for anti-cancer treatment have recently been published21.    
In the present study, we did not evaluate the immunohistochemical expression of 
VEGF. High immunoexpression of VEGF on GEP-NETs has already been shown 
by others, but opposing results regarding the prognostic role of VEGF in these 
tumours have been reported; Takahashi et al. found no correlation of VEGF-A 
immunoexpression with growth of blood vessels, haematogenous spread or 
tumour growth in pancreatic endocrine tumours. In contrast, Zhang et al. have 




revealed that strong expression of VEGF was associated with increased 
angiogenesis and poor prognosis in patients with GEP-NETs 22,23. However, we 
determined tissue VEGF expression in GEP-NETs and found that VEGF tissue 
levels showed a similar pattern to endoglin, but were not significantly related to 
any clinicopathological parameter. Therefore, we assume that, although VEGF is 
most likely to be involved in the process of neoplastic blood vessel formation in 
GEP-NETs, this key mediator of angiogenesis is not the appropriate prognostic 
marker in these tumours. In contrast, our data suggest that endoglin can function 
as a predictive marker for the development of metastases in GEP-NETs. Endoglin 
is a co-receptor for TGF-β1. Among the various members of the TGF-β family, 
TGF-β1 is mostly involved in cancer, and has been shown to stimulate 
angiogenesis24. Endoglin is an important modulator of the TGF-β response, 
particularly in tumour pathogenesis25. In another study by our group, strongly 
increased tissue levels of endoglin were observed in colorectal cancers, whereas 
premalignant lesions displayed endoglin levels comparable to those in normal 
tissues, which supports the pivotal role of endoglin in tumour progression14.  
The fact that neither endoglin nor VEGF levels were associated with patient 
survival might be due to the relatively good prognosis of the patients. 
Gastrointestinal carcinoids show a 5-year survival rate of about 70%, whereas 
PNETs have a reported 5-year survival rate ranging from 25 to 100%, even in the 
case of (unresectable) liver metastases26,27. In our study cohort, 10/18 patients in 
whom endoglin or VEGF levels were determined were still alive at the end of the 
study (median survival 8 years), which makes it unlikely to use one of these 
parameters as a predictor of outcome or survival marker. However, our data 
support a role for endoglin in identifying patients with GEP-NETs at risk for 
metastasis.  
It is worth reiterating that the current study involved a relatively small number of 
patients. Nevertheless, GEP-NETs are a rare disease with a low incidence, which 
leads to general scarcity of patients and samples. However, we believe that the 
significant differences observed here are representative and illustrate the 




In conclusion, we suggest that endoglin is a potential marker to predict present 
and future metastases, which might help to optimize the therapeutic approach in 
patients with GEP-NETs.  
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The Insulin-like Growth Factor (IGF) system plays an important role in the tumour 
development, growth, and spread of several cancers.  
Matrilysin (MMP-7) has been implicated in tumour processes like invasion and 
metastasis. Recently, matrilysin was found to be able to cleave IGF binding 
proteins (IGFBPs), thereby increasing the bioavailability of IGFs.  
The aim of the present study was to investigate the expression of IGF-1, IGFBP-3 
and matrilysin in gastroenteropancreatic neuroendocrine tumours (GEP-NETs), 
and their relation to the pathogenetic factors of the tumours.  
Tissue expression and levels of IGF-1, IGFBP-3, and matrilysin were analyzed by 
immunohistochemistry and ELISA, respectively.  
IGF-1 and IGFBP-3 tissue levels were increased in tumours compared to 
associated normal tissue. This increased IGFBP-3 expression in tumours was 
related to a larger tumour size and the presence of metastases, whereas IGF-1 was 
not related to any clinicopathological parameter. Matrilysin expression was found 
to be down-regulated in tumours, and negatively correlated to the expression of 
IGFBP-3.  
These findings suggest that IGFBP-3 plays a role in the pathogenesis of GEP-NETs, 
whereas matrilysin might indirectly be involved via regulation of this IGFBP-3 
expression. Further studies are indicated to assess the contribution of this IGF-
















Neuroendocrine tumours comprise a heterogeneous group of neoplasms, arising 
from enterochromaffin cells widespread distributed throughout the 
gastrointestinal and bronchopulmonary system1,2. In this study, we focus on 
gastroenteropancreatic neuroendocrine tumours (GEP-NETs), including the 
pancreatic neuroendocrine tumours (PNETs) and the gastrointestinal carcinoids 
(GI-NETs).  Although slowly-growing, the majority of GEP-NETs are malignant 
and characterized by angioinvasion and the presence of metastases3.  
The insulin-like growth factor (IGF) system, composed of two IGF ligands (IGF-1 
and IGF-2), three receptors and six binding proteins (IGFBPs), plays an important 
role in growth and development4. Furthermore, this system is involved in tumour 
cell processes like proliferation, survival and growth5. Increased levels of insulin-
like growth factor-1 (IGF-1) have been reported to be related to the development 
of cancer of the breast, lung, colon and prostate6-9. In NETs, mRNA levels of 
several components of the IGF-system were found to be variable in different types 
of NETs10. Furthermore, increased expression of IGF-1 and its receptor IGF-1R in 
gastrinomas were found to be associated with higher tumour aggressiveness11.  
MMPs, or matrix metalloproteinases, constitute a family of more than 20 
proteolytic enzymes, with similar protein sequences and domain structures, but 
diverse substrate specificities, which are involved in remodeling of the 
extracellular matrix under both physiological and pathological conditions12. 
Matrilysin, or MMP-7, belongs to the subgroup of stromelysins. Like other MMPs, 
matrilysin is secreted as a proenzyme, of which proteolytic removal of the 9 kDa 
prodomain from the N-terminus leads to activation of the enzyme. Uniquely, 
matrilysin is produced by epithelial rather than stromal cells13. Various studies 
have shown that matrilysin is significantly enhanced in cancer of the breast, 
prostate, lung, skin, and colorectum14-19. Furthermore, matrilysin expression has 
been related to the presence of lymph node metastases in gastric cancer patients20. 
In addition, several studies have shown that matrix metalloproteinases indirectly 
participate in controlling the levels of IGFs, through proteolytic cleavage of the 




Miyamoto et al. have recently shown that proteolysis of the IGFBP-3 by matrilysin 
increases the bioavailability of IGF-1, leading to enhanced cell survival24. In the 
present study, we aimed to evaluate the expression of matrilysin, IGF-1 and 
IGFBP-3 on GEP-NETs, to assess whether such a growth-activation cascade also 
exists in these tumours. 
 
Material and methods 
Patients 
After surgical removal, tumour tissues were collected at the Department of 
Gastroenterology, Leiden University Medical Centre (LUMC), Leiden, and either 
frozen at -80 ○C and/or embedded in paraffin for immunohistochemical staining.  
Fifty-one homogenates (23 tumour samples and 28 normal samples) of 25 patients 
were available for the determination of tissue levels of matrilysin, IGF-1 and 
IGFBP-3. For immunostaining of IGF-1, IGFBP-3 and matrilysin, 44, 44 and 36 
samples respectively, of 35 patients, were available.  
GEP-NETs comprised pancreatic neuroendocrine tumours (PNETs) and 
gastrointestinal neuroendocrine tumours (GI-NETs), which were also referred to 
as ‘carcinoids’. Clinicopathological information was obtained by evaluation of 
patients’ medical files and pathology reports, when available. According to the 
classification of the World Health Organization for GEP-NETs, tumours were 
categorized into well-differentiated neuroendocrine tumour (NET), well-
differentiated neuroendocrine carcinoma (NEC), or poorly differentiated NEC25. 
This study was performed according to the guidelines of the Medical Ethics 
Committee of the LUMC in compliance with the Helsinki Declaration.  
 
Quantitative determination of matrilysin, IGF-1 and IGFBP-3 in tissue samples 
Tissues were homogenized and protein concentrations were determined according 
to Lowry et al.26. Matrilysin, IGF-1 and IGFBP-3 levels were determined in tissue 
homogenates, using commercially available quantitative immunoassays (ELISA) 
for human matrilysin, IGF-1 and IGFBP-3, respectively, performed according to 




the manufacturer’s instructions (R&D Systems). Matrilysin, IGF-1 and IGFBP-3 
levels were expressed per mg protein.  
 
Immunohistochemistry 
Immunohistochemistry was performed as follows. Tissues were fixed in formalin, 
embedded in paraffin and cut into 5 μm sections. After deparaffinisation and 
rehydration, endogenous peroxidases were blocked in methanol containing 0.3% 
H202 (Merck, Darmstadt, Germany). Antigen retrieval was performed by boiling in 
0.01M citrate buffer pH 6.0 for 10 minutes. Slides were incubated overnight at 
room temperature (RT) with primary antibodies: monoclonal mouse anti-human 
MMP-7 (1.25 µg/mL), polyclonal goat anti-human IGF-1 (10 µg/mL), and 
polyclonal goat anti-human IGFBP-3 (5 ug/mL, all R&D Systems Europe, 
Abingdon, UK), diluted in phosphate-buffered saline (PBS) with 1% bovine serum 
albumin (BSA). Incubation with goat-anti-mouse (for MMP-7) and rabbit-anti-goat 
(for all IGF-system components) immunoglobulins for 30 minutes at RT was 
followed by incubation with horseradish peroxidase (HRP)-streptavidin complex 
(all Dako, Glostrup, Denmark) for 30 minutes at RT. Cervix carcinomas were used 
as positive controls. Negative controls were included by omitting the primary 
antibodies. Representative photomicrographs were taken with an Olympus BX-
51TF microscope equipped with a DP23-3-5 camera. 
 
Immunohistochemical evaluation 
Staining for matrilysin, IGF-1, and IGFBP-3 in tumour cells was scored 
semiquantitatively, according to a system proposed by Ruiter et al.27. As final 
score, the mean result of 2 independent individuals (P.K. and E.J.M.) was used. 
The percentage of tumour cells that stained positive were scored as follows: 0, 
absent; 1, 1–5% sporadic; 2, 6–25% local; 3, 26–50% occasional; 4, 51–75% majority 
and 5, 76–100% large majority. The intensity of tumour cell staining was scored as: 
0, no; 1; weak; 2, moderate and 3, intense staining. A total score was calculated by 






Statistical analysis was performed using Statistical Package for Social Sciences 
version 16 (SPSS) and GraphPad Prism version 5. Unpaired t test and one-way 
ANOVA were used to compare mean levels between various data sets. Pearson’s 
correlation (r) was used to explore the relationship between two variables. Results 




Patient and tumour characteristics 
The majority of the patients in this study were female (59%). Primary tumours of 
nine patients were localized in the pancreas, one in the duodenum, and six in the 
small bowel. Functional tumours were four insulinomas, two gastrinomas and one 
glucagonoma. The majority of tumours (95.7%) were well-differentiated. Tumours 
were classified according to the WHO classification into five well-differentiated 
NETs, seventeen well-differentiated NECs, and one poorly differentiated NEC. 
Carcinoid tumours were larger in size compared to pancreatic neuroendocrine 
tumours, mean size 4.9±1.2 cm vs. 2.7±0.6 cm, P=0.08. Metastases were seen in the 
majority of patients (76.5%); one patient with liver metastases, four patients with 
lymph node metastases, and eight patients with both liver and lymph node 
metastases. Angioinvasion was present in only 21.7% of the tumours.  
 
Tissue levels of matrilysin, IGF-1 and IGFBP-3 
IGF-1, IGFBP-3 and matrilysin tissue levels were measured from 25 patients with 
GEP-NETs (Table 1).  Both IGF-1 and IGFBP-3 levels were found to be increased in 
tumours compared to (associated) normal tissues, only the latter being statistically 
significant, P<0.01. In contrast, tumour levels of matrilysin were somewhat lower 
compared to matrilysin levels in normal samples. Among the various types of 
GEP-NETs, i.e., carcinoids versus functional PNETs and non-functional PNETs, 
levels of IGF-1 and IGFBP-3 were not significantly different. Matrilysin levels, 
however, were significantly higher in non-functional PNETs compared to 




functional PNETs and carcinoids, P=0.03. IGFBP-3 levels were somewhat higher in 
metastatic tumours compared to primary tumours, P=0.06. IGFBP-3 levels in 
primary tumours with and without metastases were not significantly different. 
Both IGF-1 and matrilysin levels were higher in primary tumours compared to 
metastases, and lower in primary tumour tissues of patients who had developed 
metastases than those without metastases, although not significant. IGF-1, IGFBP-
3 and matrilysin levels were not related to other tumour parameters like tumour 
size or the presence of angioinvasion.  
Table 1. Tissue levels of IGF-1, IGFBP-3 and matrilysin in GEP-NETs 
 IGF-1 (pg/mg) IGFBP-3 (ng/mg) Matrilysin (pg/mg) 
 Mean±S.E. P-value Mean±S.E. P-value Mean±S.E. P-value 
Tissues             
   Normals (n=28) 52.1±10.1  0.6±0.2  206.6±56.7   
   Tumours (n=23) 85.4±19.3  0.12 6.9±1.6  <0.01 163.0±48.1 0.57 
              
Tumour types             
   Carcinoid (n=7) 51.4±12.7  3.5±2.1  46.7±14.9   
   Functional PNET (n=12) 115.3±33.7   8.0±2.1   146.3±52.2   
   Non-functional PNET (n=4) 54.9±27.3  0.28 9.5±5.5 0.35  416.8±192.7 0.03 
              
Origin             
   Primary (n=16) 96.6±26.7  5.0±1.7  196.5±67.2   
   Metastasis (n=7) 59.6±16.3  0.39 11.2±3.0 0.06  86.4±26.3 0.30 
              
Metastases             
   Present (n=11) 79.1±29.3  4.7±2.1  120.6±57.6   
   Absent (n=5) 135.2±57.2 0.35  5.65±2.8 0.81  363.4±160.4 0.09 
 
 
Table 1. Mean values of IGF-1, IGFBP-3 and matrilysin tissue levels in relation to 
clinicopathological parameters. Significant p-values are in bold. 
 
Immunohistochemical expression of matrilysin, IGF-1 and IGFBP-3 
The results of the immunohistochemical evaluation is shown in Table 2 and Figure 
1. For IGF-1, IGFBP-3 and matrilysin the cytoplasmic staining of tumour cells was 
generally strong. Remarkably, staining of matrilysin was stronger in tumour-
associated normal tissue compared to tumour tissue in 61.5% of the samples, in 




generally absent in normal tissue, and when present, the staining was less strong 
than in tumour tissue. Nuclear staining of tumour cells by IGF-1 was seen in 75% 
of the tumours. For IGFBP-3, membrane staining was found in more than 50% of 















Table 2. Immunohistochemical staining results for IGF-1, IGF-2, IGF-1R, IGFBP-3 and matrilysin on 
tumour cells in 36<n<44 gastroenteropancreatic neuroendocrine tumours.  
 
Staining scores for matrilysin did not differ between carcinoids and the two types 
of PNETs (all 7). For IGF-1 and IGFBP-3, staining scores in carcinoids and F-
PNETs were both 6, whereas for NF-PNETs these were both 7.  
Total staining scores were mutually correlated (Table 3). IGF-1 expression was 
significantly related to the expression of IGFBP-3. Interestingly, matrilysin 
expression was negatively correlated to the expression of IGF-1 and IGFBP-3, 
although only the latter being significant, P=0.02. Furthermore, staining scores 
were evaluated in relation to clinicopathological parameters, such as tumour size, 
angioinvasion, WHO classification, and the presence of metastases. Interestingly, a 
larger tumour was correlated to more IGFBP-3 staining in tumour cells (r=0.45, 
P=0.002). No other significant correlations were found. Finally, tumour levels of 
IGF-1, IGFPBP-3 and matrilysin were not significantly correlated with the 
immunohistochemical staining scores for these proteins (-0.143<r<0.413).  
 
 
Table 2. Immunohistochemical evaluation 
 IGF-1 IGFBP-3 Matrilysin 
GEP-NETs n=44 n=44 n=36 








Staining present % % % 
     Cytoplasm 100 97.7 97.2 
     Nucleus 75.0 2.3 0 
     Membrane 0 52.3 0 
Normal tissue n=34 n=34 n=26 
     Staining present  











   
Table 3. Mutual correlations of immunostaining scores 

















Table 3. Mutual correlations between immunohistochemical staining results for IGF-1, IGFBP-3 and 
matrilysin on tumour cells of gastroenteropancreatic neuroendocrine tumours. Bold  
p-values indicate a significant correlation.  
 
 
Figure 1. Immunohistochemical staining for a, b) IGF-1, c,d) IGFBP-3 and e,f) matrilysin on tumour 
cells of a duodenopancreatic gastrinoma (a, c, d) and gastrointestinal NET (carcinoid) (b, c, e). 
Magnification x100. In the insert of d) membrane staining of IGFBP-3 is shown at a higher 











In this study, we examined the expression of IGF-1, IGFBP-3, and matrilysin in 
GEP-NETs, and find indications of an interrelated role for IGFBP-3 and matrilysin 
in the pathogenesis of these tumours.  
The IGF system is of particular interest in cancer, as it is involved in many 
processes related to tumour growth4. IGF-1 has been described to have important 
functions in tumour development, such as the inhibition of apoptosis, the 
promotion of tumour growth, the inducement of transformation, and the 
promotion of metastasis in several cancers28. In gastrinomas, IGF-1 mRNA levels 
were found to be increased, and related to tumour growth, aggressiveness and 
curability11. IGF-1 is mainly present in the circulation, where it is bound to IGFBPs 
that act to protect IGF-1 from degradation by proteases28,29. IGFBP-3 is the most 
abundant IGFBP in the circulation24. The IGFBPs have both stimulating and 
inhibiting effects on IGFs. Gigek et al. described that when IGFBP-3 binds IGF-1, it 
inhibits its binding to one of the IGF receptors, thereby counteracting the actions 
of IGF-130. In a study of Miyamoto et al., a correlation between high levels of IGF-1 
and low levels of IGFBP-3 was found24. Matrilysin has been shown to be involved 
in tumour cell invasion and the development of metastases20. In several cancers of 
the digestive tract, including gastric, oesophageal, pancreatic and colorectal 
cancer, matrilysin tissue levels were upregulated and related to malignant 
behaviour and a poor prognosis of the patients20,31-34. From previous studies it is 
known that matrix metalloproteinases are able to serve as proteinases for the 
various IGFBPs21-23,35. McGaig et al., for example, have shown that Helicobactor 
pylori-associated epithelial-derived matrilysin cleaves IGFBP-5, thereby liberating 
IGF-2, which in turns stimulates epithelial cell proliferation, suggested to 
contribute to the progression to gastric cancer36. In addition, matrilysin was shown 
to be able to cleave IGFBP-3, thereby increasing the bioavailability of IGF-1 to 
cancer cells24.  
We evaluated IGF-1, IGFBP-3, and matrilysin in GEP-NETs to assess whether they 
are part of a similar growth activation process in these tumours.  




Using ELISA, we measured tissue levels of matrilysin, IGF-1, and IGFBP-3 in the 
various neuroendocrine tumours of the gastroenteropancreatic tract. Both IGF-1 
and IGFBP-3 tumour levels were increased compared to levels in normal tissue, 
although only the latter was significant. In addition, we found that IGFBP-3 levels 
were up-regulated in metastatic tumours samples compared to primary tumours. 
Furthermore, a higher IGFBP-3 staining was be indicative of a larger tumour size. 
Together, these findings suggest that IGFBP-3 might play a role in the 
tumourigenesis of GEP-NETs, independent of IGF-1. Although the expression of 
IGF-1 and IGFBP-3 were significantly correlated, IGF-1 expression in the tumour 
alone showed no association with any clinicopathological parameter. Similarly, 
Wulbrand et al. found no relation between IGF-1 expression and the presence of 
metastases in GEP-NETs, whereas Furukawa et al. previously showed that 
enhanced levels of IGF-1 in gastrinomas were related to tumour growth, 
aggressiveness and extent10,11.  
Remarkably, matrilysin levels were lower in tumours compared to associated 
normal tissues of patients with GEP-NETs. By immunohistochemical staining of 
matrilysin, we observed a similar pattern. Furthermore, tissue levels of matrilysin 
were lower in metastatic tumours and in metastases compared to primary 
tumours. Although a high matrilysin expression in tumours has been related to a 
more malignant phenotype and a poor prognosis in several cancer types, the 
results of our study suggest that matrilysin is not directly involved in the 
pathogenesis of GEP-NETs14-20. However, matrilysin might indirectly be related to 
malignant tumour behaviour, as a negative correlation between matrilysin and 
IGFBP-3 expression on tumour cells by immunohistochemistry was observed. So 
when the expression of matrilysin on tumour cells was high, a low expression of 
IGFBP-3 was found, and vice versa. Possibly matrilysin regulates the expression of 
IGFBP-3, thereby indirectly effecting the tumour’s extent of malignancy. One 
explanation could be that matrilysin acts as a protease that cleaves IGFBP-3 
present on the tumour cells. The observation that IGFBP-3 staining is also present 
on the membrane of tumour tissue supports this assumption. Further in vitro 




gastroenteropancreatic neuroendocrine tumour cells, to reveal whether these cells 
secrete IGFBP-3, and if so, whether this process is mediated by matrilysin. In 
combination with serological analyses of GEP-NET patients these studies will 
elucidate whether matrilysin regulates secretion, complex formation and 
breakdown of IGFBP-3 in these tumours.  
In summary, we found that the levels of IGF-1 and IGFBP-3 were increased in 
GEP-NETs, whereas matrilysin was decreased. Higher IGFBP-3 expression was 
related to the presence of metastases and a larger tumour size, which might 
indicative of a more malignant tumour. For matrilysin, an opposite trend was 
observed. Together, these findings suggest that IGFBP-3 plays a direct role in the 
pathogenesis of GEP-NETs, whereas matrilysin might indirectly be involved via 
regulation of this IGFBP-3 expression. Further studies are required to investigate 
this potential growth mechanism in more detail.  
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Summary main observations 
Clinical behaviour of gastroenteropancreatic neuroendocrine tumours (GEP-
NETs) varies strikingly, both in terms of symptoms and outcome1-3. An 
understanding of the basic biology unique to GEP-NETs is necessary for optimal 
management of patients with these complex tumours. Although markers for GEP-
NETs exist, sensitive and specific markers that predict tumour growth and 
behaviour are lacking4. The general purpose of the studies described in this thesis 
was to investigate the epidemiology, diagnosis and pathogenesis of GEP-NETs in 
The Netherlands, to reveal insights in the underlying mechanisms contributing to 
the development and progression of these tumours. The major findings reported 
in this thesis are highlighted in Figure 1.  
 
Epidemiology of GEP-NETs in The Netherlands 
Although GEP-NETs were considered as rare tumours, incidence rates have been 
reported to increase substantially in recent years5-7. Furthermore, a relatively high 
number of incidental findings of clinically silent NETs by autopsy studies was 
suggested in literature8,9. We calculated the current incidence of gastrointestinal 
carcinoids and duodeno-pancreatic NETs in The Netherlands, by the use of the 
PALGA database (Chapter 2 and Chapter 3)10. Interestingly, the incidence of non-
functional pancreatic and duodenal NETs showed a significant increase from 1991 
till 2009, whereas the incidence of gastrointestinal carcinoids increased 
significantly over 2000 to 2009 as well. Although this increase in incidence of GEP-
NETs is likely to be the result of improved diagnostics rather than an actual 
increase in occurrence of these tumours, non-functional tumours are still detected 
at a relatively late stage illustrated by the larger size and a diagnosis at an older 
age than in those patients affected by a functional neuroendocrine tumour. In 
Chapter 2, we provided an overview on recent developments in the diagnosis of 
GEP-NETs, to increase the intelligibility and awareness of these tumours among 
clinicians and pathologists, in order to facilitate earlier detection and to prevent 







Gastrinomas, after insulinomas, are the most common type of functional 
neuroendocrine tumours. They are frequently located in the pancreas and 
duodenum11. However, gastrinomas can also occur at ectopic sites12-14. In Chapter 
4 we described a unique case of recurring hepatic gastrinomas in a patient 
suffering from the Zollinger-Ellison syndrome (ZES), in whom no other (primary) 
tumour was detected, even though with a follow-up of almost 20 years. In this 
context, we reviewed the literature on primary liver gastrinomas, and found 16 
studies in which gastrinomas in the liver were defined as primary. However, we 
believe that the interpretation of hepatic gastrinomas as primary lesions can still 
be questioned. Nonetheless, our study showed that a gastrin-producing tumour in 
the liver can recur. As most cases lack an investigational and well-documented 
follow-up, we recommend a long-lasting follow-up including frequent serum 
gastrin measurements and repeated imaging investigations in case of a suspected 
hepatic gastrinoma.  
Gastrinomas produce and secrete gastrin, a hormone normally produced by G-
cells in the stomach to stimulate the acid secretion. Patients with gastrinomas 
therefore suffer from symptoms related to hyperacidity, such as acid reflux, 
abdominal pain, recurrent ulcers, and diarrhoea. Together these symptoms are 
called the Zollinger-Ellison syndrome (ZES)15. Usually, ZES is suspected in case of 
increased fasting serum gastrin levels and/or the presence of symptoms. 
However, the increased use of proton pump inhibitors or other acid reducing 
medications often masks symptoms, contributing to a delay in diagnosis in these 
patients16. Furthermore, serum gastrin levels can be non-conclusive. The secretin 
stimulation test has widely been used to diagnose ZES17. In the literature, 
however, the dosage of secretin and the criteria for a positive test have been 
disputed18-22. We discussed the diagnostic efficacy of the secretin stimulation test 
in patients with ZES by comparison of two different doses of secretin and selecting 
the most optimal criteria for a positive secretin test (Chapter 5). We found a 
gastrin increase of >100 ng/L to be the most sensitive and specific criterion for a 




study and confirmation group, we found that a higher dose of secretin (0.78 
µg/kg) did not contribute to a more valuable secretin stimulation test in 
diagnosing ZES. Therefore, we recommend the use of the low dose of secretin 
(0.26 µg/kg) in combination with a gastrin increase >100 ng/L as the optimal 




























Figure 1. Summary of the results obtained in the studies as described in this thesis.  
 
Heterogeneity and tumour markers in GEP-NETs 
Neuroendocrine tumours of the gastroenteropancreatic tract are a group of 
diverse, heterogeneous tumours. Although gastrointestinal carcinoids and 
pancreatic neuroendocrine tumours share their common origin of neuroendocrine 
cells of the digestive tract, these tumours show variable histopathological 
characteristics and behaviour, making it hard to predict outcomes and prognosis 
on basis of these features23. Therefore, we aimed to identify tumour parameters 





Carcinoids are predominantly found in the gastrointestinal (2/3rd) or pulmonary 
system (1/3rd). These tumours are able to secrete bioactive peptides, such as the 
bombesin-like peptides (BLPs) gastrin releasing peptide (GRP) and neuromedin B 
(NMB). In addition to stimulating a variety of physiological responses in the 
human body, BLPs are involved in the development and progression of several 
human cancers. By binding to their membrane-bound receptors on tumour cells, 
BLPs are able to activate autocrine loops, leading to growth of the tumour24. In 
small cell and non-small cell lung cancer, an autocrine loop involving BLPs has 
been suggested, whereas in colorectal cancer BLPs have been observed to act both 
as morphogens and mitogens25-27. We investigated the quantity and localization of 
bombesin receptors in gastrointestinal and pulmonary carcinoids, and revealed 
whether bombesin-like peptides and their receptors are of any value in 
distinguishing pulmonary carcinoids from carcinoids of intestinal origin (Chapter 
6). Based on our results, we conclude that in both pulmonary and intestinal 
carcinoids, all three bombesin receptors are present, although the quantity and 
ligand binding affinities are diverse on carcinoids of different origin; apparently 
on pulmonary carcinoids, bombesin receptors have a low binding affinity for 
bombesin, while intestinal carcinoids possess predominantly receptors with a high 
ligand binding affinity. Therefore, overall bombesin receptor expression seems not 
to be a very useful marker to distinguish carcinoids based on tumour origin. The 
combined presence of bombesin and its receptors might suggest the presence of a 
paracrine or autocrine growth loop in carcinoids, although further research is 
required to confirm this hypothesis. 
Angiogenesis plays an important role in tumour growth, progression and 
metastatic development28. Vascular endothelial growth factor (VEGF) and 
endoglin (CD105) are two key factors in angiogenesis. VEGF is a potent angiogenic 
growth factor stimulating endothelial cell proliferation, whereas endoglin, a TGF-
beta co-receptor, is highly expressed on endothelial cells of newly formed blood 
vessels29,30. In Chapter 7, a study to evaluate the expression and potential 
prognostic role of VEGF and endoglin in GEP-NETs is described.  Expression of 




associated normal tissue. This increased endoglin tissue expression in tumours 
was significantly related to the tumour’s size, the presence of metastases and a 
more advanced tumour stage. These findings implicate that endoglin can serve as 
a marker to detect present and to predict future metastases in GEP-NETs. 
Assessment of endoglin tumour levels provides information on tumour 
aggressiveness, which might help to optimize the therapeutic approach in patients 
with these tumours. As several in vivo and in vitro studies using anti-endoglin 
antibodies for anti-cancer treatment show promising results, we suggest that 
endoglin might provide a new therapeutic vascular target in GEP-NETs as well31. 
Although VEGF tissue levels showed a similar pattern to endoglin, these were not 
significantly related to any clinicopathological parameter. Therefore, we assume 
that, although VEGF is most likely to be involved in the process of neoplastic 
blood vessel formation in GEP-NETs, this key mediator of angiogenesis is not the 
appropriate prognostic marker in these tumours. 
The insulin-like growth factor (IGF) system, composed of the ligands IGF-1 and 
IGF-2, three receptors and six binding proteins (IGFBPs), plays an important role 
in cancer32. Several studies have shown that the expression of IGF-1 is up-
regulated in various tumours, and related to tumour growth and malignant 
behaviour33-35. Matrix metalloproteinases (MMPs) are a family of endopeptidases 
which act to degrade the extracellular matrix and are essential for tissue 
remodelling36.  
Matrilysin (MMP-7) is exclusively produced by tumour cells and implicated to be 
involved in various tumour processes37. For example, in pancreatic and colorectal 
cancer, an increased expression of matrilysin was found to be related to invasion 
and the presence of metastases38,39. Recently, several studies have shown that 
MMPs, including matrilysin, can regulate the bioavailability of IGFs to tumour 
cells, thereby participating in IGF-induced growth activation in tumours40.  
We examined the expression of IGF-1, IGFBP-3 and matrilysin in GEP-NETs, in 
order to investigate their relation to the pathogenetic factors of these tumours 
(Chapter 8). Tissue levels and expression of IGF-1 and IGFBP-3 were found to be 





a larger tumour size and the presence of metastases, which might be indicative for 
a more malignant tumour. The expression of matrilysin was down-regulated in 
tumours compared to associated normal tissue, and negatively correlated to the 
expression of IGFBP-3. These data suggest that IGFBP-3 plays a direct role in the 
etiopathogenesis of GEP-NETs, whereas matrilysin might indirectly be involved 
via regulation of this IGFBP-3 expression.  
 
Concluding remarks 
GEP-NETs comprise a group of heterogeneous tumours, with a wide and complex 
spectrum of clinical behaviour. They originate in a great diversity of tissues and 
are characterized by their ability to produce various hormonal peptides that cause 
distinct clinical syndromes. As incidence rates of both GI carcinoids and 
duodenopancreatic NETs are increasing over the past years in the Netherlands, 
these tumours might not be as uncommon as previously thought. This increasing 
incidence and large heterogeneity of GEP-NETs underlines the urgent need for 
better understanding of the underlying pathological mechanisms, in order to 
facilitate the development of new therapeutic strategies. In this thesis, several 
studies to reveal new markers in the pathogenesis of GEP-NETs are described. 
Foremost, we suggest endoglin as a novel marker to indicate the presence and 
potential development of metastases in GEP-NETs, of potential use in the post-
resection approach in the therapy of these tumours. Next, preliminary evidence 
for a role of two autocrine growth systems, involving the bombesin-like peptides 
GRP and NMB, and the IGF-system and matrilysin, respectively, in the growth 
and development of these tumours, is provided. Although further research to 
reveal the exact mechanism of these autocrine growth systems in GEP-NETs is 
required, these studies might provide the basis for the development of new anti-
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Gastroenteropancreatische neuroendocriene tumoren (GEP-NETs) vormen een 
zeldzame groep tumoren, die onderling sterk verschillen wat betreft hun 
biologische gedrag, tumorkenmerken en prognose. Ze bestaan uit 
neuroendocriene tumoren in de alvleesklier (pancreas) en neuroendocriene 
tumoren in het maag-darmkanaal, welke ook wel carcinoïden worden genoemd.  
Neuroendocriene tumoren in de alvleesklier kunnen afkomstig zijn van 
verschillende cellen. Ze worden onderverdeeld in functionele en niet-functionele 
tumoren. Functionele tumoren kunnen hormonen als gastrine, insuline, glucagon, 
somatostatine en VIP (vasoactieve intestinaal peptide) uitscheiden. Elk hormoon 
geeft aanleiding tot een eigen klinisch beeld (syndroom). Functionele 
neuroendocriene tumoren in de alvleesklier worden vernoemd naar het 
voornaamste hormoon dat zij uitscheiden en kunnen dus gastrinomen, 
insulinomen, glucagonomen, somatostatinomen of VIPomen heten. Niet-
functionele tumoren geven echter geen klachten op basis van 
hormoonuitscheiding en worden daarom vaak pas laat ontdekt, meestal wanneer 
de tumor zo groot is dat deze een obstructie veroorzaakt of uitzaaiingen 
(metastasen) heeft gevormd.  
Neuroendocriene tumoren van de alvleesklier komen ook frequent voor op 
plaatsen buiten de alvleesklier, zoals in de twaalfvingerige darm (duodenum) of 
lymfeklieren. Minder vaak worden deze tumoren gezien op uitzonderlijke locaties 
als lever, eierstokken, schildklier en bijnieren.  
Het aantal nieuwe gevallen per jaar (incidentie) van neuroendocriene tumoren in 
de alvleesklier en de twaalfvingerige darm is laag, en betreft ongeveer 1 per 
1.000.000 personen per jaar. Onder de neuroendocriene tumoren in de alvleesklier 
worden de goedaardige insulinomen het vaakst gezien, terwijl gastrinomen de 
meest voorkomende soort kwaadaardige neuroendocriene tumoren in de 
alvleesklier zijn. Gastrinomen scheiden het hormoon gastrine uit. Normaal 
gesproken wordt gastrine in de maag geproduceerd door de G-cellen, waar het de 
uitscheiding van maagzuur stimuleert. Patiënten met gastrinomen hebben daarom 





oprispingen, buikpijn, diarree, misselijkheid en braken. Samen worden deze 
klachten het Zollinger-Ellison syndroom (ZES) genoemd. De diagnose gastrinoom 
kan in deze patiënten gesteld worden op basis van hun klachten en verhoogde 
waardes van het hormoon gastrine in het bloed. Echter door het gebruik van 
zuurremmende medicatie, waaronder bijvoorbeeld proton-pomp-remmers, wordt 
de diagnose vaak niet of pas laat gesteld. Verder zijn de bloedwaardes van 
gastrine soms niet zodanig verhoogd dat deze bewijzend zijn voor een 
gastrinoom. De secretine-stimulatietest biedt dan uitkomst. Injectie van het 
peptidehormoon secretine leidt bij patiënten met een gastrinoom tot een snelle 
stijging van de gastrinespiegels in het bloed, terwijl deze reactie veel minder is of 
uitblijft wanneer er geen tumor aanwezig is.  
Neuroendocriene tumoren in het maag-darmkanaal zijn afkomstig van serotonine-
producerende enterochromaffine cellen in de darm of histamine-uitscheidende 
enterochromaffine-achtige cellen in de maag. Opmerkelijk is dat deze tumoren 
ook in de longen kunnen voorkomen. Het aantal nieuwe gevallen per jaar van 
neuroendocriene tumoren in het maag-darmkanaal ligt op ongeveer 10 tot 20 
personen per 1.000.000 per jaar, afhankelijk van de lokalisatie. Onder deze 
tumoren worden carcinoïden in het wormvormig aanhangsel van de dikke darm 
(appendix) het vaakst gezien. Verder komen deze tumoren voor in de maag, de 
dunne darm, de dikke darm, en de endeldarm. Neuroendocriene tumoren welke 
serotonine uitscheiden veroorzaken hiermee het klassieke ‘carcinoïd syndroom’ en 
worden daarom carcinoïden genoemd. Dit syndroom wordt gekenmerkt door 
ernstige diarree, opvliegers en ademhalingsstoornissen. Verhoogde spiegels van  
5-HIAA, het afbraakproduct van serotonine, in het bloed, leiden tot de diagnose.  
Neuroendocriene tumoren zijn naast hormonen ook in staat om neuropeptiden uit 
te scheiden. Bombesine is een neuropeptide, welke voor het eerst werd geïsoleerd 
uit de huid van de kikkersoort Bombina bombina. In mensen en zoogdieren zijn 
twee varianten van bombesine bekend, namelijk neuromedine B (NMB) en 
gastrin-releasing peptide (GRP). Een viertal receptoren waar bombesine en 
bombesine-achtige peptiden aan kunnen binden is geïdentificeerd: de 




(GRPR, BRS-2), de bombesine receptor subtype 3 (BRS-3) en subtype 4 (BRS-4). Uit 
verschillende literatuurstudies blijkt dat GRP en NMB en hun receptoren een 
belangrijke rol spelen in kanker, waarbij zij onderdeel zijn van een zelfstimulerend 
(autocrien) systeem dat leidt tot tumorgroei.  
Over het algemeen hebben neuroendocriene tumoren van de alvleesklier en het 
maag-darmkanaal een goede bloedvoorziening (vascularisatie). Angiogenese, de 
vorming van nieuwe bloedvaatjes uit bestaande bloedvaten, is een belangrijk 
proces in de ontwikkeling en groei van tumoren. Wanneer tumoren ongeveer 1 tot 
2 mm groot zijn worden ze afhankelijk van de vorming van nieuwe bloedvaten 
voor hun zuurstof- en voedingsstoffenvoorziening, maar ook voor hun verdere 
groei en de vorming van uitzaaiingen. Angiogenese wordt vaak gemeten als de 
microvessel density (MVD), het aantal vaatjes in een tumor. In vele tumoren, zoals 
borst-, blaas- en maagkanker, werd een associatie gevonden tussen een toename 
van de angiogenese en de ontwikkeling van uitzaaiingen, een slechte prognose en 
een verminderde overleving van patiënten. Vascular endothelial growth factor 
(VEGF) is een belangrijke speler in het proces van angiogenese, want het reguleert 
in de bloedvaten belangrijke celprocessen als uitrijping (differentiatie), 
verplaatsing (migratie) en celdeling (proliferatie). Endogline (CD105) is een co-
receptor voor transforming growth factor beta (TGF-β), een belangrijke groeifactor 
die verscheidene tumorprocessen reguleert. Door de voornaamste expressie op 
bloedvatcellen van nieuw-gevormde bloedvaten, vormt endogline een belangrijke 
marker voor angiogenese.  
Matrilysine, of matrix metalloproteïnase 7 (MMP-7), is onderdeel van de familie 
van matrix metalloproteïnases. Dit zijn enzymen die in staat zijn om het 
bindweefsel tussen cellen af te breken waardoor ze een belangrijke rol spelen bij 
zowel normale als ziektegerelateerde processen van weefselvernieuwing. 
Matrilysine wordt geproduceerd door tumorcellen en is in verschillende 
kankertypes bewezen betrokken te zijn bij tumoringroei en de vorming van 
uitzaaiingen.  
Het insuline-achtige groei factor (IGF) systeem is een belangrijk 





Daarnaast speelt het ook een belangrijke rol in de ontwikkeling van verschillende 
tumor types. Het IGF-systeem bestaat uit de eiwitten IGF-1 en IGF-2, hun 
receptoren IGF-1R en IGF-2R, en een zestal IGF-bindingseiwitten, de IGFBP-1 tot 
en met IGFBP-6.  
Verschillende factoren zoals hierboven beschreven dragen bij het ontstaan, het 
ontwikkelen en het beloop (pathogenese) van de tumoren en de bijhorende 
ziekteprocessen. In de studies van dit proefschrift werd gekeken of verschillende 
tumormechanismen, bekend van andere kankers, ook een rol spelen bij 
neuroendocriene tumoren van de alvleesklier en het maag-darmkanaal. Omdat 
deze tumoren zeer gevarieerd zijn, is het waardevol om factoren te achterhalen die 
verantwoordelijk zijn voor deze diversiteit en de onderliggende mechanismen 
voor het ontstaan van deze tumoren, zodat in de kliniek hierop kan worden 
ingespeeld door verbeterde diagnostiek en aangepaste behandelmethoden bij deze 
patiënten. Om een goed beeld van deze tumoren te vormen, werden ook 




Het doel van de in dit proefschrift beschreven studies was inzicht te krijgen in het 
ontstaan, bestaan en beloop van neuroendocriene tumoren in het maag-
darmkanaal en de alvleesklier. 
 
Resultaten 
Zoals eerder genoemd zijn gastroenteropancreatische neuroendocriene tumoren 
een verzameling van zeer diverse tumoren met onderling grote verschillen in het 
ontstaan, hun klinische symptomen en de prognose voor de patiënten.  
Hoofdstuk 2 geeft een overzicht van de huidige diagnostiek van deze tumoren. 
Aan de hand van de besproken veelvoorkomende problemen en nieuwe 
ontwikkelingen in de diagnostiek van neuroendocriene tumoren in het maag-
darmkanaal en de alvleesklier, werd een algoritmische beslisboom opgesteld om 




tumoren staan bekend als zeldzame tumoren. Verschillende epidemiologische 
studies uit diverse landen rapporteerden echter een toename in de incidentie van 
deze tumoren over de afgelopen jaren. Daarom deden wij onderzoek naar het 
aantal nieuwe gevallen van neuroendocriene tumoren in de alvleesklier en de 
twaalfvingerige darm in Nederland per jaar, over de periode van 1991 tot 2009, 
zoals beschreven in Hoofdstuk 3. Als resultaat werd een toename in de incidentie 
van neuroendocriene tumoren van zowel de alvleesklier als twaalfvingerige darm 
over de bestudeerde onderzoeksperiode gevonden. Deze stijging was 
voornamelijk toe te schrijven aan een toename van het aantal nieuwe gevallen van 
niet-functionele tumoren, terwijl de incidentie van de functionele tumoren 
ongeveer constant bleef over de jaren. Wij denken dat de incidentiestijging van 
niet-functionele tumoren het resultaat is van een betere detectie, in plaats van een 
daadwerkelijke toename in het voorkomen van deze tumoren. Mogelijk hebben 
een verbeterde diagnostiek en beeldvormingtechnieken (zoals CT en MRI scans) 
en ook de introductie van de classificatie voor gastroenteropancreatische 
neuroendocriene tumoren volgens de World Health Organization in 2000 hieraan 
bijgedragen.  
Gastrinomen zijn de meest voorkomende soort kwaadaardige neuroendocriene 
tumor, welke meestal voorkomen in de alvleesklier, de twaalfvingerige darm en 
de daaromheen liggende lymfeklieren. Deze gastrinomen komen echter in 
zeldzame gevallen ook op andere plaatsen in het lichaam voor, zoals de 
eierstokken, het darmscheil (mesenterium), de maag, de bijschildklieren, nieren, 
galwegen, en de lever. In Hoofdstuk 4 beschreven wij een patiënt met een 
terugkerend (recidiverend) gastrinoom in de lever, waarbij het bestaan van 
primaire lever gastrinomen bediscussieerd wordt aan de hand van een uitvoerige 
literatuurstudie.  
Door hun gastrineproductie geven gastrinomen aanleiding tot het Zolliner-Ellison 
syndroom (ZES). De secretine-stimulatietest is een veelgebruikte test voor de 
diagnose van ZES. Echter, in de literatuur staat de dosis van secretine en de 
daarbij behorende grenswaarde voor een positieve test ter discussie. Aan de hand 





effectief was in het diagnosticeren van ZES, in vergelijking met een lagere dosis, 
en welk criterium bijdroeg aan de hoogste gevoeligheid (sensitiviteit) en 
specificiteit van de test voor het diagnosticeren van ZES (Hoofdstuk 5). Wij 
vonden dat het gebruik van een lage dosis secretine resulteert in een sensitieve en 
specifieke secretine-stimulatietest, wanneer als criterium voor een positieve test 
een gastrinestijging van meer dan 100 ng/L wordt gebruikt.  
Gastroenteropancreatische neuroendocriene tumoren produceren naast hormonen 
ook neuropeptiden, zoals bombesine. Gastrin-releasing peptide en Neuromedine 
B behoren tot de ‘bombesin-achtige peptides’ (BLPs). In de studie beschreven in 
Hoofdstuk 6 onderzochten we of we op basis van deze bombesine-achtige 
peptides in staat waren om carcinoïden van verschillende afkomst te 
onderscheiden. De expressie van verschillende bombesine receptoren bleek niet 
afhankelijk van de lokalisatie van de tumor. Daarom achten wij bombesine niet 
bruikbaar als specifieke marker carcinoïden, hoewel carcinoïden in de darmen en 
longen wel diverse bindingsaffiniteiten voor deze receptoren en verschillende 
bombesine peptide waardes vertoonden. Wij suggereren daarnaast dat de 
gelijktijdige expressie (co-expressie) van de bombesine-achtige peptides en hun 
receptoren op tumorcellen mogelijk de aanwezigheid van een autocrien 
groeisysteem in carcinoïden illustreert, al zal verder onderzoek nodig zijn om dit 
te kunnen bewijzen.  
Angiogenese speelt ook in het ontstaan en ontwikkeling van neuroendocriene 
tumoren een belangrijke rol. Het onderzoek naar de expressie en weefselwaardes 
van endogline en VEGF in gastroenteropancreatische neuroendocriene tumoren 
staat beschreven in Hoofdstuk 7. Hierbij werd gevonden dat endogline een 
potentiële marker is om de aanwezigheid van metastasen te detecteren en de 
mogelijke ontwikkeling van metastasen te voorspellen. Hoewel de expressie van 
VEGF verhoogd was in tumoren ten opzichte van geassocieerd normaal weefsel in 
patiënten met gastroenteropancreatische neuroendocriene tumoren, vonden wij 
geen relatie met tumorkenmerken, zodat wij VEGF niet aanbevelen als mogelijke 
marker in deze tumoren. Echter, verschillende studies onderzoeken het gebruik 




dat mogelijk ook in neuroendocriene tumoren van de alvleesklier en het maag-
darmkanaal een behandeling met anti-endogline effectief zou kunnen zijn om 
angiogenese en daarmee verdere groei en ontwikkeling van de tumor tegen te 
gaan.  
Het IGF-systeem speelt een belangrijke rol in kanker. Verschillende studies 
hebben aangetoond dat de expressie van IGF-1 verhoogd is in diverse tumoren, 
gerelateerd aan de groei en agressiviteit van de tumor. Ook blijkt de expressie van 
matrilysine in verschillende kankers, waaronder maag-, slokdarm- en 
alvleesklierkanker te zijn toegenomen en geassocieerd met een kwaadaardig 
gedrag van de tumor. Recent is aangetoond dat tumorgroei wordt gestimuleerd 
door IGF-1, nadat matrilysine IGF-1 heeft losgeknipt van IGFBP-3. In Hoofdstuk 8 
beschrijven wij een studie naar de expressie van IGF-1, IGFBP-3 en matrilysine in 
neuroendocriene tumoren van de alvleesklier en het maag-darmkanaal, om de rol 
van het IGF-matrilysine groeinetwerk in het ontstaan van deze tumoren te 
onderzoeken. Wij vonden dat matrilysine geen directe invloed heeft op de 
tumorgroei of andere tumorprocessen in gastroenteropancreatische 
neuroendocriene tumoren. Echter vonden wij wel voorlopig bewijs dat ook in 
neuroendocriene tumoren van de alvleesklier en het maag-darmkanaal een IGF-
matrilysine netwerk aanwezig is. Verder bleek in deze tumoren een hogere 
expressie van IGFBP-3 gerelateerd te zijn aan een grotere tumor en de 
aanwezigheid van metastasen.  
 
Conclusies 
De studies beschreven in dit proefschrift geven inzicht in de epidemiologie, de 
diagnostiek, het ontstaan en het beloop van gastroenteropancreatische 
neuroendocriene tumoren. De diverse studies naar het aantal nieuwe gevallen per 
jaar van deze tumoren laten zien dat neuroendocriene tumoren van de alvleesklier 
en het maag-darmkanaal, ook in Nederland, in de afgelopen jaren in incidentie 
zijn toegenomen. Mogelijk zijn deze tumoren dus niet zo zeldzaam als lange tijd 
werd gedacht. Mede daarom achten wij het een noodzaak dat de ontstaanswijze 





beschreven in dit proefschrift, hebben wij onderzoek gedaan naar factoren die een 
rol spelen in de pathogenese van neuroendocriene tumoren in de alvleesklier en 
het maagdarm-kanaal. Zo vonden wij dat endogline een potentiële marker is om 
aanwezige en toekomstige metastasen te detecteren en te voorspellen. Het meten 
van endogline spiegels in tumor weefsels geeft informatie over de mate van 
kwaadaardigheid van de tumor, wat zeer bruikbaar kan zijn in het bepalen van de 
behandelingsstrategie en follow-up na operatie van patiënten met 
gastroenteropancreatische neuroendocriene tumoren. Daarnaast vonden wij 
aanwijzingen voor de aanwezigheid van twee groeisystemen in deze tumoren. 
Allereerst doet de gelijktijdige expressie van bombesine-achtige peptides en hun 
receptoren in carcinoïden in de longen en darmen het bestaan van een autocrien 
groeisysteem in deze tumoren sterk vermoeden. Daarnaast lijkt matrilysine samen 
met IGF-1 en IGFBP-3 in neuroendocriene tumoren van de alvleesklier en het 
maag-darmkanaal een netwerk te vormen resulterend in tumorgroei. Aanvullende 
studies naar de exacte werking van deze autocriene groeisystemen in 
gastroenteropancreatische neuroendocriene tumoren zullen moeten uitwijzen of 
bombesine-achtige peptides, matrilysine en het IGF-systeem mogelijk ook 
gebruikt kunnen worden als doel voor anti-kanker behandelingsstrategieën. 
Mogelijk dragen de studies beschreven in dit proefschrift bij aan de ontwikkeling 
van meer doelgerichte behandelingen, waardoor de prognose en overleving van 
de patiënten met neuroendocriene tumoren van de alvleesklier en het maag-








































List of publications 
 
Kuiper P, Biemond I, Verspaget HW, Lamers CB. A case of recurrent gastrinoma 
in the liver with a review of “primary” hepatic gastrinomas. BMJ Case Reports 
[published online 11 June 2009].  
 
Kuiper P, Biemond I, Masclee AA, Jansen JB, Verspaget HW, Lamers CB. 
Diagnostic efficacy of the secretin stimulation test for the Zollinger-Ellison 
syndrome: an intra-individual comparison using different dosages in patients and 
controls. Pancreatology 2010;10(1):14-18.  
 
Kuiper P, Verspaget HW, van Slooten HJ, Overbeek L, Biemond I, Lamers CB. 
Pathological incidence of duodenopancreatic neuroendocrine tumors in the 
Netherlands: a Pathologisch Anatomisch Landelijk Geautomatiseerd Archief 
study. Pancreas 2010;39(8):1134-1139.   
 
Kuiper P, Verspaget HW, Biemond I, de Jonge-Muller ES, van Eeden S, van 
Velthuysen MLF, Taal BG, Lamers CB. Expression and ligand binding of bombesin 
receptors in pulmonary and intestinal carcinoids: The role of bombesin in 
carcinoids. J Endocrinol Invest 2010 Nov 8 Epub.  
 
Kuiper P, Hawinkels LJAC, de Jonge-Muller ESM, Biemond I, Lamers CB, 
Verspaget HW. Angiogenic markers endoglin and vascular endothelial growth 
factor in gastroenteropancreatic neuroendocrine tumors.  
World J Gastroenterol 2011;17(2):219-225.  
 
Kuiper P, Verspaget HW, Overbeek LIH, Biemond I, Lamers CB. An overview of 
the current diagnosis and recent developments in neuroendocrine tumours of the 
gastroenteropancreatic tract: the diagnostic approach.  





Kuiper P, Biemond I, Lamers CB, Verspaget HW. The IGF-matrilysin network in 
gastroenteropancreatic neuroendocrine tumours. Submitted.  
 
Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, Pardali E, Sier CF, 
Ten Dijke P. Matrix Metalloproteinase-14 (MT-MMP)-mediated endoglin shedding 


























De auteur van dit proefschrift, Patricia Kuiper, werd op 2 augustus 1986 geboren 
in ’s Gravenhage. Zij behaalde in 2004 haar VWO diploma aan het Segbroek 
College in ’s Gravenhage. In dit jaar begon zij met de opleiding Geneeskunde aan 
de Universiteit Leiden. Tijdens haar studie heeft zij haar wetenschapsstage van 24 
weken gelopen in het laboratorium van de afdeling Maag-, Darm- en Leverziekten 
in het Leids Universitair Medisch Centrum, Leiden, onder supervisie van Dr. 
L.J.A.C. Hawinkels, Dr. C.F.M. Sier en Dr. ir. H.W. Verspaget, waar zij onderzoek 
deed naar de rol van endoglin in colorectaal kanker. In 2008 werd in de 
Geneeskunde het doctoraal diploma behaald. In april 2008 begon zij onder 
verantwoordelijkheid van Dr. ir. I. Biemond, Dr. ir. H.W. Verspaget en Prof. dr. 
C.B.H.W. Lamers het onderzoek naar karakteristieken en groeimechanismen van 
neuroendocriene tumoren van de tractus digestivus en het pancreas aan het Leids 
Universitair Medisch Centrum, wat geresulteerd heeft in een aantal publicaties en 
de totstandkoming van dit proefschrift. Op dit moment is Patricia bezig met haar 
co-schappen en het vervolg van haar studie Geneeskunde, om haar diploma voor 
















































Dit proefschrift is tot stand gekomen met de hulp van velen. Ik wil de 
wetenschappelijk medewerkers en het analytisch personeel van de afdeling  
Maag-, Darm-, en Leverziekten (Hein, Izäk, Eveline, Wim, Johan, Annie, Marij, 
Bert-Jan, Marjolijn, Auke, Christine, Rutger, Lianne, Vanesa, Liudmilla, Jarom, 
Sanne, Manon, Niké, Luuk, Pim) bedanken voor hun steun en inzet. Daarnaast 
ben ik de afdeling Pathologie zeer erkentelijk voor het beschikbaar stellen van 
resectieweefsel. Voorts bedank ik de afdelingen Pathologie van het Antoni van 
Leeuwenhoek Ziekenhuis en het Amsterdam Medisch Centrum, Willem en Henk-
Jan van het Medisch Centrum Alkmaar, en Lucy van het Pathologisch Anatomisch 
Landelijk Geautomatiseerd Archief voor de zeer waardevolle samenwerking. 
Tenslotte gaat mijn dank uit naar mijn familie (papa, mama, Dennis, Menno en 
Joury), schoonfamilie en vrienden voor hun interesse en aanmoedigingen. Meeste 
dank gaat natuurlijk naar mijn partner Wouter voor zijn grenzeloze geduld en 























































































































































Figure 1. Immunostaining for the three bombesin receptors on an intestinal and a pulmonary 
carcinoid. Magnification x400. The carcinoids are stained with antibodies for BRS-3 (a,b), GRPR 
(c,d) and NMBR (e,f). Incidental membrane-bound staining is indicated with ►. 
Immunohistochemical scores were 3 for BRS-3 (a), 5 for GRPR (c) and 4 for NMBR (e) in the 























Figure 2. Immunostaining of gastroenteropancreatic neuroendocrine tumours
A
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Figure 2. Immunostaining of endoglin and CD31 on peritumoural and intratumoural vessels in 
GEP-NETs. A) Endoglin staining is limited to angiogenic vessels, whereas CD31 stains both old 
and new blood vessels in tumour tissue. Magnification 100x. B) Representative endoglin staining in 
a pancreatic neuroendocrine tumour and a gastrointestinal carcinoid metastasis (mesenterium of 




























Figure 1. Immunohistochemical staining for a,b) IGF-1, c,d) IGFBP-3 and e,f) matrilysin on tumour 
cells of a duodenopancreatic gastrinoma (a, c, d) and gastrointestinal NET (carcinoid) (b, c, e). 
Magnification x100. In the insert of d) membrane staining of IGFBP-3 is shown at a higher 
magnification (x200).  
 
